BMJ Open

# Trends and Predictors of Biomedical Research Quality: A Meta-Research Study



| | |
|---|---|
| Journal: | *BMJ Open* |
| Manuscript ID | bmjopen-2019-030342 |
| Article Type: | Research |
| Date Submitted by the Author: | 09-Mar-2019 |
| Complete List of Authors: | Catillon, Maryaline; Harvard University, Ph.D. Program in Health Policy |
| Keywords: | STATISTICS & RESEARCH METHODS, Health informatics < BIOTECHNOLOGY & BIOINFORMATICS, Health policy < HEALTH SERVICES ADMINISTRATION & MANAGEMENT |
| | |

# Trends and Predictors of Biomedical Research Quality:

# A Meta-Research Study

**Word count: 2,125 (main text)**



Maryaline Catillon (0000-0002-1360-8133)

Ph.D. Program in Health Policy, Harvard University, 14 Story Street, 4th Floor, Cambridge, MA 02138

mcatillon@g.harvard.edu

(+1) 857 222 6863

## ABSTRACT

**Objective:** To measure the frequency of adequate methods, inadequate methods and poor reporting in published clinical trials and test potential factors associated with adequacy of methods and reporting.

**Design:** Retrospective analysis of studies included in Cochrane reviews. Time series describe the proportion of studies using adequate methods, inadequate methods and poor reporting. A multinomial logit model tests potential factors associated with methods and reporting, including funding source, first author affiliation, clinical trial registration status, study novelty, team characteristics, technology and geography.

**Data:** Risk of bias assessment for random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data and selective reporting, for each study, mapped to bibliometric and funding data.

**Outcomes:** Risk of bias on six methodological dimensions, and study-level assessment of adequate methods, inadequate methods or poor reporting.

**Results:** This study analyzed 20,571 biomedical research articles. 5.7% of studies used adequate methods (N=1,173), 59.3% used inadequate methods (N=12,190) and 35.0% were poorly reported (N=7,208). The proportion of poorly reported studies decreased from 42.5% in 1990 to 30.2% in 2015. The proportion of studies using adequate methods increased from 2.6% in 1990 to 10.3% in 2015. The proportion of studies using inadequate methods increased from 54.9% in 1990 to 59.5% in 2015. Industry funding, top pharmaceutical company affiliation, trial registration, larger authorship teams, international teams, and drug trials were associated with a greater likelihood of using adequate methods. NIH funding and university prestige were not.

**Conclusion:** Even though reporting has improved since 1990, the proportion of studies using inadequate methods is high (59.3%) and increasing, potentially contributing to the reproducibility crisis. Stronger incentives for the use of adequate methods are needed.

## STRENGTHS AND LIMITATIONS OF THIS STUDY

- This study combines the full-text and systematic assessment of study methods with bibliometric and funding information in a sample of 20,571 biomedical research articles.
- This study analyzes trends in methods and reporting over the past 25 years and identifies factors associated with biomedical research quality including funding source, first author affiliation, clinical trial registration status, study novelty, team characteristics, technology and geography.
- This study does not identify causal mechanisms explaining biomedical research quality.
- PubMed identifier, full-text and/or funding information were not available for all studies.
- Classification of sectors relies on reported affiliation.

## INTRODUCTION

The quality and reliability of biomedical research are of paramount importance to treatment decisions and patient outcomes. Flawed research conclusions can lead to poor treatment and harm patients. As much as 85% of the annual $265 billion spent on biomedical research may be wasted due to inadequate methods.[1-8]

Previous scientific work aiming to evaluate the reliability of biomedical research has been limited by data and methodological issues. Data challenges include the time and resources necessary to assess methods and reporting, resulting in the use of small selected samples and/or limited information available for each scientific article evaluated in larger samples.[9-27] As a result, it remains unknown what the overall magnitude of waste due to inadequate methods and reporting in biomedical research is and what factors are associated with the use of adequate versus inadequate research methods.

To address these questions, this study combines the full text of studies and systematic assessment of study methods with bibliometric and funding information in a large sample of biomedical research articles included in "gold standard" systematic reviews. The study describes the evolution of adequate research methods and reporting over time. A multinomial logit model tests potential factors associated with methods and reporting, including funding source, first author affiliation, clinical trial registration status, study novelty, team characteristics, technology and geography.

## METHODS

### Data

Cochrane reviews constitute a valuable data source to assess biomedical research quality as they follow strict methods and precise reporting guidelines as defined in the Cochrane Handbook.[28-

31] The research method dimensions evaluated in Cochrane reviews include random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, and selective reporting (detailed in Supplementary Table A1).

**Sample**

Supplementary Figure A1 summarizes the data flow. All studies assessed for risk of bias after the 2011 update of the Risk of Bias Assessment Tool and through October 2017 were considered for inclusion (N=63,748 studies included in 4,195 reviews).

Criteria for study inclusion were: (1) the review included all six assessments (to allow comparison of the overall use of adequate methods, inadequate methods and poor reporting across reviews) (1,988 reviews dropped), (2) the article reporting the study was referenced in PubMed (to allow bibliometric data to enter the analysis)(N=9,201 studies dropped) and (3) the study quality was assessed consistently when assessed multiple times (N=404 studies dropped).

Applying these criteria, the analysis sample for the descriptive statistics and the time-series of methods included 20,571 study publications referenced in PubMed, and consistently assessed for risk of bias on all six dimensions of the Cochrane Risk of Bias Assessment Tool. A full-text PDF was available from the Harvard Library for 11,686 study publications. This subsample was needed to retrieve private funding information from the full-text of the paper and constitutes the analysis sample for regressions including funding information.

**Analysis**

The outcomes were risk of bias on the six assessed methodological dimensions and study-level assessment of adequate methods, inadequate methods or poor reporting. The six methodological

dimensions assessed included (1) random sequence generation, (2) allocation concealment, (3) blinding of participants and personnel, (4) blinding of outcome assessment, (5) incomplete outcome data and (6) selective reporting. The category "Other bias" was not used in this study, as it includes concerns not necessarily about methods or reporting, such as conflicts of interest.

Following guidelines for assessing the quality of evidence,[28] the study-level assessment was "adequate methods" if the study was at low risk of bias on all dimensions assessed. It was "inadequate methods" if the study was at high risk of bias for one or more reasons. It was "poorly reported" if the reviewers did not have enough information to assess whether the methods used were adequate or inadequate (if the study was at "unclear" risk of bias for at least one reason).

Of the studies assessed on all six dimensions, 69.5% matched with a PubMed identifier, which was used to retrieve bibliometric and public funding information.

Sector affiliation with university, government, hospital, non-profit, top pharmaceutical company or other firm, as well as geographic variables were derived from the first author affiliation address. Top 25 Universities were identified using the 2007 Academic Ranking of World Universities in Clinical Medicine and Pharmacy (see supplementary material, Appendix A). Firms were classified as top pharmaceutical companies or other firms using the listing of pharmaceutical companies with a revenue greater than $10 billion in any year since 2011 (see supplementary material, Appendix B). Technologies were retrieved from the keywords and abstracts of the Cochrane Reviews. Private funding information was retrieved from the full-text PDF of the main reference when available.

Two analyses were performed. The first reports the time series of the proportion of studies using adequate methods, inadequate methods and poor reporting, for each dimension and in aggregate. The second tests whether adequate methods, inadequate methods and poor reporting are associated with funding source (NIH grant or industry funding), sector affiliation of first author (Top University, Other University, Government, Hospital, Non-Profit, Top Pharmaceutical Company, Other Firm), clinical trial registration status, study novelty (first or subsequent study on a particular research question), team characteristics (number of authors and international collaboration), technology (drug, device, procedure, behavioral intervention or other intervention), and geography of first author (Canada, Europe, UK, USA, or other country). A multinomial logit model using these variables predicted overall adequate methods, inadequate methods and poor reporting, as well as risk of bias along each dimension assessed.

**Patient involvement**

Patients were not involved in any aspect of the study design, conduct, or in the development of the research question or outcome measures. This study is a meta-research study, based on existing published research. There was no patient recruitment for data collection.

## RESULTS

### Prevalence of Adequate Methods, Inadequate Methods, and Poor Reporting

Table 1 presents descriptive statistics. Only 5.7% of studies used adequate methods (N=1,173). 59.3% used inadequate methods (N=12,190) and 35.0% were poorly reported (N=7,208).

Figure 1 shows the proportion of studies at low, high or unclear risk of bias for random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data and selective reporting, for all studies assessed on all six

dimensions (N=20,571). 38% of trials used inadequate methods for blinding of participants and personnel. 15 to 20% of trials used inadequate methods for blinding of outcome assessment (20%), incomplete outcome data (19%) and selective reporting (15%). The proportion of trials using inadequate methods for random sequence generation and allocation concealment was lowest (respectively 5% and 7%), but these two dimensions were frequently poorly reported (respectively 47% and 58% of trials).

**Methods and reporting over time**

Figure 2 shows the overall proportion of studies using adequate methods, inadequate methods and poorly reported methods by year of publication. The proportion of poorly reported studies decreased from 42.5% in 1990 to 30.2% in 2015. The proportion of studies using adequate methods increased from 2.6% in 1990 to 10.3% in 2015. The proportion of studies using inadequate methods increased from 54.9% in 1990 to 59.5% in 2015.

Reporting improved on all dimensions. The proportion of studies using adequate methods for random sequence generation, allocation concealment, blinding of outcome assessment, incomplete outcome data and selective reporting increased. In contrast, the proportion of trials using inadequate methods for blinding of participants and personnel increased.

Figure A2 (supplementary material) provides graphs similar to figure 2 for all studies assessed on at least one dimension (N=63,748). Similar patterns suggest that the evolutions observed for the studies assessed on all dimensions (N=20,571) reflect the evolutions in all studies assessed on at least one dimension.

**Factors associated with methods and reporting**

Figure 3 reports regression results from a multinomial logit model predicting overall quality. Tables A2 and A3 (Supplementary material) report all regression results.

Public funding was not associated with the overall use of adequate methods. However, NIH funded studies were less likely to use inadequate methods for random sequence generation (RR=0.29, p<0.001) and allocation concealment (RR=0.51, p<0.001). Industry funded studies were slightly more likely to use adequate methods (RR=0.84, p<0.05), because of better blinding of participants and personnel (RR=0.87, p<0.05).

First author affiliation with a top pharmaceutical company was associated with increased use of adequate methods (RR=0.43, p<0.01). First author affiliation with top universities was not.

Registered trials (RR=0.42, p<0.001), larger authorship teams (RR=0.95, p<0.001), international teams (RR=0.51, p<0.01) and studies on drugs (RR=0.50, p<0.001) were less likely to use inadequate methods.

## DISCUSSION

In the context of the "reproducibility crisis", there are concerns about the quality of biomedical research. This study assessed whether or not methods and reporting improved over time and identified the characteristics of better and worse studies.

This study has five main results. First, in a large sample of studies assessed in systematic reviews, only 5.7% used adequate methods, 59.3% used inadequate methods, and 35.0% were poorly reported. Since the 1990s, the proportion of poorly reported studies has decreased. In contrast, the proportion of trials using both adequate and inadequate methods has increased. This finding is consistent with previous empirical results in small samples,[22] but contrasts with

research in larger samples analyzing each methodological dimension separately to conclude that methods improved over time.[24]

Second, NIH funded studies were not more likely to use adequate methods. This is surprising given the rigorous grant application process, shown to select better scientific proposals,[33] and the public stakes in the reliability of publicly funded research.[34] Notably, the efforts of the NIH to address the reproducibility crisis began just at the end of the study period.[35]

Third, top pharmaceutical company affiliation was significantly associated with better methods. Affiliation with other companies was not. Heterogeneity across firms may explain inconsistency of previous research on the effect of industry funding or affiliation on research methods and outcomes.[27,36]

Fourth, University prestige was not associated with greater use of adequate methods. The current scientific reward system focuses on numbers of publications and citations rather than the assessment of research methods.[37] The resulting incentives affect both scientists and institutions, as through the allocation of grant funding.[38,39] Thus, in a climate of hypercompetition,[40] the careful sharing of materials and methods yields little reward while exposing scientists to better informed scrutiny.

Finally, team size and international collaboration are associated with greater use of adequate methods. Larger teams and international teams produce more frequently cited research, [41,42] and other team characteristics were associated with performance in other settings, opening avenues for future research.[43,44]

**Limitations**

This paper does not identify causal mechanisms explaining biomedical research quality. PubMed identifier, full-text and/or funding information were not available for all studies. Classification of sectors relies on reported affiliation.

## CONCLUSION

Even though reporting has improved since 1990, the proportion of studies using inadequate methods is high (59.3%) and increasing, potentially contributing to the reproducibility crisis. Stronger incentives for the use of adequate methods are needed.

### Contributorship statement

Maryaline Catillon designed the study, performed the analysis, interpreted the results, wrote the manuscript and approved the final version to be published. Maryaline Catillon accepts full responsibility for the work and the conduct of the study, had access to the data, and controlled the decision to publish.

### Acknowledgments

The author thanks David Cutler, Richard Freeman, Mack Lipkin, Ariel Stern, Richard Zeckhauser and the participants at the NBER-IFS International Network on the Value of Medical Research meetings for helpful conversations and feedback, and Harvard Business School Research Computing Services for technical advice and support.

### Funding

The author gratefully acknowledges support by the National Institute on Aging of the National Institutes of Health under Award Number R24AG048059 to the National Bureau of Economic Research (NBER). The content of this article is solely the responsibility of the author and does not necessarily represent the official views of the National Institutes of Health or the NBER.

## Ethical approval

Not applicable. This is a meta-research study.

## Data sharing

All data sources necessary to reproduce the analysis are described in the main text or the supplementary material. No additional data available.

**What is already known on this subject**

Poor reporting and inadequate methods are common in randomized controlled trials.

Reporting has improved since the 1990s.

Previous research has been limited by the use of small selected samples and/or limited information available for each scientific article evaluated in larger samples

**What this study adds**

This study combines the full-text and systematic assessment of study methods with bibliometric and funding information to analyze trends and predictors of methods and reporting in a sample of 20,571 biomedical research studies.

Only 5.7% of studies used adequate methods, 59.3% used inadequate methods and 35.0% were poorly reported.

Since the 1990s, while the proportion of poorly reported studies decreased, both the proportion of studies using adequate methods and inadequate methods increased.

Industry funding, top pharmaceutical company affiliation, trial registration, larger authorship teams, international teams, and drug trials were associated with a greater likelihood of using adequate methods, but NIH funding and university prestige were not.

## Bibliography


1. Chalmers I, Glasziou P. Avoidable waste in the production and reporting of research evidence. The Lancet. 2009 Jul 4;374(9683):86-9.
2. Macleod MR, Michie S, Roberts I, Dirnagl U, Chalmers I, Ioannidis JP, Salman RA, Chan AW, Glasziou P. Biomedical research: increasing value, reducing waste. The Lancet. 2014 Jan 11;383(9912):101-4.
3. Chalmers I, Bracken MB, Djulbegovic B, Garattini S, Grant J, Gülmezoglu AM, Howells DW, Ioannidis JP, Oliver S. How to increase value and reduce waste when research priorities are set. The Lancet. 2014 Jan 11;383(9912):156-65.
4. Glasziou P, Altman DG, Bossuyt P, Boutron I, Clarke M, Julious S, Michie S, Moher D, Wager E. Reducing waste from incomplete or unusable reports of biomedical research. The Lancet. 2014 Jan 18;383(9913):267-76.
5. Ioannidis JP, Greenland S, Hlatky MA, Khoury MJ, Macleod MR, Moher D, Schulz KF, Tibshirani R. Increasing value and reducing waste in research design, conduct, and analysis. The Lancet. 2014 Jan 11;383(9912):166-75.
6. Moses H, Matheson DH, Cairns-Smith S, George BP, Palisch C, Dorsey ER. The anatomy of medical research: US and international comparisons. Jama. 2015 Jan 13;313(2):174-89.
7. Yordanov Y, Dechartres A, Porcher R, Boutron I, Altman DG, Ravaud P. Avoidable waste of research related to inadequate methods in clinical trials. bmj. 2015 Mar 24;350:h809.
8. Moher D, Glasziou P, Chalmers I, Nasser M, Bossuyt PM, Korevaar DA, Graham ID, Ravaud P, Boutron I. Increasing value and reducing waste in biomedical research: who's listening?. The Lancet. 2016 Apr 9;387(10027):1573-86.

9. Lee KP, Schotland M, Bacchetti P, Bero LA. Association of journal quality indicators with methodological quality of clinical research articles. Jama. 2002 Jun 5;287(21):2805-8.
10. Bala MM, Akl EA, Sun X, Bassler D, Mertz D, Mejza F, Vandvik PO, Malaga G, Johnston BC, Dahm P, Alonso-Coello P. Randomized trials published in higher vs. lower impact journals differ in design, conduct, and analysis. Journal of clinical epidemiology. 2013 Mar 1;66(3):286-95.
11. Lee SY, Teoh PJ, Camm CF, Agha RA. Compliance of randomized controlled trials in trauma surgery with the CONSORT statement. Journal of Trauma and Acute Care Surgery. 2013 Oct 1;75(4):562-72.
12. Agha RA, Camm CF, Doganay E, Edison E, Siddiqui MR, Orgill DP. Randomised controlled trials in plastic surgery: a systematic review of reporting quality. European journal of plastic surgery. 2014 Feb 1;37(2):55-62.
13. Chen B, Liu J, Zhang C, Li M. A retrospective survey of quality of reporting on randomized controlled trials of metformin for polycystic ovary syndrome. Trials. 2014 Dec;15(1):128.
14. Chen X, Zhai X, Wang X, Su J, Li M. Methodological reporting quality of randomized controlled trials in three spine journals from 2010 to 2012. European Spine Journal. 2014 Aug 1;23(8):1606-11.
15. Kim KH, Kang JW, Lee MS, Lee JD. Assessment of the quality of reporting for treatment components in Cochrane reviews of acupuncture. BMJ open. 2014 Jan 1;4(1):e004136.
16. Lempesi E, Koletsi D, Fleming PS, Pandis N. The reporting quality of randomized controlled trials in orthodontics. Journal of Evidence Based Dental Practice. 2014 Jun 1;14(2):46-52.

17. Yao AC, Khajuria A, Camm CF, Edison E, Agha R. The reporting quality of parallel randomised controlled trials in ophthalmic surgery in 2011: a systematic review. Eye. 2014 Nov;28(11):1341.

18. Zhuang L, He J, Zhuang X, Lu L. Quality of reporting on randomized controlled trials of acupuncture for stroke rehabilitation. BMC complementary and alternative medicine. 2014 Dec;14(1):151.

19. Chen Z, Chen Y, Zeng J, Wang Y, Ye T, Zhou Q, Du X, Su W, Ding Z. Quality of randomized controlled trials reporting in the treatment of melasma conducted in China. Trials. 2015 Dec;16(1):156.

20. Glujovsky D, Boggino C, Riestra B, Coscia A, Sueldo CE, Ciapponi A. Quality of reporting in infertility journals. Fertility and sterility. 2015 Jan 1;103(1):236-41.

21. Kloukos D, Papageorgiou SN, Doulis I, Petridis H, Pandis N. Reporting quality of randomised controlled trials published in prosthodontic and implantology journals. Journal of oral rehabilitation. 2015 Dec;42(12):914-25.

22. Reveiz L, Chapman E, Asial S, Munoz S, Bonfill X, Alonso-Coello P. Risk of bias of randomized trials over time. Journal of clinical epidemiology. 2015 Sep 1;68(9):1036-45.

23. Zhai X, Wang Y, Mu Q, Chen X, Huang Q, Wang Q, Li M. Methodological reporting quality of randomized controlled trials in 3 leading diabetes journals from 2011 to 2013 following CONSORT statement: a system review. Medicine. 2015 Jul;94(27).

24. Dechartres A, Trinquart L, Atal I, Moher D, Dickersin K, Boutron I, Perrodeau E, Altman DG, Ravaud P. Evolution of poor reporting and inadequate methods over time in 20 920 randomised controlled trials included in Cochrane reviews: research on research study. BMJ. 2017 Jun 8;357:j2490.

25. Saltaji H, Armijo-Olivo S, Cummings GG, Amin M, Flores-Mir C. Randomized clinical trials in dentistry: Risks of bias, risks of random errors, reporting quality, and methodologic quality over the years 1955–2013. PloS one. 2017 Dec 22;12(12):e0190089.

26. Karlsen AP, Dahl JB, Mathiesen O. Evolution of bias and sample size in postoperative pain management trials after hip and knee arthroplasty. Acta Anaesthesiologica Scandinavica. 2018 May;62(5):666-76.

27. Salandra R. Knowledge dissemination in clinical trials: exploring influences of institutional support and type of innovation on selective reporting. Research Policy. 2018 Sep 1;47(7):1215-28.

28. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savović J, Schulz KF, Weeks L, Sterne JA. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. Bmj. 2011 Oct 18;343:d5928.

29. Bunn F, Trivedi D, Alderson P, Hamilton L, Martin A, Iliffe S. The impact of Cochrane systematic reviews: a mixed method evaluation of outputs from Cochrane review groups supported by the UK National Institute for Health Research. Systematic reviews. 2014 Dec;3(1):125.

30. Davoli M, Amato L, Clark N, Farrell M, Hickman M, Hill S, Magrini N, Poznyak V, Schünemann HJ. The role of Cochrane reviews in informing international guidelines: a case study of using the Grading of Recommendations, Assessment, Development and Evaluation system to develop World Health Organization guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. Addiction. 2015 Jun;110(6):891-8.

31. Page MJ, Shamseer L, Altman DG, Tetzlaff J, Sampson M, Tricco AC, Catalá-López F, Li L, Reid EK, Sarkis-Onofre R, Moher D. Epidemiology and reporting characteristics of systematic reviews of biomedical research: a cross-sectional study. PLoS medicine. 2016 May 24;13(5):e1002028.
32. Liu NC. The story of academic ranking of world universities. International Higher Education. 2015 Mar 25(54).
33. Li D, Agha L. Big names or big ideas: do peer-review panels select the best science proposals?. Science. 2015 Apr 24;348(6233):434-8.
34. Sampat BN. Mission-oriented biomedical research at the NIH. Research Policy. 2012 Dec 1;41(10):1729-41.
35. Collins FS, Tabak LA. NIH plans to enhance reproducibility. Nature. 2014 Jan 30;505(7485):612-3.
36. Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. Industry sponsorship and research outcome. Cochrane Database Syst Rev. 2012 Dec 12;12(12).
37. Stephan, P. How Economics Shapes Science, 2012
38. Ali MM, Bhattacharyya P, Olejniczak AJ. The effects of scholarly productivity and institutional characteristics on the distribution of federal research grants. The Journal of Higher Education. 2010 Mar 1;81(2):164-78.
39. Alberts B, Kirschner MW, Tilghman S, Varmus H. Rescuing US biomedical research from its systemic flaws. Proceedings of the National Academy of Sciences. 2014 Apr 22;111(16):5773-7.

40. Edwards MA, Roy S. Academic research in the 21st century: Maintaining scientific integrity in a climate of perverse incentives and hypercompetition. Environmental Engineering Science. 2017 Jan 1;34(1):51-61.

41. Wuchty S, Jones BF, Uzzi B. The increasing dominance of teams in production of knowledge. Science. 2007 May 18;316(5827):1036-9.

42. National Research Council. Enhancing the effectiveness of team science. National Academies Press; 2015 Jul 15.

43. Huckman RS, Staats BR, Upton DM. Team familiarity, role experience, and performance: Evidence from Indian software services. Management Science. 2009 Jan;55(1):85-100.

44. Huckman RS, Staats BR. Fluid tasks and fluid teams: The impact of diversity in experience and team familiarity on team performance. Manufacturing & Service Operations Management. 2011 Jul;13(3):310-28.

**List of Figures and Tables**

| | All | Adequate | Inadequate Methods | Poor Reporting |
|---|---|---|---|---|
| Sample 1 | 20,571 (100%) | 1,173 (5.7%) | 12,190 (59.3%) | 7,208 (35.0%) |
| Sample 2 (with full text) | 11,686 (56.8%) | 833 (7.1%) | 6,783 (58.0%) | 4,070 (34.8%) |
| **Funder type** | | | | |
| NIH Grant | 2,147 (10.4%) | 146 (6.8%) | 1,282 (59.7%) | 719 (33.5%) |
| Industry funding | 2,783 (13.5%) | 283 (10.2%) | 1,464 (52.6%) | 978 (35.1%) |
| **First Author Affiliation** | | | | |
| Top University | 1,063 (5.2%) | 51 (4.8%) | 601 (56.5%) | 411 (38.7%) |
| Other University | 11,120 (54.1%) | 677 (6.1%) | 6,589 (59.3%) | 3,854 (34.7%) |
| Hospital | 4,450 (21.6%) | 185 (4.2%) | 2,608 (58.6%) | 1,657 (37.2%) |
| Government | 1,744 (8.5%) | 108 (6.2%) | 1,071 (61.4%) | 565 (32.4%) |
| Non-Profit | 751 (3.7%) | 48 (6.4%) | 454 (60.5%) | 249 (33.2%) |
| Top Pharma | 239 (1.2%) | 26 (10.9%) | 115 (48.1%) | 98 (41.0%) |
| Other Firm | 195 (1.0%) | 13 (6.7%) | 115 (59.0%) | 67 (34.3%) |
| Other research institution | 200 (1.0%) | 18 (9.0%) | 120 (60.0%) | 62 (31.0%) |
| **Other industry affiliation** | 570 (2.8%) | 44 (7.7%) | 287 (50.4%) | 239 (41.9%) |
| **Registered studies (NCT)** | 1,888 (9.2%) | 298 (15.8%) | 1,011 (53.6%) | 579 (30.7%) |
| **Novelty** | | | | |
| First study | 2,284 (11.1%) | 126 (5.5%) | 1,390 (60.9%) | 768 (33.6%) |
| Second study | 2,124 (10.3%) | 127 (6.0%) | 1262 (59.4%) | 735 (34.6%) |
| **Team characteristics** | | | | |
| Number of Authors - Avg (Std) | 6.15 (3.9) | 8.04 (5.5) | 5.99 (3.8) | 6.13 (6.8) |
| International | 748 (3.64%) | 60 (8.02%) | 379 (50.67%) | 309 (41.31%) |
| **Technology*** | | | | |
| Drug | 13,485 (65.6%) | 914 (6.8%) | 7,306 (54.2%) | 5,265 (39.0%) |
| Device | 5,347 (26.0%) | 235 (4.4%) | 3,366 (63.0%) | 1,746 (32.7%) |
| Procedure | 8,710 (42.3%) | 460 (5.3%) | 4,925 (56.5%) | 3,325 (38.2%) |
| Behavioral | 4,543 (22.1%) | 122 (2.7%) | 3,239 (71.3%) | 1,182 (26.0%) |
| Other | 1,199 (5.8%) | 78 (6.5%) | 819 (68.3%) | 302 (25.2%) |
| **Geography**** | | | | |
| Canada | 680 (3.3%) | 61 (9.0%) | 362 (53.2%) | 257 (37.8%) |
| Europe | 4,467 (21.7%) | 254 (5.7%) | 2,693 (60.3%) | 1,520 (34.0%) |
| UK | 2,306 (11.2%) | 154 (6.7%) | 1,399 (60.7%) | 753 (32.7%) |
| USA | 4,465 (21.7%) | 284 (6.4%) | 2,592 (58.1%) | 1,589 (35.6%) |
| Other | 4,165 (20.3%) | 253 (6.1%) | 2,444 (58.7%) | 1,468 (35.3%) |
| **Publication Year - Avg (Std)** | 2001 (10.2) | 2005 (8.1) | 2001 (10.4) | 2001 (9.9) |
| **Study Age at Review - Avg (Std)** | 13.44 (10.1) | 9.81 (8.0) | 13.39 (10.3) | 14.14 (9.9) |

**Table 1. Descriptive statistics.** Unless otherwise specified, column 1 reports the number of studies and their proportion as of the total number of studies (N=20,571). Columns 2-4 report the number of studies in each category and their proportion as of the number of studies in column 1. For number of authors, publication year and study age at time of review, Table 1 reports the average and standard deviation. *One study can belong to several technology categories. ** For some studies, affiliation address is not provided.




Fig. 1. Proportion of trials at low risk, high risk and unclear risk, for each dimension assessed. An observation is a study assessed on all six dimensions (N=20,571).




**Fig. 2. Evolution of methods and reporting over time.** (A) Proportion of studies using "Adequate Methods", "Inadequate Methods" and "Poorly Reported". (B) to (G) Proportion of studies at low, high and unclear risk for (B) random sequence generation, (C) allocation concealment, (D) blinding of participants and personnel, (E) blinding of outcome assessment, (F) incomplete outcome data, and (G) selective reporting (N=20,571).

Fig. 2. Evolution of methods and reporting over time.




Fig. 3. Main regression results predicting relative risk ratios (RRR) for overall quality. RRR and 95% confidence intervals from estimating the multinomial logit model. An observation is a study (N=11,686). The dependent variable can take three values: adequate methods, inadequate methods and poor reporting. The reference category is adequate methods. Omitted sector category is other university, omitted technology category includes all other interventions, and omitted countries include all other countries. The regression includes topic and year fixed effects.




Fig. A1: Data flow and analysis sample




Fig. A2: This figure represents the proportion of studies at "low risk of bias", "high risk of bias", or "unclear risk of bias" for each dimension assessed, by publication year. An observation is a study. On each dimension, all studies assessed are included.

**Supplementary Materials, Tables and Figures**

**Appendix A: List of top 25 universities in clinical medicine and pharmacy (AWRU, 2007)**

- Harvard University
- University of California, San Francisco
- University of Washington
- The Johns Hopkins University
- Columbia University
- University of California, Los Angeles
- The University of Texas Southwestern Medical Center at Dallas
- University of Michigan - Ann Arbor
- Karolinska Institute
- University of Pittsburgh
- Stanford University
- Mayo Medical School
- University of Oxford
- University of Minnesota, Twin Cities
- University of Cambridge
- Yale University
- University College London
- The University of Texas M. D. Anderson Cancer Center
- University of Wisconsin - Madison
- Vanderbilt University
- University of Pennsylvania
- Duke University
- University of California, San Diego
- Tufts University
- The Imperial College of Science, Technology and Medicine

**Appendix B: List of top pharmaceutical companies used in this study (by revenue)**

- Johnson & Johnson
- Roche
- Pfizer
- Novartis
- Bayer
- Merck & Co
- GlaxoSmithKline
- Sanofi
- Abbvie
- Abbott Laboratories
- Eli Lilly & Co
- Amgen
- Bristol-Myers Squibb
- Gilead Sciences
- AstraZeneca
- Teva Pharmaceutical Industries
- Boehringer Ingelheim
- Merck Group
- Novo Nordisk
- Takeda Pharmaceutical
- Allergan plc
- Shire
- Celgene
- Biogen

## Table A1: Cochrane Risk of Bias Assessment Tool

| Bias domain | Source of bias | Support for judgement | Review Authors judgement |
|---|---|---|---|
| Selection bias | Random sequence generation | Describe the method used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups. | Selection bias (biased allocation to intervention) due to inadequate generation of a randomized sequence. |
| Selection bias | Allocation concealment | Describe the method used to conceal the allocation sequence in sufficient detail to determine whether intervention allocations could have been foreseen before or during enrollment. | Selection bias (biased allocation to interventions) due to inadequate concealment of allocations before assignment. |
| Performance bias | Blinding of participants and personnel | Describe all measures used, if any, to blind participants and researchers from knowledge of which intervention a participant received. Provide any information relating to whether the intended blinding was effective. | Performance bias due to knowledge of the allocated intervention by participants and personnel during the study. |
| Detection bias | Blinding of outcome assessment | Describe all measures used, if any, to blind outcome assessment from knowledge of which intervention a participant received. Provide any information relating to whether the intended blinding was effective. | Performance bias due to knowledge of the allocated intervention by outcome assessment. |
| Attrition bias | Incomplete outcome data | Describe the completeness of outcome data for each main outcome, including attrition and exclusions from the analysis. State whether attritions and exclusions were reported, the numbers in each intervention group (compared with total randomized participants), reasons for attrition or exclusion where reported, and any re-inclusion in the analysis for the review. | Attrition bias due to amount, nature or handling of incomplete outcome data |
| Reporting bias | Selective reporting | State how selective outcome reporting was examined and what was found. | Reporting bias due to selective outcome reporting. |
| Other bias | Anything else, pre-specified | State any important concerns about bias not covered in other domains in the tool. | Bias due to problems not covered elsewhere. |

Source: Adapted from Higgins et al, 2011

**Table A2: Main regression results predicting adequate methods, inadequate methods and poor reporting (Relative Risk Ratios)**

| | Inadequate Methods | Poor Reporting |
|---|---|---|
| **Funding** | | |
| NIH Grant | 0.83 | 0.76 |
| Industry | 0.84* | 0.85 |
| **Sector (First Author)** | | |
| Top University | 0.76 | 0.76 |
| Government | 1.21 | 1.05 |
| Hospital | 1.19 | 1.16 |
| Non-Profit | 1.40 | 1.27 |
| Top Pharma | 0.43** | 0.74 |
| Other Firms | 1.38 | 1.06 |
| **Sector (Other Author)** | | |
| Any Firm | 0.66 | 0.79 |
| **Study/Team** | | |
| Registered trial | 0.42*** | 0.45*** |
| First Study | 0.90 | 0.80 |
| Second Study | 0.85 | 0.81 |
| Number of Authors | 0.95*** | 0.97*** |
| International | 0.51** | 0.64* |
| **Technology** | | |
| Drug | 0.50*** | 0.73* |
| Device | 1.71** | 1.23 |
| Procedure | 1.01 | 1.28 |
| Behavioral | 2.63*** | 1.44 |
| **Geography** | | |
| USA | 1.11 | 1.39* |
| Canada | 0.71 | 0.81 |
| Europe | 1.29* | 1.22 |
| UK | 1.06 | 0.91 |

* p<0.05, ** p<0.01, *** p<0.001

This table presents relative risk ratios and p-values from estimating the multinomial logit model. An observation in this regression is a study (N=11,686). The dependent variable can take three values: adequate methods, inadequate methods and poor reporting. The reference category is adequate methods. Omitted sector category is other university, omitted technology category includes all other interventions, and omitted countries include all other countries. The regression includes topic and year fixed effects.

**Table A3: Regression results predicting relative risk ratios for each dimension**

| | Random Sequence | | Allocation Conceal. | | Blinding PP | | Blinding OA | | Incomplete Data | | Selective Reporting | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | High | Unclear | High | Unclear | High | Unclear | High | Unclear | High | Unclear | High | Unclear |
| **Funding** | | | | | | | | | | | | |
| NIH Grant | 0.29*** | 0.90 | 0.51*** | 0.93 | 1.12 | 1.06 | 1.01 | 0.93 | 1.03 | 1.04 | 1.03 | 0.99 |
| Industry | 1.03 | 1.07 | 1.18 | 1.06 | 0.87* | 0.92 | 0.98 | 0.98 | 0.97 | 0.99 | 1.06 | 1.04 |
| **Sector (First Author)** | | | | | | | | | | | | |
| Top University | 0.99 | 0.96 | 0.91 | 0.88 | 0.85 | 0.83 | 0.84 | 0.85 | 0.90 | 1.05 | 1.19 | 1.08 |
| Government | 0.91 | 1.01 | 0.85 | 0.98 | 1.00 | 0.96 | 1.00 | 0.92 | 1.29** | 1.14 | 1.15 | 1.12 |
| Hospital | 1.07 | 1.06 | 1.05 | 1.00 | 1.08 | 0.96 | 1.12 | 1.04 | 1.05 | 0.95 | 0.89 | 1.03 |
| Non-Profit | 1.40 | 1.05 | 1.34 | 0.91 | 1.08 | 1.02 | 1.13 | 0.99 | 1.01 | 1.03 | 1.03 | 1.07 |
| Top Pharma | 0.49 | 0.96 | 0.60 | 0.83 | 0.34*** | 0.73 | 0.56* | 0.74 | 0.86 | 0.61 | 0.70 | 0.59* |
| Other Firms | 2.19 | 1.64* | 2.01 | 1.60* | 0.64 | 0.94 | 0.56 | 1.41 | 1.30 | 1.12 | 2.16* | 1.05 |
| **Sector (Other Author)** | | | | | | | | | | | | |
| Any Firm | 0.18** | 0.92 | 0.53 | 1.04 | 0.65** | 0.94 | 0.86 | 1.21 | 1.39* | 1.06 | 0.94 | 1.02 |
| **Study/Team** | | | | | | | | | | | | |
| Registered trial | 0.31*** | 0.42*** | 0.39*** | 0.41*** | 0.72*** | 0.60*** | 0.58*** | 0.63*** | 0.67*** | 0.71*** | 0.66*** | 0.52*** |
| First Study | 0.95 | 0.81** | 1.09 | 0.84* | 1.15 | 1.07 | 1.02 | 0.85 | 0.97 | 0.90 | 1.14 | 1.03 |
| Second Study | 1.00 | 0.83* | 1.01 | 0.80** | 1.02 | 1.03 | 1.04 | 1.01 | 0.87 | 0.88 | 1.06 | 1.01 |
| Number of Authors | 0.92*** | 0.97*** | 0.93*** | 0.95*** | 0.98** | 0.96*** | 0.95*** | 0.97*** | 0.98* | 0.99 | 0.99 | 0.96*** |
| International | 0.88 | 0.79* | 0.53* | 0.74** | 0.79 | 0.94 | 0.73* | 0.75* | 0.91 | 0.86 | 0.66* | 0.82 |
| **Technology** | | | | | | | | | | | | |
| Drug | 0.66* | 1.14 | 0.76 | 1.11 | 0.41*** | 0.48*** | 0.82 | 0.87 | 0.92 | 0.94 | 1.00 | 1.05 |
| Device | 1.31 | 1.02 | 1.34 | 1.10 | 1.52** | 0.93 | 1.27 | 0.93 | 0.91 | 1.02 | 1.02 | 0.83 |
| Procedure | 0.90 | 1.21** | 0.93 | 1.22* | 0.91 | 1.24 | 1.18 | 1.22 | 0.85 | 1.06 | 1.06 | 1.13 |
| Behavioral | 0.88 | 1.03 | 1.21 | 1.16 | 2.83*** | 1.53** | 2.09*** | 1.27 | 1.34** | 1.18 | 0.89 | 1.41* |
| **Geography** | | | | | | | | | | | | |
| USA | 1.04 | 1.15 | 0.93 | 1.12 | 0.73*** | 0.95 | 0.81 | 1.02 | 1.23* | 1.22* | 0.96 | 0.93 |
| Canada | 0.55 | 0.69** | 0.69 | 0.61*** | 0.75 | 0.75 | 0.85 | 0.66** | 0.94 | 1.09 | 0.76 | 0.88 |
| Europe | 0.80 | 1.05 | 0.79 | 0.96 | 1.13 | 1.05 | 1.29** | 1.09 | 1.13 | 0.97 | 1.01 | 0.92 |
| UK | 0.89 | 0.89 | 0.65** | 0.67*** | 1.03 | 0.87 | 1.11 | 0.96 | 1.04 | 1.01 | 1.07 | 0.86 |

Regression results predicting relative risk ratio for risk of bias for each dimension (reference category: low risk). *p<0.05, **p<0.01, ***p<0.001

STROBE Statement—checklist of items that should be included in reports of observational studies

| | Item No | Recommendation | Page No |
|---|---|---|---|
| **Title and abstract** | 1 | (*a*) Indicate the study's design with a commonly used term in the title or the abstract | 1,2 |
| | | (*b*) Provide in the abstract an informative and balanced summary of what was done and what was found | 2 |
| **Introduction** | | | |
| Background/rationale | 2 | Explain the scientific background and rationale for the investigation being reported | 4 |
| Objectives | 3 | State specific objectives, including any prespecified hypotheses | 4 |
| **Methods** | | | |
| Study design | 4 | Present key elements of study design early in the paper | 4 |
| Setting | 5 | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection | 4,5 |
| Participants | 6 | (*a*) *Cohort study*—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up<br>*Case-control study*—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls<br>*Cross-sectional study*—Give the eligibility criteria, and the sources and methods of selection of participants | 5 |
| | | (*b*) *Cohort study*—For matched studies, give matching criteria and number of exposed and unexposed<br>*Case-control study*—For matched studies, give matching criteria and the number of controls per case | N/A |
| Variables | 7 | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable | 5,6 |
| Data sources/ measurement | 8* | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group | 6 |
| Bias | 9 | Describe any efforts to address potential sources of bias | 7,8 |
| Study size | 10 | Explain how the study size was arrived at | 5 |
| Quantitative variables | 11 | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why | N/A |
| Statistical methods | 12 | (*a*) Describe all statistical methods, including those used to control for confounding | 7 |
| | | (*b*) Describe any methods used to examine subgroups and interactions | N/A |
| | | (*c*) Explain how missing data were addressed | 8 |
| | | (*d*) *Cohort study*—If applicable, explain how loss to follow-up was addressed<br>*Case-control study*—If applicable, explain how matching of cases and controls was addressed<br>*Cross-sectional study*—If applicable, describe analytical methods taking account of sampling strategy | N/A |
| | | (*e*) Describe any sensitivity analyses | N/A |

Continued on next page

| | | | |
|---|---|---|---|
| **Results** | | | |
| Participants | 13* | (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed | 5 |
| | | (b) Give reasons for non-participation at each stage | 5 |
| | | (c) Consider use of a flow diagram | 32 |
| Descriptive data | 14* | (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders | 21 |
| | | (b) Indicate number of participants with missing data for each variable of interest | 21 |
| | | (c) *Cohort study*—Summarise follow-up time (eg, average and total amount) | N/A |
| Outcome data | 15* | *Cohort study*—Report numbers of outcome events or summary measures over time | 23 |
| | | *Case-control study*—Report numbers in each exposure category, or summary measures of exposure | N/A |
| | | *Cross-sectional study*—Report numbers of outcome events or summary measures | N/A |
| Main results | 16 | (*a*) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included | 7,8,9 |
| | | (*b*) Report category boundaries when continuous variables were categorized | N/A |
| | | (*c*) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period | N/A |
| Other analyses | 17 | Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses | N/A |
| **Discussion** | | | |
| Key results | 18 | Summarise key results with reference to study objectives | 9,10 |
| Limitations | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias | 10 |
| Interpretation | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence | 9,10 |
| Generalisability | 21 | Discuss the generalisability (external validity) of the study results | 8 |
| **Other information** | | | |
| Funding | 22 | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based | 11 |

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

# Trends and Predictors of Biomedical Research Quality, 1990-2015: A Meta-Research Study



| | |
|---|---|
| Journal: | *BMJ Open* |
| Manuscript ID | bmjopen-2019-030342.R1 |
| Article Type: | Research |
| Date Submitted by the Author: | 13-May-2019 |
| Complete List of Authors: | Catillon, Maryaline; Harvard University, Ph.D. Program in Health Policy |
| Primary Subject Heading: | Research methods |
| Secondary Subject Heading: | Health policy, Health informatics, Health economics |
| Keywords: | STATISTICS & RESEARCH METHODS, Health informatics < BIOTECHNOLOGY & BIOINFORMATICS, Health policy < HEALTH SERVICES ADMINISTRATION & MANAGEMENT |
| | |

# Trends and Predictors of Biomedical Research Quality, 1990-2015:

# A Meta-Research Study

**Word count: 2855 (main text)**



Maryaline Catillon (0000-0002-1360-8133)

Ph.D. Program in Health Policy, Harvard University, 14 Story Street, 4th Floor, Cambridge, MA 02138

mcatillon@g.harvard.edu

(+1) 857 222 6863

## ABSTRACT

**Objective:** To measure the frequency of adequate methods, inadequate methods and poor reporting in published randomized controlled trials and test potential factors associated with adequacy of methods and reporting.

**Design:** Retrospective analysis of randomized controlled trials (RCTs) included in Cochrane reviews. Time series describe the proportion of RCTs using adequate methods, inadequate methods and poor reporting. A multinomial logit model tests potential factors associated with methods and reporting, including funding source, first author affiliation, clinical trial registration status, study novelty, team characteristics, technology and geography.

**Data:** Risk of bias assessments for random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data and selective reporting, for each RCT, were mapped to bibliometric and funding data.

**Outcomes:** Risk of bias on six methodological dimensions, and RCT-level overall assessment of adequate methods, inadequate methods or poor reporting.

**Results:** This study analyzed 20,571 RCTs. 5.7% of RCTs used adequate methods (N=1,173). 59.3% used inadequate methods (N=12,190) and 35.0% were poorly reported (N=7,208). The proportion of poorly reported RCTs decreased from 42.5% in 1990 to 30.2% in 2015. The proportion of RCTs using adequate methods increased from 2.6% in 1990 to 10.3% in 2015. The proportion of RCTs using inadequate methods increased from 54.9% in 1990 to 59.5% in 2015. Industry funding, top pharmaceutical company affiliation, trial registration, larger authorship teams, international teams, and drug trials were associated with a greater likelihood of using adequate methods. NIH funding and university prestige were not.

**Conclusion:** Even though reporting has improved since 1990, the proportion of RCTs using inadequate methods is high (59.3%) and increasing, potentially slowing progress in medical knowledge and contributing to the reproducibility crisis. Stronger incentives for the use of adequate methods are needed.

## STRENGTHS AND LIMITATIONS OF THIS STUDY

- This work combines the strengths of expert human assessments with data science techniques to build a comprehensive database on biomedical research quality, including the full-text and systematic assessment of RCT methods with bibliometric and funding information in a sample of 20,571 RCTs.
- The study analyzes trends in methods and reporting over 25 years and identifies factors associated with biomedical research quality including funding source, first author affiliation, clinical trial registration status, study novelty, team characteristics, technology and geography.
- PubMed identifier, full-text and/or funding information were not available for all RCTs. 30.5% of RCTs (unpublished or published in journals not indexed in PubMed) did not have a PubMed identifier. 43.2% of RCTs with PubMed identifier did not have a full-text available from the Harvard Library. 23.6% of included RCTs were reported in articles disclosing NIH or industry funding. Classification of sectors relies on primary reported affiliation.
- Cochrane reviewers may have been able to obtain more information on more recent RCTs (from authors, registries, or protocols rather than the primary report), suggesting some of the apparent improvement in reporting may reflect an improvement in access to study details.

- This study does not identify causal mechanisms explaining biomedical research quality.

## INTRODUCTION

The quality and reliability of biomedical research are of paramount importance to treatment decisions and patient outcomes. Flawed research conclusions can lead to poor treatment and harm patients. As much as 85% of the annual $265 billion spent on biomedical research may be wasted due to inadequate methods.[1-8]

Previous scientific work aiming to evaluate the reliability of biomedical research has been limited by data and methodological issues. Data challenges included the time and resources necessary to assess methods and reporting, resulting in the use of small selected samples and/or limited information available for each scientific article evaluated in larger samples.[9-28] As a result, it remains unknown what is the overall magnitude of waste due to inadequate methods and reporting in biomedical research and what factors are associated with the use of adequate versus inadequate research methods.

To address these questions, this study combines the full text of RCTs and full systematic assessment of study methods with bibliometric and funding information in a large sample of RCTs included in "gold standard" systematic reviews. The study describes the evolution of adequate research methods and reporting over time. A multinomial logit model tests potential factors associated with methods and reporting, including funding source, first author affiliation, clinical trial registration status, study novelty, team characteristics, technology and geography.

## METHODS

This work combines the strengths of human expert assessments with data science techniques to build a comprehensive database on biomedical research quality, including full-text, systematic

assessment of study methods, bibliometric and funding information in a sample of 20,571 RCTs. Python 3.6 and Stata 15 were used to assemble the database and conduct the analysis.

**Data**

Cochrane reviews constitute a valuable data source to assess biomedical research quality as they follow strict methods and precise reporting guidelines defined in the Cochrane Handbook.[29-30] This study does not involve new assessment of the methods and reporting of included RCTs, but relies entirely on the assessments available in the Cochrane reviews, which are systematically performed by two expert reviewers who compare their assessments and reach consensus on the final assessment.[29] The research method dimensions evaluated in Cochrane reviews include random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, and selective reporting (detailed in Supplementary Table A1).[31]

The database assembly had seven steps: (1) All included references were extracted from each review, including PubMed identifiers. (2) All risk of bias assessments on the six dimensions of the 2011 update of the Cochrane Risk of Bias Assessment Tool (see Table A1) were extracted from each review. Each assessment included three variables: bias type (e.g., random sequence generation), judgement (e.g., low risk) and support for judgement (e.g., computer random number generator). (3) Each RCT was matched with its main published reference as identified by Cochrane reviewers. (4) PubMed records corresponding to these publications, including bibliometric information and first author affiliation, were retrieved using the E-utilities public API. (5) Affiliation information for other authors (not available from PubMed over the study period) was retrieved from SCOPUS. (6) Full-text for references with PubMed identifier were

retrieved from the Harvard Library. (7) Industry funding information was extracted from the full-text PDFs.

Sector affiliation with university, government, hospital, non-profit, top pharmaceutical company or other firm, as well as geographic variables were derived from the first author affiliation address. Top 25 Universities were identified using the 2007 Academic Ranking of World Universities in Clinical Medicine and Pharmacy (see supplementary material, Appendix A). Firms were classified as top pharmaceutical companies or other firms using the listing of pharmaceutical companies with a revenue greater than $10 billion in any year since 2011 (see supplementary material, Appendix B). Technologies were retrieved from the keywords and abstracts of the Cochrane Reviews. Private funding information was retrieved from the full-text PDF of the main reference.

**Sample**

Figure 1 summarizes the data flow. All RCTs assessed for risk of bias after 2011 (update of the Risk of Bias Assessment Tool) and through October 2017 were considered for inclusion (N=63,748 RCTs included in 4,195 reviews). This list of Cochrane reviews is reported in Appendix C.

Criteria for study inclusion were: (1) the review included all six assessments (to allow comparison of the overall use of adequate methods, inadequate methods and poor reporting across reviews) (1,988 reviews dropped), (2) the article reporting the study was referenced in PubMed (to allow bibliometric data to enter the analysis)(N=9,201 RCTs dropped) and (3) Duplicates were removed. (4) RCTs assessed multiple times with different outcomes (e.g., high risk in one review, unclear risk in another) were dropped. (N=404 RCTs dropped).

Applying these criteria, the analysis sample for the descriptive statistics and the time-series of methods included 20,571 RCTs. A full-text PDF was available from the Harvard Library for 11,686 RCTs. This subsample was needed to retrieve private funding information from the full-text of the paper and constitutes the analysis sample for those regressions including funding information.

**Analysis**

The outcomes were risk of bias on the six assessed methodological dimensions and RCT-level assessment of adequate methods, inadequate methods or poor reporting. The six methodological dimensions assessed included (1) random sequence generation, (2) allocation concealment, (3) blinding of participants and personnel, (4) blinding of outcome assessment, (5) incomplete outcome data and (6) selective reporting (detailed in Supplementary Table A1). The category "Other bias" was not used in this study, as it includes concerns not necessarily about methods or reporting, such as conflicts of interest.

Following guidelines for assessing the quality of evidence[31] and previous empirical work [7], the RCT-level assessment was "adequate methods" if the study was at low risk of bias on all dimensions assessed. It was "inadequate methods" if the study was at high risk of bias for one or more reasons. It was "poorly reported" if the reviewers did not have enough information to assess whether the methods used were adequate or inadequate (if the study was at "unclear" risk of bias for at least one reason).

Several reasons support the use of at least one high risk of bias assessment as the definition for inadequate methods. Some risk of bias domains might translate into more statistical bias than others, but empirical evidence on the relative importance of the risk of bias domains is limited,

and the effect of several versus one high risk assessment on research outcomes is unknown[32,33] The empirical relationship between risk of bias assessments and research outcomes (including actual statistical bias) requires further research.

There is also a theoretical reason to use at least one high risk of bias assessment as the definition of method inadequacy. Cochrane risk of bias domains can be mapped to important conditions to make RCTs valuable. If not truly randomized or if differences between the treatment and control group are introduced post-randomization, a RCT may not produce an unbiased estimate of the treatment effect.[34] These two conditions imply that one inadequacy in the randomization process (non-random sequence generation or inadequate allocation concealment), or one difference introduced post randomization between the treatment and control groups (through inadequate blinding of participants, personnel, or outcome assessors) or after the trial (due to incomplete outcome data or selective reporting) should be the default threshold for assessing methods adequacy.

Two analyses were performed. The first reports the time series of the proportion of RCTs using adequate methods, inadequate methods and poor reporting, for each dimension and in aggregate. The second tests whether adequate methods, inadequate methods and poor reporting are associated with funding source (NIH grant or industry funding), sector affiliation of first author (Top University, Other University, Government, Hospital, Non-Profit, Top Pharmaceutical Company, Other Firm), other industry affiliation, clinical trial registration status, study novelty (first or subsequent study on a particular research question), team characteristics (number of authors and international collaboration), technology (drug, device, surgery, behavioral intervention or other intervention), and geography of first author (Canada, Europe, UK, USA, or other country). A multinomial logit model using these variables predicts overall adequate

methods, inadequate methods and poor reporting, as well as risk of bias along each dimension assessed.

**Patient involvement**

Patients were not involved in any aspect of the study design, conduct, or in the development of the research question or outcome measures. As a meta-research study, based on existing published research, there was no patient recruitment for data collection.

**RESULTS**

**Prevalence of Adequate Methods, Inadequate Methods, and Poor Reporting**

Table 1 presents descriptive statistics. Only 5.7% of RCTs used adequate methods on all six dimensions (N=1,173). 59.3% used inadequate methods on at least one dimension (N=12,190) and 35.0% were poorly reported (N=7,208).

Figure 2 shows the proportion of RCTs at low, high or unclear risk of bias for random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data and selective reporting, for all RCTs assessed on all six dimensions (N=20,571). 38% of trials used inadequate methods for blinding of participants and personnel. 15 to 20% of trials used inadequate methods for blinding of outcome assessment (20%), incomplete outcome data (19%) and selective reporting (15%). The proportion of trials using inadequate methods for random sequence generation and allocation concealment was lowest (respectively 5% and 7%), but these two dimensions were frequently poorly reported (respectively 47% and 58% of trials).

**Methods and reporting over time**

Figure 3 shows the overall proportion of RCTs using adequate methods, inadequate methods and poorly reported methods by year of publication. The proportion of poorly reported RCTs decreased, 5 percentage points per decade, from 42.5% in 1990 to 30.2% in 2015. The proportion of RCTs using adequate methods increased linearly, 3 percentage points per decade, from 2.6% in 1990 to 10.3% in 2015. The proportion of RCTs using inadequate methods increased from 54.9% in 1990 to 59.5% in 2015.

Reporting improved on all dimensions. The proportion of RCTs using adequate methods for random sequence generation, allocation concealment, blinding of outcome assessment, incomplete outcome data and selective reporting increased. In contrast, the proportion of trials using inadequate methods for blinding of participants and personnel increased.

Figure 4 provides graphs similar to figure 3 for all RCTs assessed on at least one dimension (N=63,748). Similar patterns suggest that the evolution over time observed for the RCTs assessed on all dimensions (N=20,571) reflects the evolution over time in all RCTs assessed on at least one dimension.

**Factors associated with methods and reporting**

Figure 5 reports regression results from a multinomial logit model predicting overall quality. Tables A2 and A3 (Supplementary material) report all regression results.

Public funding was not associated with the overall use of adequate methods. However, NIH funded RCTs were less likely to use inadequate methods for random sequence generation (RR=0.29, p<0.001) and allocation concealment (RR=0.51, p<0.001). Industry funded RCTs were slightly more likely to use adequate methods (RR=0.84, p<0.05), because of better blinding of participants and personnel (RR=0.87, p<0.05).

First author affiliation with a top pharmaceutical company was associated with increased use of adequate methods (RR=0.43, p<0.01). First author affiliation with top universities was not.

Registered trials (RR=0.42, p<0.001), larger authorship teams (RR=0.95, p<0.001), international teams (RR=0.51, p<0.01) and RCTs on drugs (RR=0.50, p<0.001) were less likely to use inadequate methods. RCTs on medical devices were more likely to use inadequate methods (RR=1.71, p<0.01).

## DISCUSSION

In 1951, the first review assessing the quality of clinical trials found that only 27 of 100 were well controlled[35,36]. Since, a steady stream of scholarly work periodically voiced concerns about the quality of medical research[37,38,1-8]. Recent medical reversals[39], and the reproducibility crisis[40], have sharpened focus on medical research quality. Newly available large scale data, and data science techniques provide powerful tools to measure the overall magnitude of the problem, investigate its determinants, and provide an evidence base to inform the design and evaluation of future interventions. This study assessed whether methods and reporting improved over time and identified the characteristics of better and worse RCTs.

This study has six main results. First, in a large sample of RCTs assessed in systematic reviews, only 5.7% used adequate methods, 59.3% used inadequate methods, and 35.0% were poorly reported. Since the 1990s, reporting has improved. But in parallel with this improvement in reporting, the proportion of trials using both adequate and inadequate methods has increased.

The overall proportion of poorly reported trials decreased by about 5 percentage points per decade. This is good news but much remains to be done. At the current rate of improvement, it would take 50 years for 95% of RCTs to be adequately reported. These results are consistent

with previous research finding improvements in reporting in several clinical areas such as physiotherapy[10], and dentistry[26]. The trends for each dimension assessed separately are also very similar to those found in another large sample of RCTs.[25]

These improvement in reporting happened over a period of time when the Consolidated Standards of Reporting Trials (CONSORT) statement, a minimum set of evidence-based reporting recommendations, and other initiatives, such as the EQUATOR Network, developed to improve reporting practices.[41-45]. Since the 1990s, the CONSORT statement has been endorsed by over 50% of the core clinical journals indexed in PubMed and may improve reporting of RCTs they publish.[46] Spurred by the CONSORT statement, the EQUATOR (Enhancing the QUAlity and Transparency Of health Research) Network, was launched in 2008 in the UK to improve the reliability of medical publications by promoting transparent and accurate reporting of health research.[47] Since, it has developed into a global initiative aiming to improve research reporting worldwide.[36]

In parallel with this improvement in reporting, the proportion of trials using both adequate and inadequate methods has increased. The linear increase in the proportion of RCTs using adequate methods is heartening. However, improvement in the use of adequate methods is even slower than improvement in reporting. At the current rate of improvement (3 percentage points per decade), it would take more than a century for half the RCTs to use adequate methods. This finding is consistent with previous empirical results in small samples,[23] but contrasts with research in larger samples analyzing each methodological dimension separately to conclude that methods improved over time.[25]

Second, NIH funded RCTs were not more likely to use adequate methods. This is surprising given the rigorous grant application process, shown to select better scientific proposals,[48] and

the public stakes in the reliability of publicly funded research.[49] Notably, the efforts of the NIH to address the reproducibility crisis began just at the end of the study period.[50]

Third, top pharmaceutical company affiliation was significantly associated with better methods. Affiliation with other companies was not. Heterogeneity across firms may explain inconsistency of previous research on the effect of industry funding or affiliation on research methods and outcomes. [28,51]

Fourth, University prestige was not associated with greater use of adequate methods. The current scientific reward system focuses on numbers of publications and citations rather than the assessment of research methods.[52] The resulting incentives affect both scientists and institutions, as through the allocation of grant funding.[53,54] Thus, in a climate of hypercompetition,[55] the use of adequate methods and reporting might yield little reward while exposing scientists to better informed scrutiny.

Fifth, team size and international collaboration were associated with greater use of adequate methods. Increasing the number of authors by one was associated with a small, but highly significant improvement in methods and reporting. Many RCTs are published by large teams so it is not surprising that the effect of one additional author was small. But this effect was also highly significant, consistent with previous research finding that larger teams and international teams produce more frequently cited research.[56,57] Other team characteristics were associated with performance in other settings, opening avenues for future research.[58,59]

Finally, RCTs on drugs were more likely to use adequate methods than RCTs on other interventions, while RCTs on devices were more likely to use inadequate methods. In many countries, trials on drugs are more tightly regulated than trials on devices. In the US, under the Federal Food, Drug, and Cosmetic Act (FDCA, 1938), drugs and devices face different

premarket review and post-market compliance requirements. The finding is also consistent with specific barriers to the conduct of RCTs on medical devices, in particular for randomization and blinding, and with the lack of scientific advice and regulations for medical device trials [60]. RCTs on drugs were using better methods and reporting than RCTs on other interventions, but much remains to be done. This finding is consistent with previous work showing that even RCTs used in the drug approval process frequently use inadequate methods and reporting.[61]

Future research should carefully evaluate the effect of method adequacy on research outcomes, and identify successful strategies and incentives to accelerate the diffusion of good reporting practices and the adoption of adequate methods. Given the size of the medical research industry and its effect on human lives, successful evidence based policies could have tremendous impact.

**Limitations**

PubMed identifier, full-text and/or funding information were not available for all RCTs. 30.5% of RCTs (unpublished or published in journals not indexed in PubMed) did not have a PubMed identifier. 43.2% of RCTs with PubMed identifier did not have a full-text available from the Harvard Library. 23.6% of included RCTs were reported in articles disclosing NIH or industry funding. Classification of sectors relies on primary reported affiliation. This paper does not identify causal mechanisms explaining biomedical research quality.

Cochrane reviewers may have been able to obtain more information on more recent RCTs (from authors, registries, or protocols rather than the primary report), suggesting that some of the apparent improvement in reporting may in fact be an improvement in access to study details.

**CONCLUSION**

Even though reporting has improved since 1990, the proportion of RCTs using inadequate methods is high (59.3%) and increasing, potentially slowing progress in medical knowledge and contributing to the reproducibility crisis. Stronger incentives for the use of adequate methods are needed.

**Contributorship statement**

Maryaline Catillon designed the study, performed the analysis, interpreted the results, wrote the manuscript and approved the final version to be published. Maryaline Catillon accepts full responsibility for the work and the conduct of the study, had access to the data, and controlled the decision to publish.

**Acknowledgments**

The author thanks David Cutler, Richard Freeman, Mack Lipkin, Ariel Stern, Richard Zeckhauser and the participants at the NBER-IFS International Network on the Value of Medical Research meetings for helpful conversations and feedback, and Harvard Business School Research Computing Services for technical advice and support. The author also thanks the editors and the two referees, Paul Glasziou and Simon Gandevia, for their most helpful and generous feedback and clear guidance.

**Funding Statement**

Maryaline Catillon gratefully acknowledges support by the National Institute on Aging of the National Institutes of Health under Award Number R24AG048059 to the National Bureau of Economic Research (NBER). The content of this article is solely the responsibility of the author and does not necessarily represent the official views of the National Institutes of Health or the NBER.

## Competing Interests Statement

Maryaline Catillon has completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declares: the author reports grants from the National Institute on Aging of the National Institutes of Health during the conduct of the study.

## Ethical approval

Not applicable. This is a meta-research study.

## Data sharing

All data sources necessary to reproduce the analysis are described in the main text or the supplementary material. No additional data available.

## Licence statement

## Bibliography


1. Chalmers I, Glasziou P. Avoidable waste in the production and reporting of research evidence. The Lancet. 2009 Jul 4;374(9683):86-9.
2. Macleod MR, Michie S, Roberts I, Dirnagl U, Chalmers I, Ioannidis JP, Salman RA, Chan AW, Glasziou P. Biomedical research: increasing value, reducing waste. The Lancet. 2014 Jan 11;383(9912):101-4.
3. Chalmers I, Bracken MB, Djulbegovic B, Garattini S, Grant J, Gülmezoglu AM, Howells DW, Ioannidis JP, Oliver S. How to increase value and reduce waste when research priorities are set. The Lancet. 2014 Jan 11;383(9912):156-65.
4. Glasziou P, Altman DG, Bossuyt P, Boutron I, Clarke M, Julious S, Michie S, Moher D, Wager E. Reducing waste from incomplete or unusable reports of biomedical research. The Lancet. 2014 Jan 18;383(9913):267-76.
5. Ioannidis JP, Greenland S, Hlatky MA, Khoury MJ, Macleod MR, Moher D, Schulz KF, Tibshirani R. Increasing value and reducing waste in research design, conduct, and analysis. The Lancet. 2014 Jan 11;383(9912):166-75.
6. Moses H, Matheson DH, Cairns-Smith S, George BP, Palisch C, Dorsey ER. The anatomy of medical research: US and international comparisons. Jama. 2015 Jan 13;313(2):174-89.
7. Yordanov Y, Dechartres A, Porcher R, Boutron I, Altman DG, Ravaud P. Avoidable waste of research related to inadequate methods in clinical trials. bmj. 2015 Mar 24;350:h809.
8. Moher D, Glasziou P, Chalmers I, Nasser M, Bossuyt PM, Korevaar DA, Graham ID, Ravaud P, Boutron I. Increasing value and reducing waste in biomedical research: who's listening?. The Lancet. 2016 Apr 9;387(10027):1573-86.

9. Lee KP, Schotland M, Bacchetti P, Bero LA. Association of journal quality indicators with methodological quality of clinical research articles. Jama. 2002 Jun 5;287(21):2805-8.
10. Moseley AM, Herbert RD, Maher CG, Sherrington C, Elkins MR. Reported quality of randomized controlled trials of physiotherapy interventions has improved over time. Journal of clinical epidemiology. 2011 Jun 1;64(6):594-601.
11. Bala MM, Akl EA, Sun X, Bassler D, Mertz D, Mejza F, Vandvik PO, Malaga G, Johnston BC, Dahm P, Alonso-Coello P. Randomized trials published in higher vs. lower impact journals differ in design, conduct, and analysis. Journal of clinical epidemiology. 2013 Mar 1;66(3):286-95.
12. Lee SY, Teoh PJ, Camm CF, Agha RA. Compliance of randomized controlled trials in trauma surgery with the CONSORT statement. Journal of Trauma and Acute Care Surgery. 2013 Oct 1;75(4):562-72.
13. Agha RA, Camm CF, Doganay E, Edison E, Siddiqui MR, Orgill DP. Randomised controlled trials in plastic surgery: a systematic review of reporting quality. European journal of plastic surgery. 2014 Feb 1;37(2):55-62.
14. Chen B, Liu J, Zhang C, Li M. A retrospective survey of quality of reporting on randomized controlled trials of metformin for polycystic ovary syndrome. Trials. 2014 Dec;15(1):128.
15. Chen X, Zhai X, Wang X, Su J, Li M. Methodological reporting quality of randomized controlled trials in three spine journals from 2010 to 2012. European Spine Journal. 2014 Aug 1;23(8):1606-11.
16. Kim KH, Kang JW, Lee MS, Lee JD. Assessment of the quality of reporting for treatment components in Cochrane reviews of acupuncture. BMJ open. 2014 Jan 1;4(1):e004136.

17. Lempesi E, Koletsi D, Fleming PS, Pandis N. The reporting quality of randomized controlled trials in orthodontics. Journal of Evidence Based Dental Practice. 2014 Jun 1;14(2):46-52.

18. Yao AC, Khajuria A, Camm CF, Edison E, Agha R. The reporting quality of parallel randomised controlled trials in ophthalmic surgery in 2011: a systematic review. Eye. 2014 Nov;28(11):1341.

19. Zhuang L, He J, Zhuang X, Lu L. Quality of reporting on randomized controlled trials of acupuncture for stroke rehabilitation. BMC complementary and alternative medicine. 2014 Dec;14(1):151.

20. Chen Z, Chen Y, Zeng J, Wang Y, Ye T, Zhou Q, Du X, Su W, Ding Z. Quality of randomized controlled trials reporting in the treatment of melasma conducted in China. Trials. 2015 Dec;16(1):156.

21. Glujovsky D, Boggino C, Riestra B, Coscia A, Sueldo CE, Ciapponi A. Quality of reporting in infertility journals. Fertility and sterility. 2015 Jan 1;103(1):236-41.

22. Kloukos D, Papageorgiou SN, Doulis I, Petridis H, Pandis N. Reporting quality of randomised controlled trials published in prosthodontic and implantology journals. Journal of oral rehabilitation. 2015 Dec;42(12):914-25.

23. Reveiz L, Chapman E, Asial S, Munoz S, Bonfill X, Alonso-Coello P. Risk of bias of randomized trials over time. Journal of clinical epidemiology. 2015 Sep 1;68(9):1036-45.

24. Zhai X, Wang Y, Mu Q, Chen X, Huang Q, Wang Q, Li M. Methodological reporting quality of randomized controlled trials in 3 leading diabetes journals from 2011 to 2013 following CONSORT statement: a system review. Medicine. 2015 Jul;94(27).

25. Dechartres A, Trinquart L, Atal I, Moher D, Dickersin K, Boutron I, Perrodeau E, Altman DG, Ravaud P. Evolution of poor reporting and inadequate methods over time in 20 920 randomised controlled trials included in Cochrane reviews: research on research study. BMJ. 2017 Jun 8;357:j2490.

26. Saltaji H, Armijo-Olivo S, Cummings GG, Amin M, Flores-Mir C. Randomized clinical trials in dentistry: Risks of bias, risks of random errors, reporting quality, and methodologic quality over the years 1955–2013. PloS one. 2017 Dec 22;12(12):e0190089.

27. Karlsen AP, Dahl JB, Mathiesen O. Evolution of bias and sample size in postoperative pain management trials after hip and knee arthroplasty. Acta Anaesthesiologica Scandinavica. 2018 May;62(5):666-76.

28. Salandra R. Knowledge dissemination in clinical trials: exploring influences of institutional support and type of innovation on selective reporting. Research Policy. 2018 Sep 1;47(7):1215-28.

29. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions [updated March 2011]. The Cochrane Collaboration 2011; Available from http://handbook.cochrane.org/.

30. Page MJ, Shamseer L, Altman DG, Tetzlaff J, Sampson M, Tricco AC, Catalá-López F, Li L, Reid EK, Sarkis-Onofre R, Moher D. Epidemiology and reporting characteristics of systematic reviews of biomedical research: a cross-sectional study. PLoS medicine. 2016 May 24;13(5):e1002028.

31. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savović J, Schulz KF, Weeks L, Sterne JA. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. Bmj. 2011 Oct 18;343:d5928.

32. Savović J, Turner RM, Mawdsley D, Jones HE, Beynon R, Higgins JP, Sterne JA. Association between risk-of-bias assessments and results of randomized trials in cochrane reviews: the ROBES meta-epidemiologic study. American Journal of Epidemiology. 2017 Oct 19;187(5):1113-22.

33. Rhodes KM, Turner RM, Savović J, Jones HE, Mawdsley D, Higgins JP. Between-trial heterogeneity in meta-analyses may be partially explained by reported design characteristics. Journal of clinical epidemiology. 2018 Mar 1;95:45-54.

34. Deaton A, Cartwright N. Understanding and misunderstanding randomized controlled trials. Social Science & Medicine. 2018 Aug 1;210:2-1.

35. Ross OB. Use of controls in medical research. Journal of the American Medical Association. 1951 Jan 13;145(2):72-5.

36. Altman, D.G. and Simera, I., 2016. A history of the evolution of guidelines for reporting medical research: the long road to the EQUATOR Network. Journal of the Royal Society of Medicine, 109(2), pp.67-77.

37. DerSimonian R, Charette LJ, McPeek B, Mosteller F. Reporting on methods in clinical trials. New England Journal of Medicine. 1982 Jun 3;306(22):1332-7.

38. Pocock SJ, Hughes MD, Lee RJ. Statistical problems in the reporting of clinical trials. New England journal of medicine. 1987 Aug 13;317(7):426-32.

39. Prasad V, Vandross A, Toomey C, Cheung M, Rho J, Quinn S, Chacko SJ, Borkar D, Gall V, Selvaraj S, Ho N. A decade of reversal: an analysis of 146 contradicted medical practices. In Mayo Clinic Proceedings 2013 Aug 1 (Vol. 88, No. 8, pp. 790-798). Elsevier.

40. Baker M. 1,500 scientists lift the lid on reproducibility. Nature News. 2016 May 26;533(7604):452.

41. Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, Pitkin R, Rennie D, Schulz KF, Simel D, Stroup DF. Improving the quality of reporting of randomized controlled trials: the CONSORT statement. Jama. 1996 Aug 28;276(8):637-9.

42. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomized trials. BMC medical research methodology. 2001 Dec;1(1):2.

43. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMC medicine. 2010 Dec;8(1):18.

44. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, Gøtzsche PC, Lang T. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Annals of internal medicine. 2001 Apr 17;134(8):663-94.

45. Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. Journal of clinical epidemiology. 2010 Aug 1;63(8):e1-37.

46. Turner L, Shamseer L, Altman DG, Schulz KF, Moher D. Does use of the CONSORT Statement impact the completeness of reporting of randomised controlled trials published in medical journals? A Cochrane review a. Systematic reviews. 2012 Dec;1(1):60.

47. Altman DG, Simera I, Hoey J, Moher D, Schulz K. EQUATOR: reporting guidelines for health research. The Lancet. 2008 Apr 5;371(9619):1149-50.

48. Li D, Agha L. Big names or big ideas: do peer-review panels select the best science proposals?. Science. 2015 Apr 24;348(6233):434-8.

49. Sampat BN. Mission-oriented biomedical research at the NIH. Research Policy. 2012 Dec 1;41(10):1729-41.

50. Collins FS, Tabak LA. NIH plans to enhance reproducibility. Nature. 2014 Jan 30;505(7485):612-3.

51. Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. Industry sponsorship and research outcome. Cochrane Database Syst Rev. 2012 Dec 12;12(12).

52. Stephan PE. How economics shapes science. Cambridge, MA: Harvard University Press; 2012 Sep.(p.228-241)

53. Ali MM, Bhattacharyya P, Olejniczak AJ. The effects of scholarly productivity and institutional characteristics on the distribution of federal research grants. The Journal of Higher Education. 2010 Mar 1;81(2):164-78.

54. Alberts B, Kirschner MW, Tilghman S, Varmus H. Rescuing US biomedical research from its systemic flaws. Proceedings of the National Academy of Sciences. 2014 Apr 22;111(16):5773-7.

55. Edwards MA, Roy S. Academic research in the 21st century: Maintaining scientific integrity in a climate of perverse incentives and hypercompetition. Environmental Engineering Science. 2017 Jan 1;34(1):51-61.

56. Wuchty S, Jones BF, Uzzi B. The increasing dominance of teams in production of knowledge. Science. 2007 May 18;316(5827):1036-9.

57. National Research Council. Enhancing the effectiveness of team science. National Academies Press; 2015 Jul 15.

58. Huckman RS, Staats BR, Upton DM. Team familiarity, role experience, and performance: Evidence from Indian software services. Management Science. 2009 Jan;55(1):85-100.

59. Huckman RS, Staats BR. Fluid tasks and fluid teams: The impact of diversity in experience and team familiarity on team performance. Manufacturing & Service Operations Management. 2011 Jul;13(3):310-28.

60. Neugebauer EA, Rath A, Antoine SL, Eikermann M, Seidel D, Koenen C, Jacobs E, Pieper D, Laville M, Pitel S, Martinho C. Specific barriers to the conduct of randomised clinical trials on medical devices. Trials. 2017 Dec;18(1):427.

61. Downing NS, Aminawung JA, Shah ND, Krumholz HM, Ross JS. Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012. Jama. 2014 Jan 22;311(4):368-77.

**List of Figures and Tables**

| | All | Adequate | Inadequate Methods | Poor Reporting |
|---|---|---|---|---|
| Sample 1 | 20,571 (100%) | 1,173 (5.7%) | 12,190 (59.3%) | 7,208 (35.0%) |
| Sample 2 (with full text) | 11,686 (56.8%) | 833 (7.1%) | 6,783 (58.0%) | 4,070 (34.8%) |
| **Funder type** | | | | |
| NIH Grant | 2,147 (10.4%) | 146 (6.8%) | 1,282 (59.7%) | 719 (33.5%) |
| Industry funding | 2,725 (13.2%) | 283 (10.2%) | 1,464 (52.6%) | 978 (35.1%) |
| **First Author Affiliation** | | | | |
| Top University | 1,063 (5.2%) | 51 (4.8%) | 601 (56.5%) | 411 (38.7%) |
| Other University | 11,120 (54.1%) | 677 (6.1%) | 6,589 (59.3%) | 3,854 (34.7%) |
| Hospital | 4,450 (21.6%) | 185 (4.2%) | 2,608 (58.6%) | 1,657 (37.2%) |
| Government | 1,744 (8.5%) | 108 (6.2%) | 1,071 (61.4%) | 565 (32.4%) |
| Non-Profit | 751 (3.7%) | 48 (6.4%) | 454 (60.5%) | 249 (33.2%) |
| Top Pharma | 239 (1.2%) | 26 (10.9%) | 115 (48.1%) | 98 (41.0%) |
| Other Firm | 195 (1.0%) | 13 (6.7%) | 115 (59.0%) | 67 (34.3%) |
| Other research institution | 200 (1.0%) | 18 (9.0%) | 120 (60.0%) | 62 (31.0%) |
| **Other industry affiliation** | 570 (2.8%) | 44 (7.7%) | 287 (50.4%) | 239 (41.9%) |
| **Registered RCTs (NCT)** | 1,888 (9.2%) | 298 (15.8%) | 1,011 (53.6%) | 579 (30.7%) |
| **Novelty** | | | | |
| First study | 2,284 (11.1%) | 126 (5.5%) | 1,390 (60.9%) | 768 (33.6%) |
| Second study | 2,124 (10.3%) | 127 (6.0%) | 1262 (59.4%) | 735 (34.6%) |
| **Team characteristics** | | | | |
| Number of Authors - Avg (Std) | 6.15 (3.9) | 8.04 (5.5) | 5.99 (3.8) | 6.13 (6.8) |
| International | 748 (3.64%) | 60 (8.02%) | 379 (50.67%) | 309 (41.31%) |
| **Technology*** | | | | |
| Drug | 13,485 (65.6%) | 914 (6.8%) | 7,306 (54.2%) | 5,265 (39.0%) |
| Device | 5,347 (26.0%) | 235 (4.4%) | 3,366 (63.0%) | 1,746 (32.7%) |
| Procedure | 8,710 (42.3%) | 460 (5.3%) | 4,925 (56.5%) | 3,325 (38.2%) |
| Behavioral | 4,543 (22.1%) | 122 (2.7%) | 3,239 (71.3%) | 1,182 (26.0%) |
| Other | 1,199 (5.8%) | 78 (6.5%) | 819 (68.3%) | 302 (25.2%) |
| **Geography**** | | | | |
| Canada | 680 (3.3%) | 61 (9.0%) | 362 (53.2%) | 257 (37.8%) |
| Europe | 4,467 (21.7%) | 254 (5.7%) | 2,693 (60.3%) | 1,520 (34.0%) |
| UK | 2,306 (11.2%) | 154 (6.7%) | 1,399 (60.7%) | 753 (32.7%) |
| USA | 4,465 (21.7%) | 284 (6.4%) | 2,592 (58.1%) | 1,589 (35.6%) |
| Other | 4,165 (20.3%) | 253 (6.1%) | 2,444 (58.7%) | 1,468 (35.3%) |
| **Publication Year - Avg (Std)** | 2001 (10.2) | 2005 (8.1) | 2001 (10.4) | 2001 (9.9) |
| **Study Age at Review - Avg (Std)** | 13.44 (10.1) | 9.81 (8.0) | 13.39 (10.3) | 14.14 (9.9) |

**Table 1. Descriptive statistics.** Unless otherwise specified, column 1 reports the number of RCTs and their proportion as of the total number of RCTs (N=20,571). A RCT uses adequate methods if it is at "low risk of bias" on all six dimensions assessed (see Table A1). Methods are inadequate if a RCT is at "high risk of bias" for at least one reason. Methods are poorly reported there is no evidence of methods inadequacy, but at least one assessment is "unclear risk of bias". Columns 2-4 report the number of RCTs in each category and their proportion as of the number of RCTs in column 1. For number of authors, publication year and study age at time of review, Table 1 reports the average and standard deviation. *One RCT can belong to several technology categories. ** For some RCTs, affiliation address is not provided.




Fig.1. Data Flow




Fig.2. Number and proportion of RCTs at low risk of bias, high risk of bias and unclear risk of bias (N=20,571)




Fig.3. Evolution of methods and reporting over time. A.: Proportion of RCTs using adequate methods, inadequate methods and poorly reported. B. to G.: Proportion of RCTs at low risk of bias, high risk of bias and unclear risk of bias for each dimension assessed. See Table A1 for the definition of each dimension. N=20,571 RCTs. An observation is a RCT assessed on all six dimensions. See Figure 1 for more detailed information about the sample.




Fig.4. Same figure as Figure 3, but including all RCTs assessed on at least one dimension (as opposed to RCTs assessed on all six dimensions). Evolution of methods and reporting over time. A.: Proportion of RCTs using adequate methods, inadequate methods and poorly reported. B. to G.: Proportion of RCTs at low risk of bias, high risk of bias and unclear risk of bias for each dimension assessed. See Table A1 for the definition of each dimension.




Fig.5. Main regression results (relative risk ratios and 95% confidence intervals) from the multinomial logit model predicting overall RCT quality. The arrow heads on the confidence intervals indicate that the upper bound of the 95% confidence interval is greater than 2. The dependent variable is a categorical variable and can take three values: adequate methods, inadequate methods and poor reporting. Adequate methods is the reference outcome category.The regression sample includes 11,686 RCTs with accessible full-text. See Figure 1 for more detailed information about the sample. The relative risk ratios represent the likelihood of a RCT with specific funding, sector, study/team, technology and country characteristics using inadequate methods (or being poorly reported), as compared to the likelihood of a RCT in a reference group without these characteristics using inadequate methods (or being poorly reported). In the regression, sector, technology and country are categorical variables. The omitted category for sector is other university. The omitted category for technology is other interventions. The omitted category for country is other countries. The regression includes topic and year fixed effects. The regression coefficients are reported in Table A2. Regression results predicting relative risk ratios for high or unclear risk of bias on each dimension assessed (as opposed to overall quality) are reported in Table A3.

289x216mm (72 x 72 DPI)

**Supplementary Materials, Tables and Figures**

## Table A1: Cochrane Risk of Bias Assessment Tool

| Bias domain | Source of bias | Support for judgement | Review Authors judgement |
|---|---|---|---|
| Selection bias | Random sequence generation | Describe the method used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups. | Selection bias (biased allocation to intervention) due to inadequate generation of a randomized sequence. |
| Selection bias | Allocation concealment | Describe the method used to conceal the allocation sequence in sufficient detail to determine whether intervention allocations could have been foreseen before or during enrollment. | Selection bias (biased allocation to interventions) due to inadequate concealment of allocations before assignment. |
| Performance bias | Blinding of participants and personnel | Describe all measures used, if any, to blind participants and researchers from knowledge of which intervention a participant received. Provide any information relating to whether the intended blinding was effective. | Performance bias due to knowledge of the allocated intervention by participants and personnel during the study. |
| Detection bias | Blinding of outcome assessment | Describe all measures used, if any, to blind outcome assessment from knowledge of which intervention a participant received. Provide any information relating to whether the intended blinding was effective. | Performance bias due to knowledge of the allocated intervention by outcome assessment. |
| Attrition bias | Incomplete outcome data | Describe the completeness of outcome data for each main outcome, including attrition and exclusions from the analysis. State whether attritions and exclusions were reported, the numbers in each intervention group (compared with total randomized participants), reasons for attrition or exclusion where reported, and any re-inclusion in the analysis for the review. | Attrition bias due to amount, nature or handling of incomplete outcome data |
| Reporting bias | Selective reporting | State how selective outcome reporting was examined and what was found. | Reporting bias due to selective outcome reporting. |
| Other bias | Anything else, pre-specified | State any important concerns about bias not covered in other domains in the tool. | Bias due to problems not covered elsewhere. |

Source: Adapted from Higgins et al, 2011

**Table A2: Main regression results predicting adequate methods, inadequate methods and poor reporting (Relative Risk Ratios)**

| | Inadequate Methods | Poor Reporting |
|---|---|---|
| **Funding** | | |
| NIH Grant | 0.83 | 0.76 |
| Industry | 0.84* | 0.85 |
| **Sector (First Author)** | | |
| Top University | 0.76 | 0.76 |
| Government | 1.21 | 1.05 |
| Hospital | 1.19 | 1.16 |
| Non-Profit | 1.40 | 1.27 |
| Top Pharma | 0.43** | 0.74 |
| Other Firms | 1.38 | 1.06 |
| **Sector (Other Author)** | | |
| Any Firm | 0.66 | 0.79 |
| **Study/Team** | | |
| Registered trial | 0.42*** | 0.45*** |
| First Study | 0.90 | 0.80 |
| Second Study | 0.85 | 0.81 |
| Number of Authors | 0.95*** | 0.97*** |
| International | 0.51** | 0.64* |
| **Technology** | | |
| Drug | 0.50*** | 0.73* |
| Device | 1.71** | 1.23 |
| Procedure | 1.01 | 1.28 |
| Behavioral | 2.63*** | 1.44 |
| **Geography** | | |
| USA | 1.11 | 1.39* |
| Canada | 0.71 | 0.81 |
| Europe | 1.29* | 1.22 |
| UK | 1.06 | 0.91 |

* p<0.05, ** p<0.01, *** p<0.001

This table presents main regression results (relative risk ratios and p-values) from estimating the multinomial logit model predicting overall RCT quality. The dependent variable is a categorical variable and can take three values: adequate methods, inadequate methods and poor reporting. Adequate methods is the reference outcome category. The regression sample includes 11,686 RCTs with accessible full-text. See Figure A1 for more detailed information about the sample. The relative risk ratios represent the likelihood of a RCT with specific funding, sector, study/team, technology and country characteristics using inadequate methods (or being poorly reported), as compared to the likelihood of a RCT in a reference group without these characteristics using inadequate methods (or being poorly reported). In the regression, sector, technology and country are categorical variables. The omitted category for sector is other university. The omitted category for technology is other interventions. The omitted category for country is other countries. The regression includes topic and year fixed effects. These results are plotted in Figure 3. Other regression results predicting relative risk ratios for high or unclear risk of bias on each dimension assessed (as opposed to overall quality) are reported in Table A3.

**Table A3: Regression results predicting relative risk ratios for each dimension**

| | Random Sequence | | Allocation Conceal. | | Blinding PP | | Blinding OA | | Incomplete Data | | Selective Reporting | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | High | Unclear | High | Unclear | High | Unclear | High | Unclear | High | Unclear | High | Unclear |
| **Funding** | | | | | | | | | | | | |
| NIH Grant | 0.29*** | 0.90 | 0.51*** | 0.93 | 1.12 | 1.06 | 1.01 | 0.93 | 1.03 | 1.04 | 1.03 | 0.99 |
| Industry | 1.03 | 1.07 | 1.18 | 1.06 | 0.87* | 0.92 | 0.98 | 0.98 | 0.97 | 0.99 | 1.06 | 1.04 |
| **Sector (First Author)** | | | | | | | | | | | | |
| Top University | 0.99 | 0.96 | 0.91 | 0.88 | 0.85 | 0.83 | 0.84 | 0.85 | 0.90 | 1.05 | 1.19 | 1.08 |
| Government | 0.91 | 1.01 | 0.85 | 0.98 | 1.00 | 0.96 | 1.00 | 0.92 | 1.29** | 1.14 | 1.15 | 1.12 |
| Hospital | 1.07 | 1.06 | 1.05 | 1.00 | 1.08 | 0.96 | 1.12 | 1.04 | 1.05 | 0.95 | 0.89 | 1.03 |
| Non-Profit | 1.40 | 1.05 | 1.34 | 0.91 | 1.08 | 1.02 | 1.13 | 0.99 | 1.01 | 1.03 | 1.03 | 1.07 |
| Top Pharma | 0.49 | 0.96 | 0.60 | 0.83 | 0.34*** | 0.73 | 0.56* | 0.74 | 0.86 | 0.61 | 0.70 | 0.59* |
| Other Firms | 2.19 | 1.64* | 2.01 | 1.60* | 0.64 | 0.94 | 0.56 | 1.41 | 1.30 | 1.12 | 2.16* | 1.05 |
| **Sector (Other Author)** | | | | | | | | | | | | |
| Any Firm | 0.18** | 0.92 | 0.53 | 1.04 | 0.65** | 0.94 | 0.86 | 1.21 | 1.39* | 1.06 | 0.94 | 1.02 |
| **Study/Team** | | | | | | | | | | | | |
| Registered trial | 0.31*** | 0.42*** | 0.39*** | 0.41*** | 0.72*** | 0.60*** | 0.58*** | 0.63*** | 0.67*** | 0.71*** | 0.66*** | 0.52*** |
| First Study | 0.95 | 0.81** | 1.09 | 0.84* | 1.15 | 1.07 | 1.02 | 0.85 | 0.97 | 0.90 | 1.14 | 1.03 |
| Second Study | 1.00 | 0.83* | 1.01 | 0.80** | 1.02 | 1.03 | 1.04 | 1.01 | 0.87 | 0.88 | 1.06 | 1.01 |
| Number of Authors | 0.92*** | 0.97*** | 0.93*** | 0.95*** | 0.98** | 0.96*** | 0.95*** | 0.97*** | 0.98* | 0.99 | 0.99 | 0.96*** |
| International | 0.88 | 0.79* | 0.53* | 0.74** | 0.79 | 0.94 | 0.73* | 0.75* | 0.91 | 0.86 | 0.66* | 0.82 |
| **Technology** | | | | | | | | | | | | |
| Drug | 0.66* | 1.14 | 0.76 | 1.11 | 0.41*** | 0.48*** | 0.82 | 0.87 | 0.92 | 0.94 | 1.00 | 1.05 |
| Device | 1.31 | 1.02 | 1.34 | 1.10 | 1.52** | 0.93 | 1.27 | 0.93 | 0.91 | 1.02 | 1.02 | 0.83 |
| Procedure | 0.90 | 1.21** | 0.93 | 1.22* | 0.91 | 1.24 | 1.18 | 1.22 | 0.85 | 1.06 | 1.06 | 1.13 |
| Behavioral | 0.88 | 1.03 | 1.21 | 1.16 | 2.83*** | 1.53** | 2.09*** | 1.27 | 1.34** | 1.18 | 0.89 | 1.41* |
| **Geography** | | | | | | | | | | | | |
| USA | 1.04 | 1.15 | 0.93 | 1.12 | 0.73*** | 0.95 | 0.81 | 1.02 | 1.23* | 1.22* | 0.96 | 0.93 |
| Canada | 0.55 | 0.69** | 0.69 | 0.61*** | 0.75 | 0.75 | 0.85 | 0.66** | 0.94 | 1.09 | 0.76 | 0.88 |
| Europe | 0.80 | 1.05 | 0.79 | 0.96 | 1.13 | 1.05 | 1.29** | 1.09 | 1.13 | 0.97 | 1.01 | 0.92 |
| UK | 0.89 | 0.89 | 0.65** | 0.67*** | 1.03 | 0.87 | 1.11 | 0.96 | 1.04 | 1.01 | 1.07 | 0.86 |

*p<0.05, **p<0.01, ***p<0.001

This table presents main regression results (relative risk ratios and p-values) from estimating the multinomial logit model predicting risk of bias for each dimension assessed. The dependent variable is a categorical variable and can take three values: low risk, high risk or unclear risk. Low risk is the reference outcome category. The regression sample includes 11,686 RCTs with accessible full-text. See Figure A1 for more detailed information about the sample. The relative risk ratios represent the likelihood of a RCT with specific funding, sector, study/team, technology and country characteristics being assessed at high risk (or unclear risk) as compared to the likelihood of a RCT in a reference group without these characteristics being assessed at high risk (or unclear risk). In the regression, sector, technology and country are categorical variables. The omitted category for sector is other university. The omitted category for technology is other interventions. The omitted category for country is other countries. The regression includes topic and year fixed effects. Other regression results predicting relative risk ratios for overall quality (as opposed to relative risk ratios for high or unclear risk of bias on each dimension assessed) are reported in Table A2.

**Appendix A: List of top 25 universities in clinical medicine and pharmacy (AWRU, 2007)**

- Harvard University
- University of California, San Francisco
- University of Washington
- The Johns Hopkins University
- Columbia University
- University of California, Los Angeles
- The University of Texas Southwestern Medical Center at Dallas
- University of Michigan - Ann Arbor
- Karolinska Institute
- University of Pittsburgh
- Stanford University
- Mayo Medical School
- University of Oxford
- University of Minnesota, Twin Cities
- University of Cambridge
- Yale University
- University College London
- The University of Texas M. D. Anderson Cancer Center
- University of Wisconsin - Madison
- Vanderbilt University
- University of Pennsylvania
- Duke University
- University of California, San Diego
- Tufts University
- The Imperial College of Science, Technology and Medicine

**Appendix B: List of top pharmaceutical companies used in this study (by revenue)**

- Johnson & Johnson
- Roche
- Pfizer
- Novartis
- Bayer
- Merck & Co
- GlaxoSmithKline
- Sanofi
- Abbvie
- Abbott Laboratories
- Eli Lilly & Co
- Amgen
- Bristol-Myers Squibb
- Gilead Sciences
- AstraZeneca
- Teva Pharmaceutical Industries
- Boehringer Ingelheim
- Merck Group
- Novo Nordisk
- Takeda Pharmaceutical
- Allergan plc
- Shire
- Celgene
- Biogen

## Appendix C: List of included Cochrane reviews (DOIs)

10.1002/14651858.CD007585.pub4
10.1002/14651858.CD009667.pub2
10.1002/14651858.CD003626.pub2
10.1002/14651858.CD006882.pub2
10.1002/14651858.CD008258.pub2
10.1002/14651858.CD007712.pub2
10.1002/14651858.CD003623.pub3
10.1002/14651858.CD007749.pub2
10.1002/14651858.CD008960.pub2
10.1002/14651858.CD004787.pub2
10.1002/14651858.CD002800.pub3
10.1002/14651858.CD006933.pub2
10.1002/14651858.CD006006.pub2
10.1002/14651858.CD003619.pub3
10.1002/14651858.CD009052.pub2
10.1002/14651858.CD006002.pub2
10.1002/14651858.CD009144.pub2
10.1002/14651858.CD007864.pub2
10.1002/14651858.CD006224.pub3
10.1002/14651858.CD007506.pub3
10.1002/14651858.CD007677.pub3
10.1002/14651858.CD008565.pub2
10.1002/14651858.CD005354.pub2
10.1002/14651858.CD006586.pub4
10.1002/14651858.CD008995.pub2
10.1002/14651858.CD003415.pub4
10.1002/14651858.CD002122.pub2
10.1002/14651858.CD004993.pub3
10.1002/14651858.CD008585.pub2
10.1002/14651858.CD006568.pub3
10.1002/14651858.CD003053.pub5
10.1002/14651858.CD006768.pub2
10.1002/14651858.CD002221.pub2
10.1002/14651858.CD008228.pub2
10.1002/14651858.CD001860.pub3
10.1002/14651858.CD007842.pub2
10.1002/14651858.CD007685.pub2
10.1002/14651858.CD007630.pub2
10.1002/14651858.CD004003.pub4
10.1002/14651858.CD006746.pub3

10.1002/14651858.CD004239.pub3
10.1002/14651858.CD007293.pub3
10.1002/14651858.CD005137.pub3
10.1002/14651858.CD004916.pub3
10.1002/14651858.CD004567.pub2
10.1002/14651858.CD005996.pub3
10.1002/14651858.CD001122.pub4
10.1002/14651858.CD008950.pub2
10.1002/14651858.CD007687.pub2
10.1002/14651858.CD005556.pub2
10.1002/14651858.CD005287.pub4
10.1002/14651858.CD007244.pub2
10.1002/14651858.CD000479.pub5
10.1002/14651858.CD003857.pub3
10.1002/14651858.CD000402.pub4
10.1002/14651858.CD001894.pub5
10.1002/14651858.CD002808.pub3
10.1002/14651858.CD008528.pub2
10.1002/14651858.CD004829.pub3
10.1002/14651858.CD005072.pub3
10.1002/14651858.CD008994.pub2
10.1002/14651858.CD000400.pub3
10.1002/14651858.CD008088.pub3
10.1002/14651858.CD010042.pub2
10.1002/14651858.CD008575.pub2
10.1002/14651858.CD009391.pub2
10.1002/14651858.CD005292.pub3
10.1002/14651858.CD009672.pub2
10.1002/14651858.CD010167.pub2
10.1002/14651858.CD001396.pub3
10.1002/14651858.CD009452.pub2
10.1002/14651858.CD005071.pub4
10.1002/14651858.CD003416.pub4
10.1002/14651858.CD006920.pub3
10.1002/14651858.CD007410.pub2
10.1002/14651858.CD010550.pub2
10.1002/14651858.CD009505.pub2
10.1002/14651858.CD001502.pub4
10.1002/14651858.CD001501.pub4
10.1002/14651858.CD000329.pub2
10.1002/14651858.CD010241.pub2
10.1002/14651858.CD006900.pub3
10.1002/14651858.CD003433.pub3

10.1002/14651858.CD007114.pub2
10.1002/14651858.CD003658.pub3
10.1002/14651858.CD002219.pub2
10.1002/14651858.CD010287.pub2
10.1002/14651858.CD007421.pub3
10.1002/14651858.CD001395.pub4
10.1002/14651858.CD001861.pub3
10.1002/14651858.CD004399.pub3
10.1002/14651858.CD006769.pub2
10.1002/14651858.CD001775.pub2
10.1002/14651858.CD009379.pub2
10.1002/14651858.CD001211.pub3
10.1002/14651858.CD005022.pub3
10.1002/14651858.CD009078.pub2
10.1002/14651858.CD009510.pub2
10.1002/14651858.CD006421.pub3
10.1002/14651858.CD005135.pub3
10.1002/14651858.CD006030.pub3
10.1002/14651858.CD003737.pub3
10.1002/14651858.CD009306.pub2
10.1002/14651858.CD006032.pub4
10.1002/14651858.CD006132.pub3
10.1002/14651858.CD008813.pub2
10.1002/14651858.CD008428.pub2
10.1002/14651858.CD003303.pub3
10.1002/14651858.CD008797.pub2
10.1002/14651858.CD005431.pub3
10.1002/14651858.CD008812.pub2
10.1002/14651858.CD008420.pub3
10.1002/14651858.CD006126.pub3
10.1002/14651858.CD007059.pub2
10.1002/14651858.CD007284.pub2
10.1002/14651858.CD001132.pub2
10.1002/14651858.CD006122.pub3
10.1002/14651858.CD004122.pub4
10.1002/14651858.CD009490
10.1002/14651858.CD008762.pub2
10.1002/14651858.CD003861.pub3
10.1002/14651858.CD001733.pub3
10.1002/14651858.CD001737.pub4
10.1002/14651858.CD008058.pub2
10.1002/14651858.CD001177.pub3
10.1002/14651858.CD004983.pub3

10.1002/14651858.CD002302.pub2
10.1002/14651858.CD000265.pub3
10.1002/14651858.CD002106.pub4
10.1002/14651858.CD006477.pub2
10.1002/14651858.CD009907.pub2
10.1002/14651858.CD010424.pub2
10.1002/14651858.CD009111.pub3
10.1002/14651858.CD009101.pub3
10.1002/14651858.CD009110.pub3
10.1002/14651858.CD009099.pub3
10.1002/14651858.CD006810.pub3
10.1002/14651858.CD009362.pub2
10.1002/14651858.CD008738.pub2
10.1002/14651858.CD009726.pub2
10.1002/14651858.CD006214.pub4
10.1002/14651858.CD010268.pub2
10.1002/14651858.CD003826.pub3
10.1002/14651858.CD003588.pub3
10.1002/14651858.CD006823.pub2
10.1002/14651858.CD006665.pub3
10.1002/14651858.CD010318.pub2
10.1002/14651858.CD006354.pub4
10.1002/14651858.CD005571.pub3
10.1002/14651858.CD010427.pub2
10.1002/14651858.CD004551.pub3
10.1002/14651858.CD005570.pub4
10.1002/14651858.CD004549.pub3
10.1002/14651858.CD008059.pub3
10.1002/14651858.CD010425.pub2
10.1002/14651858.CD006471.pub3
10.1002/14651858.CD005485.pub3
10.1002/14651858.CD010365.pub2
10.1002/14651858.CD009958.pub2
10.1002/14651858.CD005360.pub4
10.1002/14651858.CD003557.pub5
10.1002/14651858.CD001899.pub4
10.1002/14651858.CD003948.pub3
10.1002/14651858.CD008805.pub3
10.1002/14651858.CD009697.pub2
10.1002/14651858.CD003325.pub3
10.1002/14651858.CD003216.pub2
10.1002/14651858.CD009224.pub2
10.1002/14651858.CD001273.pub3

10.1002/14651858.CD002303.pub3
10.1002/14651858.CD008990.pub3
10.1002/14651858.CD009261.pub3
10.1002/14651858.CD006215.pub4
10.1002/14651858.CD008394.pub3
10.1002/14651858.CD001488.pub5
10.1002/14651858.CD010266.pub2
10.1002/14651858.CD004287.pub4
10.1002/14651858.CD007174.pub2
10.1002/14651858.CD011226.pub2
10.1002/14651858.CD004985.pub5
10.1002/14651858.CD006353.pub4
10.1002/14651858.CD003949.pub4
10.1002/14651858.CD011334.pub2
10.1002/14651858.CD011278.pub2
10.1002/14651858.CD011277.pub2
10.1002/14651858.CD005083.pub4
10.1002/14651858.CD011070.pub2
10.1002/14651858.CD001836.pub3
10.1002/14651858.CD002933.pub6
10.1002/14651858.CD004123.pub4
10.1002/14651858.CD011354.pub2
10.1002/14651858.CD010075.pub3
10.1002/14651858.CD010182.pub3
10.1002/14651858.CD002930.pub6
10.1002/14651858.CD007610.pub3
10.1002/14651858.CD010259.pub3
10.1002/14651858.CD001735.pub5
10.1002/14651858.CD010367.pub2
10.1002/14651858.CD007258.pub3
10.1002/14651858.CD008474.pub2
10.1002/14651858.CD008599.pub2
10.1002/14651858.CD009061.pub2
10.1002/14651858.CD010577.pub2
10.1002/14651858.CD008548.pub2
10.1002/14651858.CD008056.pub3
10.1002/14651858.CD010764.pub2
10.1002/14651858.CD009213.pub2
10.1002/14651858.CD009432.pub2
10.1002/14651858.CD004288.pub3
10.1002/14651858.CD011712.pub2
10.1002/14651858.CD002929.pub3
10.1002/14651858.CD008062.pub4

10.1002/14651858.CD011586.pub2
10.1002/14651858.CD008378.pub3
10.1002/14651858.CD010694.pub2
10.1002/14651858.CD006899.pub3
10.1002/14651858.CD010140.pub2
10.1002/14651858.CD011193.pub2
10.1002/14651858.CD011111.pub2
10.1002/14651858.CD011426.pub2
10.1002/14651858.CD011923.pub2
10.1002/14651858.CD008251.pub2
10.1002/14651858.CD003091.pub4
10.1002/14651858.CD011375.pub2
10.1002/14651858.CD001180.pub4
10.1002/14651858.CD005987.pub3
10.1002/14651858.CD011038.pub2
10.1002/14651858.CD011979.pub2
10.1002/14651858.CD011609.pub2
10.1002/14651858.CD011947.pub2
10.1002/14651858.CD001333.pub4
10.1002/14651858.CD005191.pub3
10.1002/14651858.CD009308
10.1002/14651858.CD008063.pub2
10.1002/14651858.CD005031.pub4
10.1002/14651858.CD009307
10.1002/14651858.CD009113
10.1002/14651858.CD004147.pub4
10.1002/14651858.CD003410.pub4
10.1002/14651858.CD004145.pub4
10.1002/14651858.CD007381.pub2
10.1002/14651858.CD009879.pub2
10.1002/14651858.CD007775.pub2
10.1002/14651858.CD003409.pub4
10.1002/14651858.CD008358.pub2
10.1002/14651858.CD009287.pub2
10.1002/14651858.CD002950.pub3
10.1002/14651858.CD006318.pub3
10.1002/14651858.CD009695.pub2
10.1002/14651858.CD006749.pub3
10.1002/14651858.CD002207.pub4
10.1002/14651858.CD007210.pub3
10.1002/14651858.CD010704.pub2
10.1002/14651858.CD008544.pub2
10.1002/14651858.CD009269.pub3

10.1002/14651858.CD003020.pub3
10.1002/14651858.CD008940.pub2
10.1002/14651858.CD006037.pub3
10.1002/14651858.CD006754.pub4
10.1002/14651858.CD009652.pub2
10.1002/14651858.CD003352.pub4
10.1002/14651858.CD010910.pub2
10.1002/14651858.CD010862.pub2
10.1002/14651858.CD008969.pub3
10.1002/14651858.CD006306.pub3
10.1002/14651858.CD010901.pub2
10.1002/14651858.CD006748.pub4
10.1002/14651858.CD002024.pub5
10.1002/14651858.CD011117.pub2
10.1002/14651858.CD011983.pub2
10.1002/14651858.CD005336.pub4
10.1002/14651858.CD007380.pub4
10.1002/14651858.CD007025.pub4
10.1002/14651858.CD008502.pub5
10.1002/14651858.CD002021.pub4
10.1002/14651858.CD002025.pub5
10.1002/14651858.CD011866.pub2
10.1002/14651858.CD011479.pub2
10.1002/14651858.CD009146.pub2
10.1002/14651858.CD004887.pub3
10.1002/14651858.CD008264.pub2
10.1002/14651858.CD009145.pub2
10.1002/14651858.CD007338.pub3
10.1002/14651858.CD007512.pub2
10.1002/14651858.CD004544.pub2
10.1002/14651858.CD008714.pub2
10.1002/14651858.CD009051.pub2
10.1002/14651858.CD002799.pub2
10.1002/14651858.CD007605.pub2
10.1002/14651858.CD005444.pub3
10.1002/14651858.CD006578.pub3
10.1002/14651858.CD008516.pub2
10.1002/14651858.CD008344.pub2
10.1002/14651858.CD009498.pub3
10.1002/14651858.CD000551.pub3
10.1002/14651858.CD009004.pub2
10.1002/14651858.CD008717.pub2
10.1002/14651858.CD009497.pub2

10.1002/14651858.CD009058.pub2
10.1002/14651858.CD003617.pub2
10.1002/14651858.CD005640.pub3
10.1002/14651858.CD005641.pub3
10.1002/14651858.CD007176.pub2
10.1002/14651858.CD007196.pub3
10.1002/14651858.CD005440.pub3
10.1002/14651858.CD004547.pub2
10.1002/14651858.CD006798.pub4
10.1002/14651858.CD007088.pub2
10.1002/14651858.CD006575.pub3
10.1002/14651858.CD010163.pub2
10.1002/14651858.CD006004.pub4
10.1002/14651858.CD006574.pub4
10.1002/14651858.CD006573.pub3
10.1002/14651858.CD006804.pub3
10.1002/14651858.CD009059.pub2
10.1002/14651858.CD006803.pub4
10.1002/14651858.CD008623.pub2
10.1002/14651858.CD003327.pub4
10.1002/14651858.CD010479.pub2
10.1002/14651858.CD003046.pub3
10.1002/14651858.CD003047.pub3
10.1002/14651858.CD007109.pub2
10.1002/14651858.CD005642.pub3
10.1002/14651858.CD009933.pub2
10.1002/14651858.CD005441.pub3
10.1002/14651858.CD010478.pub2
10.1002/14651858.CD006660.pub3
10.1002/14651858.CD007049.pub2
10.1002/14651858.CD006930.pub3
10.1002/14651858.CD009060.pub2
10.1002/14651858.CD007337.pub3
10.1002/14651858.CD008261.pub2
10.1002/14651858.CD009182.pub2
10.1002/14651858.CD011132.pub2
10.1002/14651858.CD010252.pub2
10.1002/14651858.CD010125.pub2
10.1002/14651858.CD006745.pub3
10.1002/14651858.CD010253.pub2
10.1002/14651858.CD010164.pub2
10.1002/14651858.CD011313.pub2
10.1002/14651858.CD010180.pub2

10.1002/14651858.CD007606.pub3
10.1002/14651858.CD006390.pub2
10.1002/14651858.CD003044.pub4
10.1002/14651858.CD008545.pub2
10.1002/14651858.CD011314.pub2
10.1002/14651858.CD011647.pub2
10.1002/14651858.CD011649.pub2
10.1002/14651858.CD011644.pub2
10.1002/14651858.CD008716.pub3
10.1002/14651858.CD011650.pub2
10.1002/14651858.CD010683.pub3
10.1002/14651858.CD011645.pub2
10.1002/14651858.CD011343.pub2
10.1002/14651858.CD001939.pub4
10.1002/14651858.CD011640.pub2
10.1002/14651858.CD011648.pub2
10.1002/14651858.CD011646.pub2
10.1002/14651858.CD011639.pub2
10.1002/14651858.CD002798.pub4
10.1002/14651858.CD005162.pub4
10.1002/14651858.CD011598.pub2
10.1002/14651858.CD008586.pub2
10.1002/14651858.CD007302.pub2
10.1002/14651858.CD002217.pub2
10.1002/14651858.CD009429.pub2
10.1002/14651858.CD003277.pub3
10.1002/14651858.CD002750.pub2
10.1002/14651858.CD003615.pub3
10.1002/14651858.CD001901.pub2
10.1002/14651858.CD009945.pub2
10.1002/14651858.CD005398.pub3
10.1002/14651858.CD001415.pub2
10.1002/14651858.CD001416.pub3
10.1002/14651858.CD001908.pub3
10.1002/14651858.CD001417.pub3
10.1002/14651858.CD001770.pub3
10.1002/14651858.CD006370.pub2
10.1002/14651858.CD009270.pub3
10.1002/14651858.CD005612.pub3
10.1002/14651858.CD009258.pub2
10.1002/14651858.CD006779.pub2
10.1002/14651858.CD010062.pub2
10.1002/14651858.CD003723.pub3

10.1002/14651858.CD005062.pub4
10.1002/14651858.CD010682.pub2
10.1002/14651858.CD010236.pub2
10.1002/14651858.CD001902.pub2
10.1002/14651858.CD007286.pub3
10.1002/14651858.CD008841.pub2
10.1002/14651858.CD005222.pub3
10.1002/14651858.CD002896.pub2
10.1002/14651858.CD011311.pub2
10.1002/14651858.CD009472.pub3
10.1002/14651858.CD009887.pub3
10.1002/14651858.CD009027.pub2
10.1002/14651858.CD005502.pub3
10.1002/14651858.CD005399.pub3
10.1002/14651858.CD009900.pub2
10.1002/14651858.CD006118.pub3
10.1002/14651858.CD009324.pub3
10.1002/14651858.CD006245.pub3
10.1002/14651858.CD001903.pub3
10.1002/14651858.CD006244.pub3
10.1002/14651858.CD008781.pub3
10.1002/14651858.CD007144.pub2
10.1002/14651858.CD001769.pub3
10.1002/14651858.CD001909.pub2
10.1002/14651858.CD011792.pub2
10.1002/14651858.CD006967.pub4
10.1002/14651858.CD011014.pub2
10.1002/14651858.CD011025.pub2
10.1002/14651858.CD011922.pub2
10.1002/14651858.CD001031.pub3
10.1002/14651858.CD007124.pub5
10.1002/14651858.CD012065.pub2
10.1002/14651858.CD009202.pub4
10.1002/14651858.CD003032.pub3
10.1002/14651858.CD001904.pub3
10.1002/14651858.CD008312.pub3
10.1002/14651858.CD010224.pub2
10.1002/14651858.CD010008.pub3
10.1002/14651858.CD010483.pub4
10.1002/14651858.CD003031.pub3
10.1002/14651858.CD001911.pub3
10.1002/14651858.CD008557.pub3
10.1002/14651858.CD008295.pub4

10.1002/14651858.CD001524.pub3
10.1002/14651858.CD008497.pub3
10.1002/14651858.CD011412.pub2
10.1002/14651858.CD007679.pub4
10.1002/14651858.CD006461.pub4
10.1002/14651858.CD007738.pub2
10.1002/14651858.CD009700.pub2
10.1002/14651858.CD007325.pub3
10.1002/14651858.CD005139.pub3
10.1002/14651858.CD011230.pub2
10.1002/14651858.CD008811.pub3
10.1002/14651858.CD005430.pub3
10.1002/14651858.CD008721.pub2
10.1002/14651858.CD011234.pub2
10.1002/14651858.CD008213.pub2
10.1002/14651858.CD003659.pub4
10.1002/14651858.CD010792.pub2
10.1002/14651858.CD001538.pub4
10.1002/14651858.CD010621.pub2
10.1002/14651858.CD006127.pub2
10.1002/14651858.CD010015.pub3
10.1002/14651858.CD008350.pub2
10.1002/14651858.CD004241.pub4
10.1002/14651858.CD009080.pub2
10.1002/14651858.CD008732.pub2
10.1002/14651858.CD002898.pub5
10.1002/14651858.CD009566.pub2
10.1002/14651858.CD003434.pub3
10.1002/14651858.CD008671.pub3
10.1002/14651858.CD001430.pub4
10.1002/14651858.CD007603.pub2
10.1002/14651858.CD008214.pub3
10.1002/14651858.CD007324.pub3
10.1002/14651858.CD004242.pub5
10.1002/14651858.CD006537.pub3
10.1002/14651858.CD010868.pub2
10.1002/14651858.CD006259.pub2
10.1002/14651858.CD009380.pub2
10.1002/14651858.CD004008.pub3
10.1002/14651858.CD010472.pub2
10.1002/14651858.CD011346.pub2
10.1002/14651858.CD011146.pub2
10.1002/14651858.CD009782.pub2

10.1002/14651858.CD010469.pub2
10.1002/14651858.CD005655.pub2
10.1002/14651858.CD011349.pub2
10.1002/14651858.CD009799.pub2
10.1002/14651858.CD002218.pub2
10.1002/14651858.CD011841.pub2
10.1002/14651858.CD010735.pub2
10.1002/14651858.CD004764.pub3
10.1002/14651858.CD006927.pub5
10.1002/14651858.CD009729.pub2
10.1002/14651858.CD011503.pub2
10.1002/14651858.CD010293.pub2
10.1002/14651858.CD007824.pub2
10.1002/14651858.CD011308.pub2
10.1002/14651858.CD006683.pub3
10.1002/14651858.CD011160.pub2
10.1002/14651858.CD003169.pub4
10.1002/14651858.CD006539.pub4
10.1002/14651858.CD011965.pub2
10.1002/14651858.CD011080.pub2
10.1002/14651858.CD006364.pub3
10.1002/14651858.CD006757.pub4
10.1002/14651858.CD011075.pub2
10.1002/14651858.CD010520.pub2
10.1002/14651858.CD012131.pub2
10.1002/14651858.CD007097.pub3
10.1002/14651858.CD010746.pub2
10.1002/14651858.CD009327.pub3
10.1002/14651858.CD009781.pub2
10.1002/14651858.CD006499.pub4
10.1002/14651858.CD011109.pub2
10.1002/14651858.CD006775.pub3
10.1002/14651858.CD007419.pub5
10.1002/14651858.CD000253.pub4
10.1002/14651858.CD010516.pub2
10.1002/14651858.CD004918.pub3
10.1002/14651858.CD000254.pub4
10.1002/14651858.CD010510.pub2
10.1002/14651858.CD006210.pub3
10.1002/14651858.CD009094
10.1002/14651858.CD006563.pub2
10.1002/14651858.CD005528.pub2
10.1002/14651858.CD003318.pub3

10.1002/14651858.CD008451.pub2
10.1002/14651858.CD007673.pub2
10.1002/14651858.CD007019.pub2
10.1002/14651858.CD000125.pub4
10.1002/14651858.CD001270.pub2
10.1002/14651858.CD006413.pub2
10.1002/14651858.CD004538.pub2
10.1002/14651858.CD002212.pub2
10.1002/14651858.CD005609.pub2
10.1002/14651858.CD007899.pub2
10.1002/14651858.CD009401.pub2
10.1002/14651858.CD007672.pub2
10.1002/14651858.CD000259.pub3
10.1002/14651858.CD005315.pub2
10.1002/14651858.CD002964.pub2
10.1002/14651858.CD007990.pub2
10.1002/14651858.CD008476.pub2
10.1002/14651858.CD007813.pub2
10.1002/14651858.CD008959.pub2
10.1002/14651858.CD007849.pub2
10.1002/14651858.CD008223.pub2
10.1002/14651858.CD007992.pub2
10.1002/14651858.CD009009.pub2
10.1002/14651858.CD004398.pub3
10.1002/14651858.CD006411.pub4
10.1002/14651858.CD010398
10.1002/14651858.CD002213.pub3
10.1002/14651858.CD009035.pub2
10.1002/14651858.CD002097.pub3
10.1002/14651858.CD006559.pub2
10.1002/14651858.CD009853.pub2
10.1002/14651858.CD002894.pub3
10.1002/14651858.CD010076.pub2
10.1002/14651858.CD008194.pub3
10.1002/14651858.CD006208.pub3
10.1002/14651858.CD005979.pub2
10.1002/14651858.CD004749.pub3
10.1002/14651858.CD005610.pub2
10.1002/14651858.CD006732.pub3
10.1002/14651858.CD009186.pub2
10.1002/14651858.CD008165.pub3
10.1002/14651858.CD009404.pub3
10.1002/14651858.CD007071.pub3

10.1002/14651858.CD009149.pub2
10.1002/14651858.CD001730.pub3
10.1002/14651858.CD005470.pub3
10.1002/14651858.CD007193.pub2
10.1002/14651858.CD005314.pub3
10.1002/14651858.CD007017.pub2
10.1002/14651858.CD006731.pub2
10.1002/14651858.CD007988.pub2
10.1002/14651858.CD000313.pub5
10.1002/14651858.CD009095.pub3
10.1002/14651858.CD009231.pub2
10.1002/14651858.CD009926.pub2
10.1002/14651858.CD007492.pub2
10.1002/14651858.CD008986.pub3
10.1002/14651858.CD006560.pub3
10.1002/14651858.CD009794.pub2
10.1002/14651858.CD010123.pub2
10.1002/14651858.CD009855.pub2
10.1002/14651858.CD007495.pub2
10.1002/14651858.CD008145.pub3
10.1002/14651858.CD009677.pub2
10.1002/14651858.CD008856.pub2
10.1002/14651858.CD010669.pub2
10.1002/14651858.CD003540.pub3
10.1002/14651858.CD002098.pub2
10.1002/14651858.CD007491.pub2
10.1002/14651858.CD010034.pub2
10.1002/14651858.CD008992.pub3
10.1002/14651858.CD011227.pub2
10.1002/14651858.CD009844.pub2
10.1002/14651858.CD011153.pub2
10.1002/14651858.CD004910.pub3
10.1002/14651858.CD000072.pub3
10.1002/14651858.CD000356.pub4
10.1002/14651858.CD001175.pub4
10.1002/14651858.CD003543.pub4
10.1002/14651858.CD008131.pub2
10.1002/14651858.CD003681.pub3
10.1002/14651858.CD009218.pub2
10.1002/14651858.CD008372.pub2
10.1002/14651858.CD009085.pub2
10.1002/14651858.CD003018.pub3
10.1002/14651858.CD003495.pub3

10.1002/14651858.CD001930.pub3
10.1002/14651858.CD005039.pub3
10.1002/14651858.CD008511.pub2
10.1002/14651858.CD007986.pub2
10.1002/14651858.CD009260.pub2
10.1002/14651858.CD009456.pub2
10.1002/14651858.CD007991.pub2
10.1002/14651858.CD008225.pub2
10.1002/14651858.CD004796.pub2
10.1002/14651858.CD005652.pub2
10.1002/14651858.CD007507.pub2
10.1002/14651858.CD002796.pub2
10.1002/14651858.CD009115.pub2
10.1002/14651858.CD009084.pub2
10.1002/14651858.CD008898.pub2
10.1002/14651858.CD009774.pub2
10.1002/14651858.CD009000.pub2
10.1002/14651858.CD001444.pub2
10.1002/14651858.CD005038.pub3
10.1002/14651858.CD004383.pub3
10.1002/14651858.CD004534.pub3
10.1002/14651858.CD004677.pub3
10.1002/14651858.CD009584.pub2
10.1002/14651858.CD009728.pub2
10.1002/14651858.CD008785.pub2
10.1002/14651858.CD006546.pub3
10.1002/14651858.CD004381.pub3
10.1002/14651858.CD006997.pub2
10.1002/14651858.CD010544.pub2
10.1002/14651858.CD002020.pub4
10.1002/14651858.CD010543.pub2
10.1002/14651858.CD003942.pub3
10.1002/14651858.CD010534.pub2
10.1002/14651858.CD007989.pub2
10.1002/14651858.CD009383.pub2
10.1002/14651858.CD009384.pub2
10.1002/14651858.CD009924.pub2
10.1002/14651858.CD010766.pub2
10.1002/14651858.CD003406.pub4
10.1002/14651858.CD010012.pub2
10.1002/14651858.CD008958.pub2
10.1002/14651858.CD004380.pub3
10.1002/14651858.CD010459.pub2

10.1002/14651858.CD009257.pub2
10.1002/14651858.CD011546.pub2
10.1002/14651858.CD007007.pub3
10.1002/14651858.CD009996.pub2
10.1002/14651858.CD009043.pub3
10.1002/14651858.CD009398.pub3
10.1002/14651858.CD005043.pub3
10.1002/14651858.CD009999.pub2
10.1002/14651858.CD003680.pub3
10.1002/14651858.CD009747.pub2
10.1002/14651858.CD010922.pub2
10.1002/14651858.CD006047.pub5
10.1002/14651858.CD010973.pub2
10.1002/14651858.CD010971.pub2
10.1002/14651858.CD010972.pub2
10.1002/14651858.CD008524.pub3
10.1002/14651858.CD009242.pub3
10.1002/14651858.CD008559.pub3
10.1002/14651858.CD010914.pub2
10.1002/14651858.CD011660.pub2
10.1002/14651858.CD009885.pub2
10.1002/14651858.CD005198.pub3
10.1002/14651858.CD008818.pub2
10.1002/14651858.CD008235.pub2
10.1002/14651858.CD006505.pub2
10.1002/14651858.CD007678.pub2
10.1002/14651858.CD008078.pub2
10.1002/14651858.CD003188.pub3
10.1002/14651858.CD009355.pub2
10.1002/14651858.CD009045.pub2
10.1002/14651858.CD004626.pub3
10.1002/14651858.CD004269.pub3
10.1002/14651858.CD008079.pub2
10.1002/14651858.CD008238.pub3
10.1002/14651858.CD009159.pub2
10.1002/14651858.CD006503.pub3
10.1002/14651858.CD009411.pub2
10.1002/14651858.CD008909.pub2
10.1002/14651858.CD009594.pub2
10.1002/14651858.CD006407.pub2
10.1002/14651858.CD010146.pub2
10.1002/14651858.CD010189.pub2
10.1002/14651858.CD009211.pub2

10.1002/14651858.CD010280.pub2
10.1002/14651858.CD003407.pub5
10.1002/14651858.CD010340.pub2
10.1002/14651858.CD009075.pub2
10.1002/14651858.CD010533.pub2
10.1002/14651858.CD010298.pub2
10.1002/14651858.CD009311.pub2
10.1002/14651858.CD008562.pub3
10.1002/14651858.CD010615.pub2
10.1002/14651858.CD011577.pub2
10.1002/14651858.CD010432.pub2
10.1002/14651858.CD010981.pub2
10.1002/14651858.CD010248.pub2
10.1002/14651858.CD010984.pub2
10.1002/14651858.CD011157.pub2
10.1002/14651858.CD010983.pub2
10.1002/14651858.CD007107.pub3
10.1002/14651858.CD009624.pub2
10.1002/14651858.CD009310.pub2
10.1002/14651858.CD009733.pub3
10.1002/14651858.CD010816.pub2
10.1002/14651858.CD011756.pub2
10.1002/14651858.CD010982.pub2
10.1002/14651858.CD012055.pub2
10.1002/14651858.CD011305.pub2
10.1002/14651858.CD007941.pub3
10.1002/14651858.CD007110.pub3
10.1002/14651858.CD008814.pub2
10.1002/14651858.CD008414.pub2
10.1002/14651858.CD008013.pub2
10.1002/14651858.CD008538.pub2
10.1002/14651858.CD007443.pub2
10.1002/14651858.CD006913.pub2
10.1002/14651858.CD008424.pub2
10.1002/14651858.CD004118.pub2
10.1002/14651858.CD009710.pub2
10.1002/14651858.CD009400.pub2
10.1002/14651858.CD005111.pub3
10.1002/14651858.CD006095.pub3
10.1002/14651858.CD010410.pub2
10.1002/14651858.CD003460.pub3
10.1002/14651858.CD006320.pub4
10.1002/14651858.CD008486.pub2

10.1002/14651858.CD003459.pub4
10.1002/14651858.CD010233.pub2
10.1002/14651858.CD007571.pub2
10.1002/14651858.CD006884.pub3
10.1002/14651858.CD006618.pub3
10.1002/14651858.CD002913.pub3
10.1002/14651858.CD007744.pub2
10.1002/14651858.CD006774.pub4
10.1002/14651858.CD007560.pub3
10.1002/14651858.CD006790.pub3
10.1002/14651858.CD000296.pub4
10.1002/14651858.CD008655.pub3
10.1002/14651858.CD001176.pub3
10.1002/14651858.CD000067.pub3
10.1002/14651858.CD007698.pub3
10.1002/14651858.CD011661.pub2
10.1002/14651858.CD007348.pub2
10.1002/14651858.CD004827.pub4
10.1002/14651858.CD000478.pub4
10.1002/14651858.CD000299.pub3
10.1002/14651858.CD000543.pub4
10.1002/14651858.CD000544.pub4
10.1002/14651858.CD010642.pub2
10.1002/14651858.CD008870.pub2
10.1002/14651858.CD003715.pub3
10.1002/14651858.CD009118.pub3
10.1002/14651858.CD000545.pub5
10.1002/14651858.CD010873.pub4
10.1002/14651858.CD007572.pub3
10.1002/14651858.CD006096.pub4
10.1002/14651858.CD011256.pub2
10.1002/14651858.CD004610.pub5
10.1002/14651858.CD012351.pub2
10.1002/14651858.CD005606.pub2
10.1002/14651858.CD008234.pub2
10.1002/14651858.CD002211.pub2
10.1002/14651858.CD001935.pub3
10.1002/14651858.CD008607.pub2
10.1002/14651858.CD008514.pub2
10.1002/14651858.CD008515.pub2
10.1002/14651858.CD002851.pub4
10.1002/14651858.CD007960.pub2
10.1002/14651858.CD008263.pub2

10.1002/14651858.CD003997.pub2
10.1002/14651858.CD003423.pub3
10.1002/14651858.CD007946.pub2
10.1002/14651858.CD008675.pub2
10.1002/14651858.CD009238.pub2
10.1002/14651858.CD008693.pub2
10.1002/14651858.CD006987.pub2
10.1002/14651858.CD004461.pub3
10.1002/14651858.CD004739.pub4
10.1002/14651858.CD005053.pub4
10.1002/14651858.CD006371.pub3
10.1002/14651858.CD005607.pub4
10.1002/14651858.CD005395.pub3
10.1002/14651858.CD003852.pub3
10.1002/14651858.CD007904.pub3
10.1002/14651858.CD006285.pub2
10.1002/14651858.CD008512.pub2
10.1002/14651858.CD009441.pub2
10.1002/14651858.CD003998.pub3
10.1002/14651858.CD007806.pub4
10.1002/14651858.CD009810.pub2
10.1002/14651858.CD010151.pub2
10.1002/14651858.CD008669.pub2
10.1002/14651858.CD006991.pub2
10.1002/14651858.CD001802.pub3
10.1002/14651858.CD002027.pub2
10.1002/14651858.CD003162.pub3
10.1002/14651858.CD008419.pub2
10.1002/14651858.CD005397.pub4
10.1002/14651858.CD010198.pub2
10.1002/14651858.CD010591.pub2
10.1002/14651858.CD011165.pub2
10.1002/14651858.CD010375.pub2
10.1002/14651858.CD011992.pub2
10.1002/14651858.CD011991.pub2
10.1002/14651858.CD011995.pub2
10.1002/14651858.CD011996.pub2
10.1002/14651858.CD011994.pub2
10.1002/14651858.CD010696.pub2
10.1002/14651858.CD011993.pub2
10.1002/14651858.CD009163.pub3
10.1002/14651858.CD011112.pub2
10.1002/14651858.CD010342.pub3

10.1002/14651858.CD009832.pub2
10.1002/14651858.CD011684.pub2
10.1002/14651858.CD006287.pub4
10.1002/14651858.CD007294.pub2
10.1002/14651858.CD007584.pub2
10.1002/14651858.CD003752.pub3
10.1002/14651858.CD007697.pub2
10.1002/14651858.CD002224.pub2
10.1002/14651858.CD001040.pub2
10.1002/14651858.CD003911.pub2
10.1002/14651858.CD002834.pub2
10.1002/14651858.CD007930.pub2
10.1002/14651858.CD001035.pub2
10.1002/14651858.CD003175.pub2
10.1002/14651858.CD007565.pub2
10.1002/14651858.CD008018.pub2
10.1002/14651858.CD007927.pub3
10.1002/14651858.CD006013.pub3
10.1002/14651858.CD008664.pub2
10.1002/14651858.CD007945.pub2
10.1002/14651858.CD003916.pub4
10.1002/14651858.CD005007.pub3
10.1002/14651858.CD007583.pub3
10.1002/14651858.CD004386.pub3
10.1002/14651858.CD005343.pub3
10.1002/14651858.CD003915.pub4
10.1002/14651858.CD006655.pub2
10.1002/14651858.CD007406.pub3
10.1002/14651858.CD006469.pub2
10.1002/14651858.CD007064.pub2
10.1002/14651858.CD005196.pub4
10.1002/14651858.CD008765.pub3
10.1002/14651858.CD006812.pub3
10.1002/14651858.CD007566.pub2
10.1002/14651858.CD008465.pub2
10.1002/14651858.CD007730.pub2
10.1002/14651858.CD008217.pub3
10.1002/14651858.CD003751.pub3
10.1002/14651858.CD007415.pub2
10.1002/14651858.CD009620.pub2
10.1002/14651858.CD003296.pub3
10.1002/14651858.CD007414.pub3
10.1002/14651858.CD003038.pub2

10.1002/14651858.CD006910.pub2
10.1002/14651858.CD009884.pub2
10.1002/14651858.CD006651.pub3
10.1002/14651858.CD008215.pub2
10.1002/14651858.CD010482.pub2
10.1002/14651858.CD003992.pub3
10.1002/14651858.CD010192.pub2
10.1002/14651858.CD008983.pub2
10.1002/14651858.CD001421.pub3
10.1002/14651858.CD003295.pub3
10.1002/14651858.CD009685.pub2
10.1002/14651858.CD009896.pub2
10.1002/14651858.CD004707.pub3
10.1002/14651858.CD001318.pub3
10.1002/14651858.CD009454.pub2
10.1002/14651858.CD007928.pub3
10.1002/14651858.CD012023.pub2
10.1002/14651858.CD004121.pub3
10.1002/14651858.CD005216.pub2
10.1002/14651858.CD004861.pub2
10.1002/14651858.CD007104.pub2
10.1002/14651858.CD010681.pub2
10.1002/14651858.CD006912.pub2
10.1002/14651858.CD002855.pub4
10.1002/14651858.CD003553.pub3
10.1002/14651858.CD006649.pub6
10.1002/14651858.CD009447.pub2
10.1002/14651858.CD006466.pub5
10.1002/14651858.CD000969.pub2
10.1002/14651858.CD002033.pub2
10.1002/14651858.CD000239.pub2
10.1002/14651858.CD006650.pub4
10.1002/14651858.CD000026.pub2
10.1002/14651858.CD006119.pub3
10.1002/14651858.CD008218.pub3
10.1002/14651858.CD007563.pub3
10.1002/14651858.CD005590.pub3
10.1002/14651858.CD010401.pub2
10.1002/14651858.CD007287.pub3
10.1002/14651858.CD003039.pub2
10.1002/14651858.CD006468.pub5
10.1002/14651858.CD011335.pub2
10.1002/14651858.CD011422

10.1002/14651858.CD007103.pub3
10.1002/14651858.CD010260.pub2
10.1002/14651858.CD007929.pub3
10.1002/14651858.CD009229.pub2
10.1002/14651858.CD005341.pub3
10.1002/14651858.CD007924.pub3
10.1002/14651858.CD011006.pub2
10.1002/14651858.CD008478.pub2
10.1002/14651858.CD004706.pub5
10.1002/14651858.CD006014.pub7
10.1002/14651858.CD009464.pub2
10.1002/14651858.CD005340.pub4
10.1002/14651858.CD011837.pub2
10.1002/14651858.CD011732.pub2
10.1002/14651858.CD007731.pub3
10.1002/14651858.CD011376.pub2
10.1002/14651858.CD005008.pub4
10.1002/14651858.CD005005.pub4
10.1002/14651858.CD007102.pub4
10.1002/14651858.CD003455.pub2
10.1002/14651858.CD005339.pub2
10.1002/14651858.CD011322.pub2
10.1002/14651858.CD006120.pub4
10.1002/14651858.CD011475.pub2
10.1002/14651858.CD011325.pub2
10.1002/14651858.CD009957.pub2
10.1002/14651858.CD005342.pub4
10.1002/14651858.CD006911.pub3
10.1002/14651858.CD009836.pub2
10.1002/14651858.CD010931.pub2
10.1002/14651858.CD008216.pub5
10.1002/14651858.CD007387.pub4
10.1002/14651858.CD011773.pub2
10.1002/14651858.CD003914.pub4
10.1002/14651858.CD007289.pub3
10.1002/14651858.CD009038.pub2
10.1002/14651858.CD005217.pub2
10.1002/14651858.CD008896.pub2
10.1002/14651858.CD009251.pub2
10.1002/14651858.CD004316.pub4
10.1002/14651858.CD006260.pub3
10.1002/14651858.CD003990.pub4
10.1002/14651858.CD004425.pub6

10.1002/14651858.CD006964.pub3
10.1002/14651858.CD003989.pub5
10.1002/14651858.CD003449.pub5
10.1002/14651858.CD007541.pub3
10.1002/14651858.CD010662.pub2
10.1002/14651858.CD005218.pub4
10.1002/14651858.CD004317.pub4
10.1002/14651858.CD003552.pub4
10.1002/14651858.CD003987.pub5
10.1002/14651858.CD004112.pub4
10.1002/14651858.CD003991.pub4
10.1002/14651858.CD006134.pub5
10.1002/14651858.CD010915.pub2
10.1002/14651858.CD006133.pub5
10.1002/14651858.CD006033.pub5
10.1002/14651858.CD001777.pub4
10.1002/14651858.CD007444.pub4
10.1002/14651858.CD011298.pub2
10.1002/14651858.CD004695.pub3
10.1002/14651858.CD007595.pub3
10.1002/14651858.CD003988.pub2
10.1002/14651858.CD011159.pub2
10.1002/14651858.CD011242.pub2
10.1002/14651858.CD009849.pub3
10.1002/14651858.CD003036.pub3
10.1002/14651858.CD009805.pub3
10.1002/14651858.CD001863.pub4
10.1002/14651858.CD001329.pub2
10.1002/14651858.CD007373.pub3
10.1002/14651858.CD011054.pub2
10.1002/14651858.CD011528.pub2
10.1002/14651858.CD012025.pub2
10.1002/14651858.CD012249
10.1002/14651858.CD003034.pub4
10.1002/14651858.CD005215.pub3
10.1002/14651858.CD010243.pub3
10.1002/14651858.CD008452.pub4
10.1002/14651858.CD008815.pub4
10.1002/14651858.CD011913.pub2
10.1002/14651858.CD011031.pub2
10.1002/14651858.CD008582.pub2
10.1002/14651858.CD007683.pub3
10.1002/14651858.CD007249.pub5

10.1002/14651858.CD001298.pub4
10.1002/14651858.CD009592.pub2
10.1002/14651858.CD006567.pub3
10.1002/14651858.CD005289.pub3
10.1002/14651858.CD005355.pub5
10.1002/14651858.CD010047.pub2
10.1002/14651858.CD010461.pub2
10.1002/14651858.CD010001.pub2
10.1002/14651858.CD004638.pub3
10.1002/14651858.CD006108.pub4
10.1002/14651858.CD004508.pub4
10.1002/14651858.CD005999.pub2
10.1002/14651858.CD008046.pub4
10.1002/14651858.CD006105.pub3
10.1002/14651858.CD006942.pub3
10.1002/14651858.CD007411.pub3
10.1002/14651858.CD011320.pub2
10.1002/14651858.CD011066.pub2
10.1002/14651858.CD009461.pub3
10.1002/14651858.CD011345.pub2
10.1002/14651858.CD005073.pub4
10.1002/14651858.CD010854.pub2
10.1002/14651858.CD005998.pub2
10.1002/14651858.CD009517.pub3
10.1002/14651858.CD000475.pub3
10.1002/14651858.CD003718.pub4
10.1002/14651858.CD009577.pub3
10.1002/14651858.CD002126.pub3
10.1002/14651858.CD003677.pub5
10.1002/14651858.CD010290.pub2
10.1002/14651858.CD006106.pub3
10.1002/14651858.CD006583.pub4
10.1002/14651858.CD003357.pub4
10.1002/14651858.CD006919.pub4
10.1002/14651858.CD001751.pub3
10.1002/14651858.CD009154.pub3
10.1002/14651858.CD007245.pub3
10.1002/14651858.CD009749.pub2
10.1002/14651858.CD009814.pub2
10.1002/14651858.CD007876.pub2
10.1002/14651858.CD003855.pub3
10.1002/14651858.CD001838.pub5
10.1002/14651858.CD012079

10.1002/14651858.CD000360.pub5
10.1002/14651858.CD009023.pub2
10.1002/14651858.CD006107.pub4
10.1002/14651858.CD002124.pub2
10.1002/14651858.CD011034.pub2
10.1002/14651858.CD007854.pub3
10.1002/14651858.CD003719.pub4
10.1002/14651858.CD007689.pub3
10.1002/14651858.CD011537.pub2
10.1002/14651858.CD001750.pub4
10.1002/14651858.CD011424.pub2
10.1002/14651858.CD002118.pub5
10.1002/14651858.CD001302.pub3
10.1002/14651858.CD010407.pub2
10.1002/14651858.CD012376
10.1002/14651858.CD004832.pub4
10.1002/14651858.CD001500.pub3
10.1002/14651858.CD008536.pub3
10.1002/14651858.CD007535.pub3
10.1002/14651858.CD003938.pub2
10.1002/14651858.CD008741.pub2
10.1002/14651858.CD007501.pub2
10.1002/14651858.CD001220.pub3
10.1002/14651858.CD007496.pub2
10.1002/14651858.CD009337
10.1002/14651858.CD007844.pub2
10.1002/14651858.CD008739.pub2
10.1002/14651858.CD006045.pub3
10.1002/14651858.CD004776.pub3
10.1002/14651858.CD009513
10.1002/14651858.CD005274.pub3
10.1002/14651858.CD009756
10.1002/14651858.CD005272.pub3
10.1002/14651858.CD007189.pub3
10.1002/14651858.CD009755
10.1002/14651858.CD009748.pub2
10.1002/14651858.CD001224.pub4
10.1002/14651858.CD003510.pub3
10.1002/14651858.CD009192.pub2
10.1002/14651858.CD009468.pub2
10.1002/14651858.CD007191.pub2
10.1002/14651858.CD005175.pub3
10.1002/14651858.CD010119

10.1002/14651858.CD009190.pub2
10.1002/14651858.CD009153.pub3
10.1002/14651858.CD004536.pub3
10.1002/14651858.CD009012.pub2
10.1002/14651858.CD005481.pub3
10.1002/14651858.CD009189.pub2
10.1002/14651858.CD008270.pub2
10.1002/14651858.CD010929.pub2
10.1002/14651858.CD009826.pub2
10.1002/14651858.CD010309.pub2
10.1002/14651858.CD009987.pub2
10.1002/14651858.CD010666
10.1002/14651858.CD004772.pub4
10.1002/14651858.CD008439.pub3
10.1002/14651858.CD009886.pub2
10.1002/14651858.CD007331.pub3
10.1002/14651858.CD008720.pub2
10.1002/14651858.CD007497.pub2
10.1002/14651858.CD003256.pub2
10.1002/14651858.CD003363.pub3
10.1002/14651858.CD011323
10.1002/14651858.CD008605.pub3
10.1002/14651858.CD002249.pub5
10.1002/14651858.CD004014.pub6
10.1002/14651858.CD004378.pub3
10.1002/14651858.CD004753.pub4
10.1002/14651858.CD009090.pub2
10.1002/14651858.CD004752.pub2
10.1002/14651858.CD010503.pub2
10.1002/14651858.CD011872.pub2
10.1002/14651858.CD002811.pub4
10.1002/14651858.CD011184.pub2
10.1002/14651858.CD010770.pub2
10.1002/14651858.CD004143.pub5
10.1002/14651858.CD005070.pub3
10.1002/14651858.CD009881.pub2
10.1002/14651858.CD003414.pub3
10.1002/14651858.CD006150.pub2
10.1002/14651858.CD006109.pub3
10.1002/14651858.CD004637.pub2
10.1002/14651858.CD004472.pub3
10.1002/14651858.CD007038.pub2
10.1002/14651858.CD008012.pub3

10.1002/14651858.CD005566.pub3
10.1002/14651858.CD001561.pub3
10.1002/14651858.CD003040.pub2
10.1002/14651858.CD005158.pub3
10.1002/14651858.CD004466.pub3
10.1002/14651858.CD007101.pub2
10.1002/14651858.CD007224.pub2
10.1002/14651858.CD002752.pub3
10.1002/14651858.CD008523.pub2
10.1002/14651858.CD004194.pub3
10.1002/14651858.CD003334.pub2
10.1002/14651858.CD002137.pub3
10.1002/14651858.CD008844.pub2
10.1002/14651858.CD008685.pub2
10.1002/14651858.CD010118.pub2
10.1002/14651858.CD009581.pub2
10.1002/14651858.CD009671.pub2
10.1002/14651858.CD003611.pub3
10.1002/14651858.CD004816.pub5
10.1002/14651858.CD009874.pub2
10.1002/14651858.CD003464.pub2
10.1002/14651858.CD005151.pub2
10.1002/14651858.CD009507.pub2
10.1002/14651858.CD002751.pub3
10.1002/14651858.CD009934.pub2
10.1002/14651858.CD005351.pub3
10.1002/14651858.CD009825.pub2
10.1002/14651858.CD004471.pub3
10.1002/14651858.CD010392.pub2
10.1002/14651858.CD010393.pub2
10.1002/14651858.CD010395.pub2
10.1002/14651858.CD002128.pub5
10.1002/14651858.CD002130.pub4
10.1002/14651858.CD003336.pub3
10.1002/14651858.CD008842.pub2
10.1002/14651858.CD006577.pub3
10.1002/14651858.CD007260.pub3
10.1002/14651858.CD010366.pub2
10.1002/14651858.CD002901.pub3
10.1002/14651858.CD010072.pub2
10.1002/14651858.CD009917.pub2
10.1002/14651858.CD003463.pub2
10.1002/14651858.CD008684.pub2

10.1002/14651858.CD003331.pub4
10.1002/14651858.CD009752.pub2
10.1002/14651858.CD009669.pub2
10.1002/14651858.CD007131.pub3
10.1002/14651858.CD009387.pub2
10.1002/14651858.CD003462.pub3
10.1002/14651858.CD010652.pub2
10.1002/14651858.CD010191.pub2
10.1002/14651858.CD010405.pub2
10.1002/14651858.CD006870.pub3
10.1002/14651858.CD009502.pub3
10.1002/14651858.CD007259.pub2
10.1002/14651858.CD009217.pub3
10.1002/14651858.CD003712.pub3
10.1002/14651858.CD009515.pub2
10.1002/14651858.CD002229.pub4
10.1002/14651858.CD007398.pub3
10.1002/14651858.CD005050.pub3
10.1002/14651858.CD004370.pub3
10.1002/14651858.CD009503.pub3
10.1002/14651858.CD003176.pub3
10.1002/14651858.CD010237.pub2
10.1002/14651858.CD005049.pub4
10.1002/14651858.CD010390.pub2
10.1002/14651858.CD004101.pub5
10.1002/14651858.CD004818.pub4
10.1002/14651858.CD007614.pub2
10.1002/14651858.CD006886.pub2
10.1002/14651858.CD011148.pub2
10.1002/14651858.CD011163.pub2
10.1002/14651858.CD011737
10.1002/14651858.CD011168.pub2
10.1002/14651858.CD011583.pub2
10.1002/14651858.CD008553.pub2
10.1002/14651858.CD009580.pub2
10.1002/14651858.CD011094.pub2
10.1002/14651858.CD009889.pub2
10.1002/14651858.CD006536.pub4
10.1002/14651858.CD008093.pub2
10.1002/14651858.CD009386.pub2
10.1002/14651858.CD006781.pub3
10.1002/14651858.CD011834
10.1002/14651858.CD011472.pub2

10.1002/14651858.CD007037.pub3
10.1002/14651858.CD006762.pub2
10.1002/14651858.CD001800.pub3
10.1002/14651858.CD010411.pub2
10.1002/14651858.CD010988.pub2
10.1002/14651858.CD011047.pub2
10.1002/14651858.CD007228.pub3
10.1002/14651858.CD011637.pub2
10.1002/14651858.CD010876.pub2
10.1002/14651858.CD004815.pub4
10.1002/14651858.CD009586.pub3
10.1002/14651858.CD009077.pub3
10.1002/14651858.CD009880.pub2
10.1002/14651858.CD009571.pub2
10.1002/14651858.CD003839.pub3
10.1002/14651858.CD003333.pub3
10.1002/14651858.CD009753.pub2
10.1002/14651858.CD009462.pub2
10.1002/14651858.CD007160.pub4
10.1002/14651858.CD012088.pub2
10.1002/14651858.CD011747.pub2
10.1002/14651858.CD011197.pub2
10.1002/14651858.CD009868.pub3
10.1002/14651858.CD008966.pub2
10.1002/14651858.CD004371.pub4
10.1002/14651858.CD011814.pub2
10.1002/14651858.CD007888.pub3
10.1002/14651858.CD012264.pub2
10.1002/14651858.CD011114.pub2
10.1002/14651858.CD006887.pub4
10.1002/14651858.CD011793.pub2
10.1002/14651858.CD011851.pub2
10.1002/14651858.CD011986.pub2
10.1002/14651858.CD011719.pub3
10.1002/14651858.CD008600.pub3
10.1002/14651858.CD011748.pub2
10.1002/14651858.CD007130.pub4
10.1002/14651858.CD011312.pub3
10.1002/14651858.CD008895.pub3
10.1002/14651858.CD009744.pub2
10.1002/14651858.CD004467.pub3
10.1002/14651858.CD006612.pub5
10.1002/14651858.CD005051.pub3

10.1002/14651858.CD002902.pub4
10.1002/14651858.CD012481.pub2
10.1002/14651858.CD003186.pub3
10.1002/14651858.CD008118.pub2
10.1002/14651858.CD005184.pub2
10.1002/14651858.CD004184.pub2
10.1002/14651858.CD007653.pub2
10.1002/14651858.CD004643.pub3
10.1002/14651858.CD006742.pub2
10.1002/14651858.CD009096.pub2
10.1002/14651858.CD008167.pub3
10.1002/14651858.CD007452.pub2
10.1002/14651858.CD008277.pub2
10.1002/14651858.CD003824.pub2
10.1002/14651858.CD010052.pub2
10.1002/14651858.CD008117.pub2
10.1002/14651858.CD007450.pub2
10.1002/14651858.CD004937.pub2
10.1002/14651858.CD008170.pub2
10.1002/14651858.CD003825.pub4
10.1002/14651858.CD010037.pub2
10.1002/14651858.CD007449.pub2
10.1002/14651858.CD010254.pub2
10.1002/14651858.CD007435.pub3
10.1002/14651858.CD007654.pub4
10.1002/14651858.CD011745.pub2
10.1002/14651858.CD008274.pub3
10.1002/14651858.CD010316.pub2
10.1002/14651858.CD007451.pub2
10.1002/14651858.CD002003.pub5
10.1002/14651858.CD008996.pub2
10.1002/14651858.CD007655.pub3
10.1002/14651858.CD011499.pub2
10.1002/14651858.CD007066.pub3
10.1002/14651858.CD008652.pub3
10.1002/14651858.CD008276.pub2
10.1002/14651858.CD011575.pub2
10.1002/14651858.CD004022.pub4
10.1002/14651858.CD008893.pub3
10.1002/14651858.CD008226.pub3
10.1002/14651858.CD003882.pub4
10.1002/14651858.CD002240.pub4
10.1002/14651858.CD009252

10.1002/14651858.CD005493.pub3
10.1002/14651858.CD005230.pub2
10.1002/14651858.CD004201.pub3
10.1002/14651858.CD003306.pub2
10.1002/14651858.CD009508
10.1002/14651858.CD008224.pub2
10.1002/14651858.CD004997.pub3
10.1002/14651858.CD007471.pub2
10.1002/14651858.CD003193.pub4
10.1002/14651858.CD006934.pub3
10.1002/14651858.CD005429.pub2
10.1002/14651858.CD007959.pub3
10.1002/14651858.CD004010.pub3
10.1002/14651858.CD002238.pub2
10.1002/14651858.CD001405.pub3
10.1002/14651858.CD001202.pub5
10.1002/14651858.CD002116.pub2
10.1002/14651858.CD009408.pub2
10.1002/14651858.CD002111.pub3
10.1002/14651858.CD005428.pub2
10.1002/14651858.CD001757.pub4
10.1002/14651858.CD002114.pub2
10.1002/14651858.CD003637.pub3
10.1002/14651858.CD003195.pub3
10.1002/14651858.CD004927.pub4
10.1002/14651858.CD006744.pub3
10.1002/14651858.CD002115.pub5
10.1002/14651858.CD008306.pub3
10.1002/14651858.CD005654.pub3
10.1002/14651858.CD004013.pub4
10.1002/14651858.CD010258.pub2
10.1002/14651858.CD001756.pub6
10.1002/14651858.CD005086.pub4
10.1002/14651858.CD011179.pub2
10.1002/14651858.CD010217.pub2
10.1002/14651858.CD004464.pub3
10.1002/14651858.CD003505.pub5
10.1002/14651858.CD010551.pub3
10.1002/14651858.CD001843.pub5
10.1002/14651858.CD011115.pub2
10.1002/14651858.CD004012.pub5
10.1002/14651858.CD001758.pub3
10.1002/14651858.CD004203.pub3

10.1002/14651858.CD003636.pub4
10.1002/14651858.CD011627.pub2
10.1002/14651858.CD002117.pub2
10.1002/14651858.CD003881.pub4
10.1002/14651858.CD002239.pub3
10.1002/14651858.CD008709.pub3
10.1002/14651858.CD001755.pub2
10.1002/14651858.CD001754.pub4
10.1002/14651858.CD002912.pub7
10.1002/14651858.CD001088.pub3
10.1002/14651858.CD006375.pub4
10.1002/14651858.CD010098.pub4
10.1002/14651858.CD005353.pub4
10.1002/14651858.CD001837.pub3
10.1002/14651858.CD009046.pub2
10.1002/14651858.CD005084.pub3
10.1002/14651858.CD001291.pub2
10.1002/14651858.CD006219.pub3
10.1002/14651858.CD000214.pub2
10.1002/14651858.CD000191.pub2
10.1002/14651858.CD007072.pub2
10.1002/14651858.CD009325.pub2
10.1002/14651858.CD002928.pub3
10.1002/14651858.CD008033.pub3
10.1002/14651858.CD009187.pub2
10.1002/14651858.CD000165.pub4
10.1002/14651858.CD004705.pub4
10.1002/14651858.CD003086.pub3
10.1002/14651858.CD007253.pub3
10.1002/14651858.CD001188.pub4
10.1002/14651858.CD003999.pub4
10.1002/14651858.CD006102.pub2
10.1002/14651858.CD000146.pub4
10.1002/14651858.CD001293.pub3
10.1002/14651858.CD002850.pub3
10.1002/14651858.CD000009.pub4
10.1002/14651858.CD002294.pub4
10.1002/14651858.CD009990.pub2
10.1002/14651858.CD002295.pub5
10.1002/14651858.CD008743.pub3
10.1002/14651858.CD001746.pub3
10.1002/14651858.CD001118.pub3
10.1002/14651858.CD009164.pub2

10.1002/14651858.CD003440.pub4
10.1002/14651858.CD005549.pub3
10.1002/14651858.CD004493.pub3
10.1002/14651858.CD007505.pub2
10.1002/14651858.CD004307.pub5
10.1002/14651858.CD006936.pub3
10.1002/14651858.CD009670.pub3
10.1002/14651858.CD004306.pub5
10.1002/14651858.CD000031.pub4
10.1002/14651858.CD006611.pub4
10.1002/14651858.CD005992.pub3
10.1002/14651858.CD010078.pub2
10.1002/14651858.CD008286.pub3
10.1002/14651858.CD011120.pub2
10.1002/14651858.CD011045.pub2
10.1002/14651858.CD010274.pub2
10.1002/14651858.CD010742.pub2
10.1002/14651858.CD010216.pub3
10.1002/14651858.CD011856.pub2
10.1002/14651858.CD005231.pub3
10.1002/14651858.CD006103.pub7
10.1002/14651858.CD008645.pub3
10.1002/14651858.CD001006.pub3
10.1002/14651858.CD007078.pub5
10.1002/14651858.CD011244.pub2
10.1002/14651858.CD001292.pub3
10.1002/14651858.CD001007.pub3
10.1002/14651858.CD001055.pub5
10.1002/14651858.CD008976.pub2
10.1002/14651858.CD007349.pub2
10.1002/14651858.CD006885.pub2
10.1002/14651858.CD006576.pub2
10.1002/14651858.CD008195.pub2
10.1002/14651858.CD001532.pub4
10.1002/14651858.CD009294.pub2
10.1002/14651858.CD004926.pub3
10.1002/14651858.CD009427.pub2
10.1002/14651858.CD007234.pub2
10.1002/14651858.CD004292.pub3
10.1002/14651858.CD008007.pub2
10.1002/14651858.CD006029.pub4
10.1002/14651858.CD004135.pub3
10.1002/14651858.CD009063.pub2

10.1002/14651858.CD008871.pub2
10.1002/14651858.CD004720.pub3
10.1002/14651858.CD008569.pub2
10.1002/14651858.CD003382.pub3
10.1002/14651858.CD003546.pub3
10.1002/14651858.CD009071.pub2
10.1002/14651858.CD007044.pub3
10.1002/14651858.CD001423.pub3
10.1002/14651858.CD008973.pub2
10.1002/14651858.CD008529.pub3
10.1002/14651858.CD011442.pub2
10.1002/14651858.CD010716.pub2
10.1002/14651858.CD009266.pub2
10.1002/14651858.CD012111.pub2
10.1002/14651858.CD012112.pub2
10.1002/14651858.CD012045.pub2
10.1002/14651858.CD009625.pub2
10.1002/14651858.CD010723.pub2
10.1002/14651858.CD011673.pub2
10.1002/14651858.CD007152.pub2
10.1002/14651858.CD001168.pub2
10.1002/14651858.CD006545.pub2
10.1002/14651858.CD005205.pub3
10.1002/14651858.CD008092.pub2
10.1002/14651858.CD008596.pub2
10.1002/14651858.CD001541.pub3
10.1002/14651858.CD008240.pub2
10.1002/14651858.CD008838.pub2
10.1002/14651858.CD003584.pub2
10.1002/14651858.CD006983.pub3
10.1002/14651858.CD008946.pub2
10.1002/14651858.CD002086.pub2
10.1002/14651858.CD004416.pub2
10.1002/14651858.CD007633.pub2
10.1002/14651858.CD008955.pub2
10.1002/14651858.CD008642.pub2
10.1002/14651858.CD007281.pub2
10.1002/14651858.CD004054.pub3
10.1002/14651858.CD009481.pub2
10.1002/14651858.CD009446.pub2
10.1002/14651858.CD004415.pub2
10.1002/14651858.CD005028.pub3
10.1002/14651858.CD005506.pub5

10.1002/14651858.CD008533.pub3
10.1002/14651858.CD009779.pub2
10.1002/14651858.CD004778.pub3
10.1002/14651858.CD009662.pub2
10.1002/14651858.CD008370.pub3
10.1002/14651858.CD008107.pub2
10.1002/14651858.CD002095.pub5
10.1002/14651858.CD009179.pub2
10.1002/14651858.CD010326.pub2
10.1002/14651858.CD007999.pub2
10.1002/14651858.CD005096.pub4
10.1002/14651858.CD008415.pub2
10.1002/14651858.CD010244.pub2
10.1002/14651858.CD008446.pub3
10.1002/14651858.CD008945.pub2
10.1002/14651858.CD005584.pub3
10.1002/14651858.CD008487.pub2
10.1002/14651858.CD006640.pub3
10.1002/14651858.CD005048.pub4
10.1002/14651858.CD008337.pub2
10.1002/14651858.CD005046.pub3
10.1002/14651858.CD003353.pub2
10.1002/14651858.CD008550.pub2
10.1002/14651858.CD010623.pub2
10.1002/14651858.CD010605.pub2
10.1002/14651858.CD005583.pub2
10.1002/14651858.CD008788.pub3
10.1002/14651858.CD007884.pub3
10.1002/14651858.CD001556.pub3
10.1002/14651858.CD001964.pub4
10.1002/14651858.CD008096.pub4
10.1002/14651858.CD003243.pub3
10.1002/14651858.CD008688.pub2
10.1002/14651858.CD011382.pub2
10.1002/14651858.CD011522.pub2
10.1002/14651858.CD011521.pub2
10.1002/14651858.CD004520.pub7
10.1002/14651858.CD006053.pub6
10.1002/14651858.CD011498.pub2
10.1002/14651858.CD009621.pub2
10.1002/14651858.CD011523.pub2
10.1002/14651858.CD011390.pub2
10.1002/14651858.CD009477.pub2

10.1002/14651858.CD011389.pub2
10.1002/14651858.CD011392.pub2
10.1002/14651858.CD011391.pub2
10.1002/14651858.CD008914.pub3
10.1002/14651858.CD010571.pub2
10.1002/14651858.CD011383.pub2
10.1002/14651858.CD011461.pub2
10.1002/14651858.CD009034.pub2
10.1002/14651858.CD011862.pub2
10.1002/14651858.CD011194.pub2
10.1002/14651858.CD011969.pub2
10.1002/14651858.CD010511.pub2
10.1002/14651858.CD010583.pub3
10.1002/14651858.CD011384.pub2
10.1002/14651858.CD012257.pub2
10.1002/14651858.CD004064.pub4
10.1002/14651858.CD000536.pub2
10.1002/14651858.CD008472.pub2
10.1002/14651858.CD008826.pub2
10.1002/14651858.CD001272.pub2
10.1002/14651858.CD007162.pub2
10.1002/14651858.CD002070.pub2
10.1002/14651858.CD007921.pub2
10.1002/14651858.CD006687.pub3
10.1002/14651858.CD000188.pub2
10.1002/14651858.CD003635.pub3
10.1002/14651858.CD009536.pub2
10.1002/14651858.CD003230.pub4
10.1002/14651858.CD002071.pub3
10.1002/14651858.CD006512.pub2
10.1002/14651858.CD007057.pub3
10.1002/14651858.CD001368.pub4
10.1002/14651858.CD000988.pub4
10.1002/14651858.CD004001.pub3
10.1002/14651858.CD000095.pub2
10.1002/14651858.CD000986.pub3
10.1002/14651858.CD001486.pub2
10.1002/14651858.CD006888.pub3
10.1002/14651858.CD003833.pub4
10.1002/14651858.CD002784.pub2
10.1002/14651858.CD009894.pub2
10.1002/14651858.CD003074.pub3
10.1002/14651858.CD004982.pub5

10.1002/14651858.CD003285.pub2
10.1002/14651858.CD005507.pub3
10.1002/14651858.CD005508.pub3
10.1002/14651858.CD008201.pub2
10.1002/14651858.CD005263.pub3
10.1002/14651858.CD010308.pub2
10.1002/14651858.CD010389.pub2
10.1002/14651858.CD008426.pub2
10.1002/14651858.CD009436.pub2
10.1002/14651858.CD006137.pub2
10.1002/14651858.CD010307.pub2
10.1002/14651858.CD009992.pub2
10.1002/14651858.CD003263.pub5
10.1002/14651858.CD008138.pub3
10.1002/14651858.CD008736.pub2
10.1002/14651858.CD009864.pub2
10.1002/14651858.CD010497.pub2
10.1002/14651858.CD010017.pub2
10.1002/14651858.CD010095.pub2
10.1002/14651858.CD003262.pub5
10.1002/14651858.CD007346.pub3
10.1002/14651858.CD010081.pub2
10.1002/14651858.CD010334.pub2
10.1002/14651858.CD008774.pub2
10.1002/14651858.CD005491.pub3
10.1002/14651858.CD004685.pub3
10.1002/14651858.CD011946.pub2
10.1002/14651858.CD009687.pub2
10.1002/14651858.CD011161.pub2
10.1002/14651858.CD002954.pub3
10.1002/14651858.CD004767.pub4
10.1002/14651858.CD006345.pub3
10.1002/14651858.CD009758.pub2
10.1002/14651858.CD007628.pub4
10.1002/14651858.CD004981.pub4
10.1002/14651858.CD007917.pub2
10.1002/14651858.CD010031.pub2
10.1002/14651858.CD012119.pub2
10.1002/14651858.CD003075.pub3
10.1002/14651858.CD010525.pub2
10.1002/14651858.CD001099.pub3
10.1002/14651858.CD008819.pub3
10.1002/14651858.CD005983.pub3

10.1002/14651858.CD003504.pub2
10.1002/14651858.CD004178.pub2
10.1002/14651858.CD010196.pub2
10.1002/14651858.CD005982.pub2
10.1002/14651858.CD003749.pub3
10.1002/14651858.CD006680.pub2
10.1002/14651858.CD001999.pub2
10.1002/14651858.CD003747.pub4
10.1002/14651858.CD009162.pub2
10.1002/14651858.CD008207.pub3
10.1002/14651858.CD001367.pub3
10.1002/14651858.CD006767.pub3
10.1002/14651858.CD010149.pub2
10.1002/14651858.CD000990.pub3
10.1002/14651858.CD009638.pub2
10.1002/14651858.CD005624.pub3
10.1002/14651858.CD003748.pub4
10.1002/14651858.CD008462.pub2
10.1002/14651858.CD010019.pub2
10.1002/14651858.CD009543.pub3
10.1002/14651858.CD002944.pub2
10.1002/14651858.CD008347.pub3
10.1002/14651858.CD006342.pub2
10.1002/14651858.CD008203.pub3
10.1002/14651858.CD001484.pub3
10.1002/14651858.CD001835.pub4
10.1002/14651858.CD001097.pub3
10.1002/14651858.CD007561.pub2
10.1002/14651858.CD005260.pub3
10.1002/14651858.CD000535.pub3
10.1002/14651858.CD009658.pub2
10.1002/14651858.CD009648.pub3
10.1002/14651858.CD007798.pub4
10.1002/14651858.CD002786.pub3
10.1002/14651858.CD010956.pub2
10.1002/14651858.CD005625.pub3
10.1002/14651858.CD010996.pub2
10.1002/14651858.CD011015.pub2
10.1002/14651858.CD005262.pub3
10.1002/14651858.CD004437.pub4
10.1002/14651858.CD010373.pub2
10.1002/14651858.CD007699.pub3
10.1002/14651858.CD010957.pub2

10.1002/14651858.CD007371.pub3
10.1002/14651858.CD011033.pub3
10.1002/14651858.CD004179.pub2
10.1002/14651858.CD002069.pub5
10.1002/14651858.CD009541.pub2
10.1002/14651858.CD008942.pub2
10.1002/14651858.CD003229.pub3
10.1002/14651858.CD011319.pub2
10.1002/14651858.CD005258.pub3
10.1002/14651858.CD004002.pub3
10.1002/14651858.CD009418.pub3
10.1002/14651858.CD010878.pub2
10.1002/14651858.CD002783.pub4
10.1002/14651858.CD010637.pub2
10.1002/14651858.CD008500.pub4
10.1002/14651858.CD010447.pub3
10.1002/14651858.CD011188.pub2
10.1002/14651858.CD005134.pub3
10.1002/14651858.CD010185.pub3
10.1002/14651858.CD006771.pub3
10.1002/14651858.CD001100.pub4
10.1002/14651858.CD012302.pub2
10.1002/14651858.CD002000.pub3
10.1002/14651858.CD007557.pub3
10.1002/14651858.CD005261.pub4
10.1002/14651858.CD002001.pub3
10.1002/14651858.CD011741.pub2
10.1002/14651858.CD006681.pub4
10.1002/14651858.CD010837.pub3
10.1002/14651858.CD004174.pub3
10.1002/14651858.CD009170.pub2
10.1002/14651858.CD006308.pub3
10.1002/14651858.CD010183.pub2
10.1002/14651858.CD008570.pub2
10.1002/14651858.CD009209.pub2
10.1002/14651858.CD010208.pub2
10.1002/14651858.CD008742.pub2
10.1002/14651858.CD009776.pub2
10.1002/14651858.CD006237.pub3
10.1002/14651858.CD010090.pub2
10.1002/14651858.CD002892.pub5
10.1002/14651858.CD010305.pub2
10.1002/14651858.CD007569.pub3

10.1002/14651858.CD009573.pub2
10.1002/14651858.CD009385.pub2
10.1002/14651858.CD006955.pub3
10.1002/14651858.CD008881.pub2
10.1002/14651858.CD010306.pub2
10.1002/14651858.CD011621.pub2
10.1002/14651858.CD010912.pub3
10.1002/14651858.CD010157.pub2
10.1002/14651858.CD009778.pub2
10.1002/14651858.CD010641.pub2
10.1002/14651858.CD011899.pub2
10.1002/14651858.CD011618.pub2
10.1002/14651858.CD011867.pub2
10.1002/14651858.CD006396.pub4
10.1002/14651858.CD011255.pub2
10.1002/14651858.CD012462.pub2
10.1002/14651858.CD011918.pub2
10.1002/14651858.CD006868.pub3
10.1002/14651858.CD011202.pub2
10.1002/14651858.CD007238.pub2
10.1002/14651858.CD009701.pub2
10.1002/14651858.CD004075.pub4
10.1002/14651858.CD000112.pub3
10.1002/14651858.CD008825.pub2
10.1002/14651858.CD010660.pub2
10.1002/14651858.CD001807.pub2
10.1002/14651858.CD010385.pub2
10.1002/14651858.CD009708.pub2
10.1002/14651858.CD007482.pub3
10.1002/14651858.CD007772.pub3
10.1002/14651858.CD007873.pub3
10.1002/14651858.CD009394.pub2
10.1002/14651858.CD004453.pub3
10.1002/14651858.CD007715.pub2
10.1002/14651858.CD006167.pub4
10.1002/14651858.CD007123.pub3
10.1002/14651858.CD009243.pub3
10.1002/14651858.CD009241.pub3
10.1002/14651858.CD006431.pub3
10.1002/14651858.CD007201.pub3
10.1002/14651858.CD005461.pub4
10.1002/14651858.CD004074.pub3
10.1002/14651858.CD008534.pub2

10.1002/14651858.CD000493.pub2
10.1002/14651858.CD008982.pub2
10.1002/14651858.CD006760.pub2
10.1002/14651858.CD010088.pub2
10.1002/14651858.CD003767.pub3
10.1002/14651858.CD004665.pub3
10.1002/14651858.CD008019.pub2
10.1002/14651858.CD008580.pub2
10.1002/14651858.CD003094.pub3
10.1002/14651858.CD002256.pub2
10.1002/14651858.CD004226.pub3
10.1002/14651858.CD001337.pub2
10.1002/14651858.CD000220.pub2
10.1002/14651858.CD008410.pub2
10.1002/14651858.CD006168.pub2
10.1002/14651858.CD004908.pub2
10.1002/14651858.CD006907.pub2
10.1002/14651858.CD009215
10.1002/14651858.CD009514
10.1002/14651858.CD007559.pub2
10.1002/14651858.CD005943.pub4
10.1002/14651858.CD009232
10.1002/14651858.CD009107.pub2
10.1002/14651858.CD000013.pub2
10.1002/14651858.CD004456.pub3
10.1002/14651858.CD000331.pub3
10.1002/14651858.CD009290.pub2
10.1002/14651858.CD009037.pub2
10.1002/14651858.CD005544.pub2
10.1002/14651858.CD008679.pub2
10.1002/14651858.CD009148.pub2
10.1002/14651858.CD001233.pub2
10.1002/14651858.CD006176.pub2
10.1002/14651858.CD003928.pub3
10.1002/14651858.CD003518.pub3
10.1002/14651858.CD009200.pub2
10.1002/14651858.CD008681.pub2
10.1002/14651858.CD001064.pub2
10.1002/14651858.CD005457.pub4
10.1002/14651858.CD008510.pub2
10.1002/14651858.CD001065.pub2
10.1002/14651858.CD004945.pub3
10.1002/14651858.CD001062.pub2

10.1002/14651858.CD009062.pub2
10.1002/14651858.CD006304.pub3
10.1002/14651858.CD007113.pub3
10.1002/14651858.CD000108.pub2
10.1002/14651858.CD009021.pub2
10.1002/14651858.CD003248.pub3
10.1002/14651858.CD007426.pub2
10.1002/14651858.CD003517.pub2
10.1002/14651858.CD000012.pub4
10.1002/14651858.CD009223.pub2
10.1002/14651858.CD006636.pub3
10.1002/14651858.CD000004.pub2
10.1002/14651858.CD008678.pub2
10.1002/14651858.CD000176.pub2
10.1002/14651858.CD005460.pub3
10.1002/14651858.CD007096.pub3
10.1002/14651858.CD000352.pub2
10.1002/14651858.CD003397.pub2
10.1002/14651858.CD000494.pub4
10.1002/14651858.CD005937.pub3
10.1002/14651858.CD000133.pub3
10.1002/14651858.CD009351.pub2
10.1002/14651858.CD007579.pub2
10.1002/14651858.CD003401.pub3
10.1002/14651858.CD007239.pub3
10.1002/14651858.CD007748.pub2
10.1002/14651858.CD004350.pub3
10.1002/14651858.CD000051.pub2
10.1002/14651858.CD000066.pub2
10.1002/14651858.CD003577.pub3
10.1002/14651858.CD000947.pub3
10.1002/14651858.CD007885.pub2
10.1002/14651858.CD000136.pub2
10.1002/14651858.CD000114.pub2
10.1002/14651858.CD007235.pub3
10.1002/14651858.CD003927.pub3
10.1002/14651858.CD000262.pub4
10.1002/14651858.CD007707.pub2
10.1002/14651858.CD005458.pub3
10.1002/14651858.CD009395.pub2
10.1002/14651858.CD009617.pub2
10.1002/14651858.CD008611.pub2
10.1002/14651858.CD006896.pub2

10.1002/14651858.CD008407.pub2
10.1002/14651858.CD007623.pub3
10.1002/14651858.CD001134.pub3
10.1002/14651858.CD004351.pub3
10.1002/14651858.CD007752.pub3
10.1002/14651858.CD005123.pub3
10.1002/14651858.CD000940.pub3
10.1002/14651858.CD008635.pub2
10.1002/14651858.CD000330.pub4
10.1002/14651858.CD003099.pub2
10.1002/14651858.CD006780.pub3
10.1002/14651858.CD003106.pub2
10.1002/14651858.CD009338.pub2
10.1002/14651858.CD005627.pub3
10.1002/14651858.CD010041.pub2
10.1002/14651858.CD006795.pub3
10.1002/14651858.CD006794.pub4
10.1002/14651858.CD004947.pub3
10.1002/14651858.CD003930.pub3
10.1002/14651858.CD006764.pub3
10.1002/14651858.CD010073.pub2
10.1002/14651858.CD001449.pub3
10.1002/14651858.CD000078.pub3
10.1002/14651858.CD004907.pub3
10.1002/14651858.CD010648.pub2
10.1002/14651858.CD008977.pub2
10.1002/14651858.CD009278.pub2
10.1002/14651858.CD006947.pub3
10.1002/14651858.CD008878.pub2
10.1002/14651858.CD005938.pub3
10.1002/14651858.CD009104.pub2
10.1002/14651858.CD003934.pub4
10.1002/14651858.CD001808.pub2
10.1002/14651858.CD003096.pub2
10.1002/14651858.CD010087.pub2
10.1002/14651858.CD007372.pub3
10.1002/14651858.CD003511.pub3
10.1002/14651858.CD004071.pub3
10.1002/14651858.CD009328.pub2
10.1002/14651858.CD003396.pub2
10.1002/14651858.CD000019.pub3
10.1002/14651858.CD002963.pub2
10.1002/14651858.CD000246.pub2

10.1002/14651858.CD002866.pub3
10.1002/14651858.CD001058.pub3
10.1002/14651858.CD004224.pub3
10.1002/14651858.CD004068.pub4
10.1002/14651858.CD002073.pub3
10.1002/14651858.CD000014.pub4
10.1002/14651858.CD006770.pub3
10.1002/14651858.CD010441.pub2
10.1002/14651858.CD003582.pub2
10.1002/14651858.CD004352.pub3
10.1002/14651858.CD009951.pub2
10.1002/14651858.CD010800.pub2
10.1002/14651858.CD002252.pub3
10.1002/14651858.CD000942.pub3
10.1002/14651858.CD007062.pub3
10.1002/14651858.CD004943.pub4
10.1002/14651858.CD003249.pub3
10.1002/14651858.CD008053.pub3
10.1002/14651858.CD000937.pub2
10.1002/14651858.CD010312.pub2
10.1002/14651858.CD010322.pub2
10.1002/14651858.CD002860.pub2
10.1002/14651858.CD008758.pub2
10.1002/14651858.CD002255.pub2
10.1002/14651858.CD004452.pub3
10.1002/14651858.CD007467.pub4
10.1002/14651858.CD003101.pub3
10.1002/14651858.CD006169.pub2
10.1002/14651858.CD004734.pub4
10.1002/14651858.CD004732.pub3
10.1002/14651858.CD001059.pub4
10.1002/14651858.CD009166.pub2
10.1002/14651858.CD001338.pub3
10.1002/14651858.CD004070.pub3
10.1002/14651858.CD001060.pub2
10.1002/14651858.CD007462.pub3
10.1002/14651858.CD005125.pub4
10.1002/14651858.CD010209.pub2
10.1002/14651858.CD000163.pub2
10.1002/14651858.CD000203.pub3
10.1002/14651858.CD000209.pub2
10.1002/14651858.CD004718.pub3
10.1002/14651858.CD006626.pub2

10.1002/14651858.CD006622.pub2
10.1002/14651858.CD002831.pub2
10.1002/14651858.CD004026.pub2
10.1002/14651858.CD000381.pub3
10.1002/14651858.CD007967.pub2
10.1002/14651858.CD004162.pub2
10.1002/14651858.CD000525.pub3
10.1002/14651858.CD006374.pub2
10.1002/14651858.CD008712.pub2
10.1002/14651858.CD007198.pub2
10.1002/14651858.CD001236.pub2
10.1002/14651858.CD008296.pub2
10.1002/14651858.CD009414.pub3
10.1002/14651858.CD008016.pub2
10.1002/14651858.CD009516.pub2
10.1002/14651858.CD007892.pub5
10.1002/14651858.CD010976.pub2
10.1002/14651858.CD008726.pub2
10.1002/14651858.CD009298.pub2
10.1002/14651858.CD003520.pub3
10.1002/14651858.CD007366.pub2
10.1002/14651858.CD004903.pub4
10.1002/14651858.CD008020.pub2
10.1002/14651858.CD006178.pub3
10.1002/14651858.CD007622.pub3
10.1002/14651858.CD000230.pub5
10.1002/14651858.CD000184.pub4
10.1002/14651858.CD007079.pub3
10.1002/14651858.CD000083.pub3
10.1002/14651858.CD003581.pub3
10.1002/14651858.CD007412.pub4
10.1002/14651858.CD010450.pub2
10.1002/14651858.CD007754.pub3
10.1002/14651858.CD006174.pub3
10.1002/14651858.CD010708.pub2
10.1002/14651858.CD001450.pub4
10.1002/14651858.CD000032.pub3
10.1002/14651858.CD006965.pub4
10.1002/14651858.CD009982.pub2
10.1002/14651858.CD001992.pub3
10.1002/14651858.CD000179.pub3
10.1002/14651858.CD010762.pub2
10.1002/14651858.CD001067.pub3

10.1002/14651858.CD005547.pub3
10.1002/14651858.CD007872.pub3
10.1002/14651858.CD011158.pub2
10.1002/14651858.CD002250.pub3
10.1002/14651858.CD001451.pub4
10.1002/14651858.CD007145.pub3
10.1002/14651858.CD003935.pub4
10.1002/14651858.CD002959.pub4
10.1002/14651858.CD007058.pub3
10.1002/14651858.CD007901.pub3
10.1002/14651858.CD000084.pub3
10.1002/14651858.CD000166.pub2
10.1002/14651858.CD000934.pub3
10.1002/14651858.CD010085.pub2
10.1002/14651858.CD010655.pub2
10.1002/14651858.CD000490.pub3
10.1002/14651858.CD007208.pub3
10.1002/14651858.CD009279.pub3
10.1002/14651858.CD011448.pub2
10.1002/14651858.CD004069.pub3
10.1002/14651858.CD000020.pub3
10.1002/14651858.CD010490.pub2
10.1002/14651858.CD008136.pub3
10.1002/14651858.CD007863.pub4
10.1002/14651858.CD010861.pub2
10.1002/14651858.CD007575.pub4
10.1002/14651858.CD011379.pub2
10.1002/14651858.CD011263.pub2
10.1002/14651858.CD011625.pub2
10.1002/14651858.CD001066.pub3
10.1002/14651858.CD002856.pub3
10.1002/14651858.CD001139.pub4
10.1002/14651858.CD004736.pub5
10.1002/14651858.CD004909.pub3
10.1002/14651858.CD006171.pub4
10.1002/14651858.CD008666.pub3
10.1002/14651858.CD010826.pub2
10.1002/14651858.CD011445.pub2
10.1002/14651858.CD009997.pub2
10.1002/14651858.CD005300.pub4
10.1002/14651858.CD004072.pub3
10.1002/14651858.CD009954.pub2
10.1002/14651858.CD000491.pub3

10.1002/14651858.CD007708.pub3
10.1002/14651858.CD009433.pub2
10.1002/14651858.CD008076.pub2
10.1002/14651858.CD008186.pub2
10.1002/14651858.CD007755.pub2
10.1002/14651858.CD006609.pub2
10.1002/14651858.CD007551.pub2
10.1002/14651858.CD007039.pub2
10.1002/14651858.CD002005.pub2
10.1002/14651858.CD001719.pub4
10.1002/14651858.CD009929.pub2
10.1002/14651858.CD005950.pub4
10.1002/14651858.CD009777.pub2
10.1002/14651858.CD006391.pub2
10.1002/14651858.CD003079.pub3
10.1002/14651858.CD007815.pub2
10.1002/14651858.CD005147.pub2
10.1002/14651858.CD006352.pub2
10.1002/14651858.CD001951.pub2
10.1002/14651858.CD001711.pub2
10.1002/14651858.CD008297.pub2
10.1002/14651858.CD009531.pub2
10.1002/14651858.CD009582.pub2
10.1002/14651858.CD001949.pub3
10.1002/14651858.CD006196.pub2
10.1002/14651858.CD003082.pub3
10.1002/14651858.CD006625.pub3
10.1002/14651858.CD010226.pub2
10.1002/14651858.CD002832.pub3
10.1002/14651858.CD009802.pub2
10.1002/14651858.CD000384.pub3
10.1002/14651858.CD000284.pub3
10.1002/14651858.CD008567.pub3
10.1002/14651858.CD006569.pub5
10.1002/14651858.CD009413.pub2
10.1002/14651858.CD007479.pub2
10.1002/14651858.CD007811.pub2
10.1002/14651858.CD009960.pub2
10.1002/14651858.CD001258.pub3
10.1002/14651858.CD001470.pub2
10.1002/14651858.CD009396.pub2
10.1002/14651858.CD009268.pub2
10.1002/14651858.CD009227.pub2

10.1002/14651858.CD009230.pub2
10.1002/14651858.CD009369.pub2
10.1002/14651858.CD004837.pub3
10.1002/14651858.CD009928.pub2
10.1002/14651858.CD005475.pub2
10.1002/14651858.CD010501.pub2
10.1002/14651858.CD010823.pub2
10.1002/14651858.CD009831.pub2
10.1002/14651858.CD009785.pub2
10.1002/14651858.CD010540.pub2
10.1002/14651858.CD000307.pub2
10.1002/14651858.CD004716.pub4
10.1002/14651858.CD009006.pub2
10.1002/14651858.CD010554.pub2
10.1002/14651858.CD006081.pub2
10.1002/14651858.CD010598.pub2
10.1002/14651858.CD003834.pub3
10.1002/14651858.CD011458.pub2
10.1002/14651858.CD003443.pub3
10.1002/14651858.CD001087.pub5
10.1002/14651858.CD006995.pub2
10.1002/14651858.CD012122.pub2
10.1002/14651858.CD008802.pub3
10.1002/14651858.CD010832.pub2
10.1002/14651858.CD008919.pub2
10.1002/14651858.CD012029.pub2
10.1002/14651858.CD004161.pub2
10.1002/14651858.CD009830.pub2
10.1002/14651858.CD010631.pub2
10.1002/14651858.CD004028.pub4
10.1002/14651858.CD009780.pub3
10.1002/14651858.CD002830.pub3
10.1002/14651858.CD005146.pub3
10.1002/14651858.CD011464.pub2
10.1002/14651858.CD011128.pub2
10.1002/14651858.CD004408.pub5
10.1002/14651858.CD006324.pub3
10.1002/14651858.CD006918.pub3
10.1002/14651858.CD011810.pub2
10.1002/14651858.CD010006.pub2
10.1002/14651858.CD007906.pub3
10.1002/14651858.CD007778.pub2
10.1002/14651858.CD011655.pub2

10.1002/14651858.CD004025.pub4
10.1002/14651858.CD012217.pub2
10.1002/14651858.CD011831.pub2
10.1002/14651858.CD009005.pub2
10.1002/14651858.CD012052.pub2
10.1002/14651858.CD009377.pub3
10.1002/14651858.CD011200.pub2
10.1002/14651858.CD008925.pub2
10.1002/14651858.CD010994.pub2
10.1002/14651858.CD004733.pub4
10.1002/14651858.CD009916.pub2
10.1002/14651858.CD006553.pub3
10.1002/14651858.CD011507.pub2
10.1002/14651858.CD000116.pub5
10.1002/14651858.CD010845.pub2
10.1002/14651858.CD010568.pub2
10.1002/14651858.CD004944.pub3
10.1002/14651858.CD007950.pub3
10.1002/14651858.CD008873.pub3
10.1002/14651858.CD010647.pub2
10.1002/14651858.CD005944.pub3
10.1002/14651858.CD011624.pub2
10.1002/14651858.CD011491.pub2
10.1002/14651858.CD008540.pub4
10.1002/14651858.CD010607.pub2
10.1002/14651858.CD009356.pub3
10.1002/14651858.CD005542.pub3
10.1002/14651858.CD004073.pub4
10.1002/14651858.CD004667.pub5
10.1002/14651858.CD000938.pub2
10.1002/14651858.CD011876.pub2
10.1002/14651858.CD006946.pub3
10.1002/14651858.CD010218.pub2
10.1002/14651858.CD008968.pub3
10.1002/14651858.CD008883.pub2
10.1002/14651858.CD011622.pub2
10.1002/14651858.CD006641.pub3
10.1002/14651858.CD007202.pub4
10.1002/14651858.CD011352.pub2
10.1002/14651858.CD006462.pub4
10.1002/14651858.CD012048.pub2
10.1002/14651858.CD011562.pub2
10.1002/14651858.CD006170.pub5

10.1002/14651858.CD010378.pub3
10.1002/14651858.CD001688.pub3
10.1002/14651858.CD006425.pub4
10.1002/14651858.CD009273.pub2
10.1002/14651858.CD005122.pub5
10.1002/14651858.CD011967.pub2
10.1002/14651858.CD006901.pub3
10.1002/14651858.CD005302.pub3
10.1002/14651858.CD006674.pub3
10.1002/14651858.CD003519.pub4
10.1002/14651858.CD011880.pub2
10.1002/14651858.CD006066.pub3
10.1002/14651858.CD007223.pub4
10.1002/14651858.CD008070.pub3
10.1002/14651858.CD000081.pub3
10.1002/14651858.CD012129.pub2
10.1002/14651858.CD008680.pub2
10.1002/14651858.CD006172.pub4
10.1002/14651858.CD012003.pub2
10.1002/14651858.CD009275.pub3
10.1002/14651858.CD012031.pub2
10.1002/14651858.CD001141.pub5
10.1002/14651858.CD006067.pub3
10.1002/14651858.CD004735.pub4
10.1002/14651858.CD000161.pub2
10.1002/14651858.CD009124.pub3
10.1002/14651858.CD011761.pub2
10.1002/14651858.CD004454.pub3
10.1002/14651858.CD011516.pub2
10.1002/14651858.CD004905.pub5
10.1002/14651858.CD011970.pub2
10.1002/14651858.CD002006.pub4
10.1002/14651858.CD008991.pub3
10.1002/14651858.CD011989.pub2
10.1002/14651858.CD009792.pub3
10.1002/14651858.CD009613.pub3
10.1002/14651858.CD012202.pub2
10.1002/14651858.CD003766.pub6
10.1002/14651858.CD009326.pub3
10.1002/14651858.CD007529.pub4
10.1002/14651858.CD004455.pub4
10.1002/14651858.CD007222.pub4
10.1002/14651858.CD007122.pub4

10.1002/14651858.CD007776.pub3
10.1002/14651858.CD011192.pub2
10.1002/14651858.CD002251.pub3
10.1002/14651858.CD007701.pub3
10.1002/14651858.CD009963.pub2
10.1002/14651858.CD009382.pub2
10.1002/14651858.CD010067.pub2
10.1002/14651858.CD007825.pub6
10.1002/14651858.CD008366.pub3
10.1002/14651858.CD008657.pub2
10.1002/14651858.CD001871.pub3
10.1002/14651858.CD011247.pub2
10.1002/14651858.CD009823.pub3
10.1002/14651858.CD010697.pub2
10.1002/14651858.CD011779.pub2
10.1002/14651858.CD010321.pub2
10.1002/14651858.CD010166.pub2
10.1002/14651858.CD011683.pub2
10.1002/14651858.CD009905.pub2
10.1002/14651858.CD009467.pub2
10.1002/14651858.CD010351.pub2
10.1002/14651858.CD003261.pub3
10.1002/14651858.CD010638.pub2
10.1002/14651858.CD010522.pub2
10.1002/14651858.CD009820.pub2
10.1002/14651858.CD009542.pub2
10.1002/14651858.CD009014.pub2
10.1002/14651858.CD008711.pub3
10.1002/14651858.CD000064.pub2
10.1002/14651858.CD003435.pub2
10.1002/14651858.CD009264.pub2
10.1002/14651858.CD007230.pub2
10.1002/14651858.CD008389.pub2
10.1002/14651858.CD008530.pub2
10.1002/14651858.CD008388.pub2
10.1002/14651858.CD008179.pub2
10.1002/14651858.CD000091.pub2
10.1002/14651858.CD000419.pub3
10.1002/14651858.CD009360.pub2
10.1002/14651858.CD008354.pub2
10.1002/14651858.CD006755.pub2
10.1002/14651858.CD008449.pub2
10.1002/14651858.CD001928.pub2

10.1002/14651858.CD001342.pub3
10.1002/14651858.CD008348.pub3
10.1002/14651858.CD008656.pub2
10.1002/14651858.CD000323.pub2
10.1002/14651858.CD001919.pub3
10.1002/14651858.CD008184.pub2
10.1002/14651858.CD000515.pub4
10.1002/14651858.CD009286.pub2
10.1002/14651858.CD002842.pub2
10.1002/14651858.CD008862.pub2
10.1002/14651858.CD008391.pub2
10.1002/14651858.CD000514.pub3
10.1002/14651858.CD008444.pub2
10.1002/14651858.CD008728.pub2
10.1002/14651858.CD004294.pub3
10.1002/14651858.CD010116.pub2
10.1002/14651858.CD005207.pub4
10.1002/14651858.CD009689.pub2
10.1002/14651858.CD008980.pub2
10.1002/14651858.CD003586.pub3
10.1002/14651858.CD001245.pub2
10.1002/14651858.CD010255.pub2
10.1002/14651858.CD000197.pub3
10.1002/14651858.CD008357.pub2
10.1002/14651858.CD000126.pub4
10.1002/14651858.CD005346.pub4
10.1002/14651858.CD005208.pub3
10.1002/14651858.CD000029.pub3
10.1002/14651858.CD009893.pub2
10.1002/14651858.CD007890.pub3
10.1002/14651858.CD007232.pub4
10.1002/14651858.CD000103.pub2
10.1002/14651858.CD000190.pub3
10.1002/14651858.CD009103.pub2
10.1002/14651858.CD001920.pub3
10.1002/14651858.CD004954.pub3
10.1002/14651858.CD000213.pub3
10.1002/14651858.CD008349.pub3
10.1002/14651858.CD000039.pub3
10.1002/14651858.CD010200.pub2
10.1002/14651858.CD009760.pub3
10.1002/14651858.CD007028.pub3
10.1002/14651858.CD000024.pub4

10.1002/14651858.CD009570.pub2
10.1002/14651858.CD007030.pub3
10.1002/14651858.CD011398.pub2
10.1002/14651858.CD011138.pub2
10.1002/14651858.CD009938.pub2
10.1002/14651858.CD010693.pub3
10.1002/14651858.CD004433.pub3
10.1002/14651858.CD004955.pub3
10.1002/14651858.CD008445.pub3
10.1002/14651858.CD010882.pub2
10.1002/14651858.CD006876.pub4
10.1002/14651858.CD009645.pub3
10.1002/14651858.CD009622.pub4
10.1002/14651858.CD010442.pub2
10.1002/14651858.CD002293.pub3
10.1002/14651858.CD011401.pub2
10.1002/14651858.CD004131.pub3
10.1002/14651858.CD010362.pub2
10.1002/14651858.CD000425.pub4
10.1002/14651858.CD003316.pub6
10.1002/14651858.CD002088.pub3
10.1002/14651858.CD006073.pub3
10.1002/14651858.CD011058.pub2
10.1002/14651858.CD000119.pub4
10.1002/14651858.CD006787.pub3
10.1002/14651858.CD000398.pub2
10.1002/14651858.CD007933.pub2
10.1002/14651858.CD007026.pub5
10.1002/14651858.CD007270.pub2
10.1002/14651858.CD007961.pub2
10.1002/14651858.CD011317.pub2
10.1002/14651858.CD011701.pub2
10.1002/14651858.CD010866.pub2
10.1002/14651858.CD009036.pub2
10.1002/14651858.CD010285.pub2
10.1002/14651858.CD010684.pub2
10.1002/14651858.CD008860.pub3
10.1002/14651858.CD001081.pub3
10.1002/14651858.CD002843.pub2
10.1002/14651858.CD006185.pub4
10.1002/14651858.CD007513.pub3
10.1002/14651858.CD011968.pub2
10.1002/14651858.CD012144.pub2

10.1002/14651858.CD000443.pub4
10.1002/14651858.CD003585.pub3
10.1002/14651858.CD012432.pub2
10.1002/14651858.CD002840.pub4
10.1002/14651858.CD011367.pub2
10.1002/14651858.CD001080.pub2
10.1002/14651858.CD006979.pub2
10.1002/14651858.CD007374.pub2
10.1002/14651858.CD001534.pub3
10.1002/14651858.CD006023.pub2
10.1002/14651858.CD007751.pub2
10.1002/14651858.CD006124.pub2
10.1002/14651858.CD003962.pub2
10.1002/14651858.CD005279.pub4
10.1002/14651858.CD007857.pub2
10.1002/14651858.CD007016.pub2
10.1002/14651858.CD006800.pub2
10.1002/14651858.CD003964.pub3
10.1002/14651858.CD003264.pub3
10.1002/14651858.CD006943.pub2
10.1002/14651858.CD008000.pub2
10.1002/14651858.CD003236.pub2
10.1002/14651858.CD006857.pub2
10.1002/14651858.CD003265.pub3
10.1002/14651858.CD005426.pub3
10.1002/14651858.CD001321.pub5
10.1002/14651858.CD008176.pub2
10.1002/14651858.CD004136.pub3
10.1002/14651858.CD005016.pub2
10.1002/14651858.CD006740.pub2
10.1002/14651858.CD007248.pub2
10.1002/14651858.CD006182.pub2
10.1002/14651858.CD003309.pub2
10.1002/14651858.CD008308.pub2
10.1002/14651858.CD003062.pub2
10.1002/14651858.CD008309.pub2
10.1002/14651858.CD007645.pub2
10.1002/14651858.CD004214.pub4
10.1002/14651858.CD002922.pub3
10.1002/14651858.CD004213.pub3
10.1002/14651858.CD004595.pub2
10.1002/14651858.CD001817.pub2
10.1002/14651858.CD007615.pub3

10.1002/14651858.CD003956.pub2
10.1002/14651858.CD001453.pub2
10.1002/14651858.CD007453.pub3
10.1002/14651858.CD001452.pub4
10.1002/14651858.CD001819.pub2
10.1002/14651858.CD000512.pub2
10.1002/14651858.CD003662.pub4
10.1002/14651858.CD007969.pub2
10.1002/14651858.CD004500.pub2
10.1002/14651858.CD007966.pub2
10.1002/14651858.CD003740.pub2
10.1002/14651858.CD003065.pub2
10.1002/14651858.CD001454.pub3
10.1002/14651858.CD000510.pub2
10.1002/14651858.CD005095.pub2
10.1002/14651858.CD005257.pub3
10.1002/14651858.CD003953.pub3
10.1002/14651858.CD006818.pub2
10.1002/14651858.CD004496.pub3
10.1002/14651858.CD006817.pub3
10.1002/14651858.CD007448.pub2
10.1002/14651858.CD008310.pub2
10.1002/14651858.CD004865.pub3
10.1002/14651858.CD005249.pub2
10.1002/14651858.CD001456.pub2
10.1002/14651858.CD009017.pub2
10.1002/14651858.CD003952.pub3
10.1002/14651858.CD004950.pub3
10.1002/14651858.CD004866.pub4
10.1002/14651858.CD003487.pub3
10.1002/14651858.CD003483.pub2
10.1002/14651858.CD003311.pub3
10.1002/14651858.CD003951.pub3
10.1002/14651858.CD000504.pub4
10.1002/14651858.CD006474.pub3
10.1002/14651858.CD004591.pub3
10.1002/14651858.CD003486.pub2
10.1002/14651858.CD008771.pub2
10.1002/14651858.CD000122.pub2
10.1002/14651858.CD001691.pub3
10.1002/14651858.CD007263.pub2
10.1002/14651858.CD001073.pub2
10.1002/14651858.CD000361.pub3

10.1002/14651858.CD005387.pub3
10.1002/14651858.CD003959.pub3
10.1002/14651858.CD005496.pub4
10.1002/14651858.CD002971.pub3
10.1002/14651858.CD004863.pub4
10.1002/14651858.CD007805.pub2
10.1002/14651858.CD004868.pub4
10.1002/14651858.CD001145.pub3
10.1002/14651858.CD001146.pub4
10.1002/14651858.CD010018.pub2
10.1002/14651858.CD000503.pub3
10.1002/14651858.CD001970.pub5
10.1002/14651858.CD002054.pub3
10.1002/14651858.CD005947.pub4
10.1002/14651858.CD000366.pub3
10.1002/14651858.CD010333.pub2
10.1002/14651858.CD004205.pub3
10.1002/14651858.CD007835.pub2
10.1002/14651858.CD010061.pub2
10.1002/14651858.CD003481.pub6
10.1002/14651858.CD001239.pub5
10.1002/14651858.CD000104.pub4
10.1002/14651858.CD003774.pub4
10.1002/14651858.CD008817.pub2
10.1002/14651858.CD008568.pub2
10.1002/14651858.CD006861.pub3
10.1002/14651858.CD008834.pub3
10.1002/14651858.CD004925.pub3
10.1002/14651858.CD005133.pub3
10.1002/14651858.CD007594.pub3
10.1002/14651858.CD004289.pub5
10.1002/14651858.CD006335.pub3
10.1002/14651858.CD005425.pub2
10.1002/14651858.CD008597.pub2
10.1002/14651858.CD002290.pub4
10.1002/14651858.CD006022.pub4
10.1002/14651858.CD008927.pub2
10.1002/14651858.CD009297.pub2
10.1002/14651858.CD008509.pub2
10.1002/14651858.CD005019.pub4
10.1002/14651858.CD008566.pub2
10.1002/14651858.CD007004.pub3
10.1002/14651858.CD005284.pub3

10.1002/14651858.CD003895.pub3
10.1002/14651858.CD007034.pub3
10.1002/14651858.CD007554.pub2
10.1002/14651858.CD007333.pub2
10.1002/14651858.CD009120.pub2
10.1002/14651858.CD007784.pub2
10.1002/14651858.CD003078.pub2
10.1002/14651858.CD007669.pub2
10.1002/14651858.CD006881.pub2
10.1002/14651858.CD003772.pub4
10.1002/14651858.CD009735.pub2
10.1002/14651858.CD007861.pub2
10.1002/14651858.CD008369.pub2
10.1002/14651858.CD009535.pub2
10.1002/14651858.CD004293.pub3
10.1002/14651858.CD010699.pub2
10.1002/14651858.CD006254.pub2
10.1002/14651858.CD008353.pub2
10.1002/14651858.CD010138.pub2
10.1002/14651858.CD009403.pub2
10.1002/14651858.CD010590.pub2
10.1002/14651858.CD010070.pub2
10.1002/14651858.CD010480.pub2
10.1002/14651858.CD009534.pub2
10.1002/14651858.CD007910.pub2
10.1002/14651858.CD006819.pub2
10.1002/14651858.CD001533.pub5
10.1002/14651858.CD010446.pub2
10.1002/14651858.CD006027.pub2
10.1002/14651858.CD006258.pub2
10.1002/14651858.CD010294.pub2
10.1002/14651858.CD005128.pub3
10.1002/14651858.CD010350.pub2
10.1002/14651858.CD007013.pub2
10.1002/14651858.CD007003.pub2
10.1002/14651858.CD003965.pub2
10.1002/14651858.CD009698.pub2
10.1002/14651858.CD010057.pub2
10.1002/14651858.CD003232.pub3
10.1002/14651858.CD010481.pub2
10.1002/14651858.CD008327.pub2
10.1002/14651858.CD008772.pub2
10.1002/14651858.CD010344.pub2

10.1002/14651858.CD010709.pub2
10.1002/14651858.CD003266.pub3
10.1002/14651858.CD009631.pub2
10.1002/14651858.CD010737.pub2
10.1002/14651858.CD006420.pub2
10.1002/14651858.CD010741.pub2
10.1002/14651858.CD010850.pub2
10.1002/14651858.CD005282.pub3
10.1002/14651858.CD004541.pub3
10.1002/14651858.CD007746.pub2
10.1002/14651858.CD010613.pub2
10.1002/14651858.CD009440.pub2
10.1002/14651858.CD010690.pub2
10.1002/14651858.CD004683.pub4
10.1002/14651858.CD011690.pub2
10.1002/14651858.CD003594.pub5
10.1002/14651858.CD004759.pub2
10.1002/14651858.CD010777.pub2
10.1002/14651858.CD011998.pub2
10.1002/14651858.CD005632.pub3
10.1002/14651858.CD004679.pub3
10.1002/14651858.CD009966.pub2
10.1002/14651858.CD004756.pub4
10.1002/14651858.CD010137.pub2
10.1002/14651858.CD006750.pub2
10.1002/14651858.CD009904.pub2
10.1002/14651858.CD005085.pub2
10.1002/14651858.CD003600.pub3
10.1002/14651858.CD004172.pub2
10.1002/14651858.CD002041.pub3
10.1002/14651858.CD001208.pub4
10.1002/14651858.CD003985.pub3
10.1002/14651858.CD008931.pub3
10.1002/14651858.CD001886.pub4
10.1002/14651858.CD001046.pub2
10.1002/14651858.CD006676.pub3
10.1002/14651858.CD001319.pub5
10.1002/14651858.CD010245.pub2
10.1002/14651858.CD005011.pub4
10.1002/14651858.CD004609.pub3
10.1002/14651858.CD000033.pub2
10.1002/14651858.CD005014.pub3
10.1002/14651858.CD007700.pub3

10.1002/14651858.CD008303.pub2
10.1002/14651858.CD000567.pub6
10.1002/14651858.CD006020.pub3
10.1002/14651858.CD008481.pub2
10.1002/14651858.CD010562.pub2
10.1002/14651858.CD001049.pub5
10.1002/14651858.CD010109.pub2
10.1002/14651858.CD009331.pub2
10.1002/14651858.CD002245.pub2
10.1002/14651858.CD008507.pub2
10.1002/14651858.CD008084.pub4
10.1002/14651858.CD003109.pub3
10.1002/14651858.CD009532.pub2
10.1002/14651858.CD007379.pub2
10.1002/14651858.CD011386.pub2
10.1002/14651858.CD009457.pub2
10.1002/14651858.CD004896.pub4
10.1002/14651858.CD009177.pub2
10.1002/14651858.CD009439.pub2
10.1002/14651858.CD010801.pub2
10.1002/14651858.CD004446.pub4
10.1002/14651858.CD009330.pub2
10.1002/14651858.CD009919.pub2
10.1002/14651858.CD002043.pub3
10.1002/14651858.CD010640.pub2
10.1002/14651858.CD007383.pub3
10.1002/14651858.CD009745.pub2
10.1002/14651858.CD011588.pub2
10.1002/14651858.CD009871.pub2
10.1002/14651858.CD004170.pub3
10.1002/14651858.CD010415.pub2
10.1002/14651858.CD009228.pub3
10.1002/14651858.CD002042.pub4
10.1002/14651858.CD008409.pub4
10.1002/14651858.CD011402.pub2
10.1002/14651858.CD011020.pub2
10.1002/14651858.CD010246.pub2
10.1002/14651858.CD001884.pub3
10.1002/14651858.CD010336.pub2
10.1002/14651858.CD003669.pub2
10.1002/14651858.CD008432.pub2
10.1002/14651858.CD003743.pub2
10.1002/14651858.CD005248.pub3

10.1002/14651858.CD002271.pub2
10.1002/14651858.CD000144.pub3
10.1002/14651858.CD009106.pub2
10.1002/14651858.CD011078.pub2
10.1002/14651858.CD010464.pub2
10.1002/14651858.CD000437.pub3
10.1002/14651858.CD004219.pub4
10.1002/14651858.CD003478.pub5
10.1002/14651858.CD009816.pub2
10.1002/14651858.CD003850.pub5
10.1002/14651858.CD003064.pub3
10.1002/14651858.CD011724.pub2
10.1002/14651858.CD001150.pub3
10.1002/14651858.CD011484.pub2
10.1002/14651858.CD010435.pub2
10.1002/14651858.CD010249.pub2
10.1002/14651858.CD009734.pub2
10.1002/14651858.CD011493.pub2
10.1002/14651858.CD006405.pub3
10.1002/14651858.CD005495.pub4
10.1002/14651858.CD011636.pub2
10.1002/14651858.CD009172.pub2
10.1002/14651858.CD001816.pub3
10.1002/14651858.CD011082.pub2
10.1002/14651858.CD001457.pub6
10.1002/14651858.CD008313.pub3
10.1002/14651858.CD011027.pub2
10.1002/14651858.CD001240.pub3
10.1002/14651858.CD011718.pub2
10.1002/14651858.CD011877.pub2
10.1002/14651858.CD011878.pub2
10.1002/14651858.CD000343.pub3
10.1002/14651858.CD010531.pub2
10.1002/14651858.CD006982.pub4
10.1002/14651858.CD001243.pub3
10.1002/14651858.CD001069.pub5
10.1002/14651858.CD002771.pub4
10.1002/14651858.CD005092.pub3
10.1002/14651858.CD005255.pub5
10.1002/14651858.CD000501.pub4
10.1002/14651858.CD000456.pub5
10.1002/14651858.CD009720.pub2
10.1002/14651858.CD007480.pub3

10.1002/14651858.CD005252.pub4
10.1002/14651858.CD001071.pub3
10.1002/14651858.CD011219.pub3
10.1002/14651858.CD003668.pub4
10.1002/14651858.CD003214.pub3
10.1002/14651858.CD004696.pub5
10.1002/14651858.CD005384.pub2
10.1002/14651858.CD010112.pub2
10.1002/14651858.CD000375.pub5
10.1002/14651858.CD005091.pub4
10.1002/14651858.CD000509.pub5
10.1002/14651858.CD000399.pub3
10.1002/14651858.CD001969.pub4
10.1002/14651858.CD003059.pub3
10.1002/14651858.CD004951.pub3
10.1002/14651858.CD002052.pub3
10.1002/14651858.CD010941.pub2
10.1002/14651858.CD005389.pub2
10.1002/14651858.CD003212.pub3
10.1002/14651858.CD010331.pub2
10.1002/14651858.CD003310.pub2
10.1002/14651858.CD006980.pub3
10.1002/14651858.CD008435.pub3
10.1002/14651858.CD011065.pub2
10.1002/14651858.CD000376.pub4
10.1002/14651858.CD004339.pub4
10.1002/14651858.CD000216.pub2
10.1002/14651858.CD010332.pub2
10.1002/14651858.CD011791.pub2
10.1002/14651858.CD007137.pub5
10.1002/14651858.CD006183.pub2
10.1002/14651858.CD011190.pub2
10.1002/14651858.CD012468.pub2
10.1002/14651858.CD012362.pub2
10.1002/14651858.CD011891.pub2
10.1002/14651858.CD005494.pub4
10.1002/14651858.CD004953.pub3
10.1002/14651858.CD001241.pub7
10.1002/14651858.CD002311.pub4
10.1002/14651858.CD008050.pub2
10.1002/14651858.CD003315.pub3
10.1002/14651858.CD006205.pub3
10.1002/14651858.CD007592.pub2

10.1002/14651858.CD004970.pub5
10.1002/14651858.CD006386.pub3
10.1002/14651858.CD008934.pub2
10.1002/14651858.CD003814.pub2
10.1002/14651858.CD000978.pub5
10.1002/14651858.CD008829.pub2
10.1002/14651858.CD006697.pub2
10.1002/14651858.CD006963.pub2
10.1002/14651858.CD006540.pub2
10.1002/14651858.CD007261.pub2
10.1002/14651858.CD003877.pub4
10.1002/14651858.CD008948.pub2
10.1002/14651858.CD005411.pub2
10.1002/14651858.CD003811.pub2
10.1002/14651858.CD004621.pub3
10.1002/14651858.CD006968.pub2
10.1002/14651858.CD008305.pub2
10.1002/14651858.CD006383.pub2
10.1002/14651858.CD008488.pub2
10.1002/14651858.CD008288.pub2
10.1002/14651858.CD006423.pub2
10.1002/14651858.CD006165.pub3
10.1002/14651858.CD005060.pub3
10.1002/14651858.CD008101.pub2
10.1002/14651858.CD007675.pub2
10.1002/14651858.CD007845.pub3
10.1002/14651858.CD007315.pub2
10.1002/14651858.CD005449.pub2
10.1002/14651858.CD009361.pub2
10.1002/14651858.CD007170.pub2
10.1002/14651858.CD008650.pub2
10.1002/14651858.CD008381.pub2
10.1002/14651858.CD008613.pub2
10.1002/14651858.CD010223.pub2
10.1002/14651858.CD008776.pub2
10.1002/14651858.CD010063.pub2
10.1002/14651858.CD007651.pub2
10.1002/14651858.CD009560.pub2
10.1002/14651858.CD009128.pub3
10.1002/14651858.CD009518.pub2
10.1002/14651858.CD010492.pub2
10.1002/14651858.CD007469.pub2
10.1002/14651858.CD009578.pub2

10.1002/14651858.CD004098.pub2
10.1002/14651858.CD008066.pub3
10.1002/14651858.CD003641.pub4
10.1002/14651858.CD009122.pub2
10.1002/14651858.CD007470.pub3
10.1002/14651858.CD010370.pub2
10.1002/14651858.CD010888.pub2
10.1002/14651858.CD005525.pub3
10.1002/14651858.CD010094.pub2
10.1002/14651858.CD011740
10.1002/14651858.CD012008
10.1002/14651858.CD010576.pub2
10.1002/14651858.CD012105
10.1002/14651858.CD006424.pub3
10.1002/14651858.CD011281.pub2
10.1002/14651858.CD011361.pub2
10.1002/14651858.CD012151.pub2
10.1002/14651858.CD012204.pub2
10.1002/14651858.CD012161
10.1002/14651858.CD009840.pub2
10.1002/14651858.CD006992.pub2
10.1002/14651858.CD012691
10.1002/14651858.CD011469.pub2
10.1002/14651858.CD012436
10.1002/14651858.CD012651
10.1002/14651858.CD007795.pub2
10.1002/14651858.CD003279.pub3
10.1002/14651858.CD006981.pub2
10.1002/14651858.CD007312.pub2
10.1002/14651858.CD004156.pub4
10.1002/14651858.CD009318.pub2
10.1002/14651858.CD008496.pub2
10.1002/14651858.CD009600
10.1002/14651858.CD006283.pub3
10.1002/14651858.CD001447.pub3
10.1002/14651858.CD006281.pub4
10.1002/14651858.CD004426.pub3
10.1002/14651858.CD004157.pub2
10.1002/14651858.CD006282.pub4
10.1002/14651858.CD007543.pub2
10.1002/14651858.CD009899
10.1002/14651858.CD003643.pub4
10.1002/14651858.CD010003

10.1002/14651858.CD002064.pub3
10.1002/14651858.CD009402.pub2
10.1002/14651858.CD002948.pub2
10.1002/14651858.CD003525.pub2
10.1002/14651858.CD000333.pub2
10.1002/14651858.CD003113.pub3
10.1002/14651858.CD008920.pub2
10.1002/14651858.CD008886.pub2
10.1002/14651858.CD008951.pub2
10.1002/14651858.CD008872.pub2
10.1002/14651858.CD008921.pub2
10.1002/14651858.CD008922.pub2
10.1002/14651858.CD009807
10.1002/14651858.CD009147.pub2
10.1002/14651858.CD006193.pub2
10.1002/14651858.CD007323.pub3
10.1002/14651858.CD007911.pub2
10.1002/14651858.CD002277.pub4
10.1002/14651858.CD005081.pub3
10.1002/14651858.CD005225.pub3
10.1002/14651858.CD005229.pub3
10.1002/14651858.CD007963.pub2
10.1002/14651858.CD005582.pub4
10.1002/14651858.CD008554.pub3
10.1002/14651858.CD009601.pub2
10.1002/14651858.CD004760.pub4
10.1002/14651858.CD003907.pub4
10.1002/14651858.CD007468.pub3
10.1002/14651858.CD008314.pub3
10.1002/14651858.CD007796.pub3
10.1002/14651858.CD010044.pub2
10.1002/14651858.CD004029.pub4
10.1002/14651858.CD001797.pub3
10.1002/14651858.CD006832.pub3
10.1002/14651858.CD006866.pub3
10.1002/14651858.CD007115.pub3
10.1002/14651858.CD008123.pub3
10.1002/14651858.CD008265.pub2
10.1002/14651858.CD002063.pub6
10.1002/14651858.CD008602.pub3
10.1002/14651858.CD006986.pub3
10.1002/14651858.CD005228.pub4
10.1002/14651858.CD007218.pub3

10.1002/14651858.CD003458.pub5
10.1002/14651858.CD008953.pub2
10.1002/14651858.CD010404.pub2
10.1002/14651858.CD008146.pub2
10.1002/14651858.CD001941.pub3
10.1002/14651858.CD003217.pub5
10.1002/14651858.CD009950.pub3
10.1002/14651858.CD005044.pub3
10.1002/14651858.CD005376.pub3
10.1002/14651858.CD001869.pub8
10.1002/14651858.CD003906.pub4
10.1002/14651858.CD007818.pub3
10.1002/14651858.CD001555.pub5
10.1002/14651858.CD004303.pub4
10.1002/14651858.CD011952
10.1002/14651858.CD001942.pub5
10.1002/14651858.CD007791.pub4
10.1002/14651858.CD002827.pub4
10.1002/14651858.CD003725.pub4
10.1002/14651858.CD004158.pub3
10.1002/14651858.CD006839.pub4
10.1002/14651858.CD008630.pub4
10.1002/14651858.CD001446.pub5
10.1002/14651858.CD006978.pub2
10.1002/14651858.CD006049.pub2
10.1002/14651858.CD001798.pub3
10.1002/14651858.CD010899.pub2
10.1002/14651858.CD006521.pub4
10.1002/14651858.CD003280.pub5
10.1002/14651858.CD003726.pub4
10.1002/14651858.CD012765
10.1002/14651858.CD008653.pub2
10.1002/14651858.CD008618.pub2
10.1002/14651858.CD010292
10.1002/14651858.CD002265.pub3
10.1002/14651858.CD004524.pub4
10.1002/14651858.CD000332.pub3
10.1002/14651858.CD010039.pub2
10.1002/14651858.CD007070.pub2
10.1002/14651858.CD010538
10.1002/14651858.CD000951.pub2
10.1002/14651858.CD003686.pub2
10.1002/14651858.CD008322.pub2

10.1002/14651858.CD004803.pub3
10.1002/14651858.CD004525.pub2
10.1002/14651858.CD003523.pub2
10.1002/14651858.CD004260.pub3
10.1002/14651858.CD010519.pub2
10.1002/14651858.CD010884
10.1002/14651858.CD008963.pub2
10.1002/14651858.CD007912.pub2
10.1002/14651858.CD003526.pub3
10.1002/14651858.CD000957.pub2
10.1002/14651858.CD009993.pub2
10.1002/14651858.CD005117.pub3
10.1002/14651858.CD002947.pub2
10.1002/14651858.CD006190.pub2
10.1002/14651858.CD011275
10.1002/14651858.CD005467.pub2
10.1002/14651858.CD003115.pub4
10.1002/14651858.CD010156.pub2
10.1002/14651858.CD010455.pub2
10.1002/14651858.CD010120.pub2
10.1002/14651858.CD011324
10.1002/14651858.CD006077.pub3
10.1002/14651858.CD010069.pub2
10.1002/14651858.CD003528.pub2
10.1002/14651858.CD004019.pub4
10.1002/14651858.CD004376.pub3
10.1002/14651858.CD003130.pub3
10.1002/14651858.CD004800.pub3
10.1002/14651858.CD010457.pub2
10.1002/14651858.CD004020.pub3
10.1002/14651858.CD011336
10.1002/14651858.CD000518.pub2
10.1002/14651858.CD001980.pub3
10.1002/14651858.CD011735
10.1002/14651858.CD005468.pub2
10.1002/14651858.CD006349.pub2
10.1002/14651858.CD007356.pub2
10.1002/14651858.CD005614.pub2
10.1002/14651858.CD010643.pub2
10.1002/14651858.CD010952.pub2
10.1002/14651858.CD005328.pub3
10.1002/14651858.CD010143.pub2
10.1002/14651858.CD005523.pub3

10.1002/14651858.CD008334.pub2
10.1002/14651858.CD010203.pub2
10.1002/14651858.CD010815.pub2
10.1002/14651858.CD012225
10.1002/14651858.CD001347.pub2
10.1002/14651858.CD012224
10.1002/14651858.CD010388.pub2
10.1002/14651858.CD007455.pub3
10.1002/14651858.CD012095.pub2
10.1002/14651858.CD009865.pub2
10.1002/14651858.CD012700
10.1002/14651858.CD007649.pub4
10.1002/14651858.CD007295.pub2
10.1002/14651858.CD008386.pub3
10.1002/14651858.CD007280.pub3
10.1002/14651858.CD007621.pub2
10.1002/14651858.CD005181.pub3
10.1002/14651858.CD006921.pub3
10.1002/14651858.CD004192.pub3
10.1002/14651858.CD009974.pub2
10.1002/14651858.CD002127.pub3
10.1002/14651858.CD010475.pub2
10.1002/14651858.CD009130.pub3
10.1002/14651858.CD008933.pub2
10.1002/14651858.CD008127.pub4
10.1002/14651858.CD010242.pub2
10.1002/14651858.CD008876.pub3
10.1002/14651858.CD010508.pub2
10.1002/14651858.CD008757.pub2
10.1002/14651858.CD009131.pub3
10.1002/14651858.CD011076.pub2
10.1002/14651858.CD010422.pub2
10.1002/14651858.CD009956.pub2
10.1002/14651858.CD009882.pub3
10.1002/14651858.CD011381.pub2
10.1002/14651858.CD008754.pub3
10.1002/14651858.CD011203.pub2
10.1002/14651858.CD009371.pub2
10.1002/14651858.CD009333.pub3
10.1002/14651858.CD012200.pub2
10.1002/14651858.CD007464.pub2
10.1002/14651858.CD004282.pub3
10.1002/14651858.CD002141.pub2

10.1002/14651858.CD009955.pub2
10.1002/14651858.CD004284.pub3
10.1002/14651858.CD009256.pub2
10.1002/14651858.CD001991.pub3
10.1002/14651858.CD001990.pub3
10.1002/14651858.CD009948.pub2
10.1002/14651858.CD002143.pub4
10.1002/14651858.CD010355.pub2
10.1002/14651858.CD011430
10.1002/14651858.CD006849.pub3
10.1002/14651858.CD010463.pub2
10.1002/14651858.CD002142.pub4
10.1002/14651858.CD012020.pub2
10.1002/14651858.CD010383.pub2
10.1002/14651858.CD011917.pub2
10.1002/14651858.MR000031.pub2
10.1002/14651858.MR000012.pub3
10.1002/14651858.MR000027.pub2
10.1002/14651858.MR000025.pub2
10.1002/14651858.MR000024.pub3
10.1002/14651858.MR000034.pub2
10.1002/14651858.MR000022.pub3
10.1002/14651858.MR000030.pub2
10.1002/14651858.MR000035.pub2
10.1002/14651858.MR000032.pub2
10.1002/14651858.MR000036.pub2
10.1002/14651858.MR000042.pub2
10.1002/14651858.MR000043.pub2
10.1002/14651858.MR000038.pub2
10.1002/14651858.MR000033.pub3
10.1002/14651858.CD005504.pub2
10.1002/14651858.CD009097.pub2
10.1002/14651858.CD006009.pub2
10.1002/14651858.CD007834.pub2
10.1002/14651858.CD002814.pub2
10.1002/14651858.CD009646.pub2
10.1002/14651858.CD002812.pub2
10.1002/14651858.CD008624.pub3
10.1002/14651858.CD002817.pub4
10.1002/14651858.CD002815.pub2
10.1002/14651858.CD005578.pub2
10.1002/14651858.CD009681.pub2
10.1002/14651858.CD007830.pub4

10.1002/14651858.CD010925.pub2
10.1002/14651858.CD006941.pub2
10.1002/14651858.CD004315.pub3
10.1002/14651858.CD004552.pub2
10.1002/14651858.CD010916.pub2
10.1002/14651858.CD009682.pub2
10.1002/14651858.CD004314.pub3
10.1002/14651858.CD009684.pub2
10.1002/14651858.CD009683.pub2
10.1002/14651858.CD010760.pub2
10.1002/14651858.CD007859.pub3
10.1002/14651858.CD003808.pub3
10.1002/14651858.CD003878.pub5
10.1002/14651858.CD009378.pub2
10.1002/14651858.CD006087.pub3
10.1002/14651858.CD002279.pub2
10.1002/14651858.CD004152.pub4
10.1002/14651858.CD003603.pub3
10.1002/14651858.CD009603.pub3
10.1002/14651858.CD003813.pub4
10.1002/14651858.CD003451.pub2
10.1002/14651858.CD008375.pub2
10.1002/14651858.CD004625.pub4
10.1002/14651858.CD004150.pub4
10.1002/14651858.CD003452.pub3
10.1002/14651858.CD005516.pub2
10.1002/14651858.CD004624.pub2
10.1002/14651858.CD003809.pub3
10.1002/14651858.CD010514.pub2
10.1002/14651858.CD004346.pub4
10.1002/14651858.CD009857.pub2
10.1002/14651858.CD005620.pub2
10.1002/14651858.CD005293.pub2
10.1002/14651858.CD000979.pub2
10.1002/14651858.CD010136.pub2
10.1002/14651858.CD008397.pub2
10.1002/14651858.CD004345.pub2
10.1002/14651858.CD003220.pub2
10.1002/14651858.CD003815.pub4
10.1002/14651858.CD002281.pub3
10.1002/14651858.CD005515.pub3
10.1002/14651858.CD005098.pub3
10.1002/14651858.CD005101.pub3

10.1002/14651858.CD008694.pub2
10.1002/14651858.CD009742.pub2
10.1002/14651858.CD010470.pub2
10.1002/14651858.CD010743.pub2
10.1002/14651858.CD011018.pub2
10.1002/14651858.CD008457.pub2
10.1002/14651858.CD004622.pub3
10.1002/14651858.CD010176.pub2
10.1002/14651858.CD010572.pub2
10.1002/14651858.CD003876.pub4
10.1002/14651858.CD002280.pub2
10.1002/14651858.CD009109.pub3
10.1002/14651858.CD011116.pub2
10.1002/14651858.CD010431.pub2
10.1002/14651858.CD010887.pub2
10.1002/14651858.CD010856.pub2
10.1002/14651858.CD004714.pub3
10.1002/14651858.CD010341.pub2
10.1002/14651858.CD005512.pub3
10.1002/14651858.CD011552.pub2
10.1002/14651858.CD004969.pub4
10.1002/14651858.CD003067.pub4
10.1002/14651858.CD002283.pub4
10.1002/14651858.CD007517.pub3
10.1002/14651858.CD008455.pub2
10.1002/14651858.CD011784.pub2
10.1002/14651858.CD008392.pub3
10.1002/14651858.CD003879.pub4
10.1002/14651858.CD009858.pub2
10.1002/14651858.CD002284.pub2
10.1002/14651858.CD001829.pub4
10.1002/14651858.CD010535.pub2
10.1002/14651858.CD010403.pub2
10.1002/14651858.CD005520.pub3
10.1002/14651858.CD004485.pub4
10.1002/14651858.CD010526.pub2
10.1002/14651858.CD010229.pub2
10.1002/14651858.CD005511.pub3
10.1002/14651858.CD008367.pub3
10.1002/14651858.CD005517.pub2
10.1002/14651858.CD005296.pub3
10.1002/14651858.CD002779.pub3
10.1002/14651858.CD008236.pub3

10.1002/14651858.CD010263.pub2
10.1002/14651858.CD005297.pub3
10.1002/14651858.CD006966.pub3
10.1002/14651858.CD006204.pub3
10.1002/14651858.CD008676.pub2
10.1002/14651858.CD012744
10.1002/14651858.CD001830.pub5
10.1002/14651858.CD007556.pub2
10.1002/14651858.CD007553.pub2
10.1002/14651858.CD007519.pub2
10.1002/14651858.CD009183.pub2
10.1002/14651858.CD007132.pub2
10.1002/14651858.CD009664
10.1002/14651858.CD009007.pub2
10.1002/14651858.CD009663
10.1002/14651858.CD006276.pub3
10.1002/14651858.CD008615.pub2
10.1002/14651858.CD009665
10.1002/14651858.CD007544.pub2
10.1002/14651858.CD002067.pub2
10.1002/14651858.CD008943.pub2
10.1002/14651858.CD010111
10.1002/14651858.CD004770.pub2
10.1002/14651858.CD008025.pub2
10.1002/14651858.CD008768.pub2
10.1002/14651858.CD006145.pub3
10.1002/14651858.CD008411.pub2
10.1002/14651858.CD007407.pub3
10.1002/14651858.CD008041.pub3
10.1002/14651858.CD001792.pub3
10.1002/14651858.CD008783.pub3
10.1002/14651858.CD008039.pub3
10.1002/14651858.CD004310.pub3
10.1002/14651858.CD008040.pub3
10.1002/14651858.CD005539.pub2
10.1002/14651858.CD010609
10.1002/14651858.CD010210.pub2
10.1002/14651858.CD010608
10.1002/14651858.CD010289.pub2
10.1002/14651858.CD007760.pub2
10.1002/14651858.CD010611
10.1002/14651858.CD004844.pub3
10.1002/14651858.CD006146.pub2

10.1002/14651858.CD010610
10.1002/14651858.CD009796.pub2
10.1002/14651858.CD010270.pub2
10.1002/14651858.CD008307.pub2
10.1002/14651858.CD009455.pub2
10.1002/14651858.CD004233.pub4
10.1002/14651858.CD007550.pub3
10.1002/14651858.CD005179.pub3
10.1002/14651858.CD009688.pub2
10.1002/14651858.CD006044.pub4
10.1002/14651858.CD008042.pub3
10.1002/14651858.CD006273.pub3
10.1002/14651858.CD002918.pub3
10.1002/14651858.CD004309.pub4
10.1002/14651858.CD010152.pub2
10.1002/14651858.CD005451.pub3
10.1002/14651858.CD003968.pub4
10.1002/14651858.CD008208.pub3
10.1002/14651858.CD010769.pub2
10.1002/14651858.CD008616.pub2
10.1002/14651858.CD010943.pub2
10.1002/14651858.CD010958.pub2
10.1002/14651858.CD007533.pub3
10.1002/14651858.CD011056.pub2
10.1002/14651858.CD009583.pub2
10.1002/14651858.CD011003.pub2
10.1002/14651858.CD006601.pub4
10.1002/14651858.CD005622.pub4
10.1002/14651858.CD007403.pub3
10.1002/14651858.CD009281.pub3
10.1002/14651858.CD010206.pub2
10.1002/14651858.CD011209.pub2
10.1002/14651858.CD010937.pub2
10.1002/14651858.CD011241.pub2
10.1002/14651858.CD010107.pub3
10.1002/14651858.CD011404.pub2
10.1002/14651858.CD010750.pub2
10.1002/14651858.CD009574.pub2
10.1002/14651858.CD011118.pub2
10.1002/14651858.CD002919.pub3
10.1002/14651858.CD002286.pub3
10.1002/14651858.CD009596.pub4
10.1002/14651858.CD010756.pub2

10.1002/14651858.CD009660.pub3
10.1002/14651858.CD003448.pub4
10.1002/14651858.CD007771.pub3
10.1002/14651858.CD008408.pub3
10.1002/14651858.CD011681
10.1002/14651858.CD009923.pub2
10.1002/14651858.CD007881.pub3
10.1002/14651858.CD006788.pub3
10.1002/14651858.CD003348.pub3
10.1002/14651858.CD009389.pub3
10.1002/14651858.CD007402.pub3
10.1002/14651858.CD006142.pub3
10.1002/14651858.CD011789
10.1002/14651858.CD010720.pub2
10.1002/14651858.CD011509.pub2
10.1002/14651858.CD007887.pub3
10.1002/14651858.CD011824
10.1002/14651858.CD011474.pub2
10.1002/14651858.CD004768.pub3
10.1002/14651858.CD008242.pub3
10.1002/14651858.CD011091.pub2
10.1002/14651858.CD009509.pub3
10.1002/14651858.CD011460.pub2
10.1002/14651858.CD006716.pub3
10.1002/14651858.CD003782.pub3
10.1002/14651858.CD010967.pub2
10.1002/14651858.CD007753.pub3
10.1002/14651858.CD011259.pub2
10.1002/14651858.CD008244.pub3
10.1002/14651858.CD010902.pub2
10.1002/14651858.CD006271.pub3
10.1002/14651858.CD005219.pub3
10.1002/14651858.CD002764.pub2
10.1002/14651858.CD008006.pub4
10.1002/14651858.CD005540.pub3
10.1002/14651858.CD009199.pub3
10.1002/14651858.CD006275.pub3
10.1002/14651858.CD011131.pub2
10.1002/14651858.CD011008.pub2
10.1002/14651858.CD010853.pub2
10.1002/14651858.CD005220.pub2
10.1002/14651858.CD007587.pub2
10.1002/14651858.CD011421.pub2

10.1002/14651858.CD008541.pub3
10.1002/14651858.CD003868.pub4
10.1002/14651858.CD008918.pub2
10.1002/14651858.CD007400.pub3
10.1002/14651858.CD011604.pub2
10.1002/14651858.CD011804.pub2
10.1002/14651858.CD009873.pub3
10.1002/14651858.CD010529.pub2
10.1002/14651858.CD007126.pub3
10.1002/14651858.CD011694.pub2
10.1002/14651858.CD001218.pub3
10.1002/14651858.CD011889.pub2
10.1002/14651858.CD010692.pub3
10.1002/14651858.CD011476.pub2
10.1002/14651858.CD004598.pub4
10.1002/14651858.CD012190.pub2
10.1002/14651858.CD012232.pub2
10.1002/14651858.CD011108.pub2
10.1002/14651858.CD011790.pub2
10.1002/14651858.CD011605.pub2
10.1002/14651858.CD009419.pub3
10.1002/14651858.CD006380.pub3
10.1002/14651858.CD007354.pub3
10.1002/14651858.CD011248.pub2
10.1002/14651858.CD012188.pub2
10.1002/14651858.CD003971.pub4
10.1002/14651858.CD008144.pub2
10.1002/14651858.CD011888.pub2
10.1002/14651858.CD007393.pub4
10.1002/14651858.CD011419.pub2
10.1002/14651858.CD008320.pub3
10.1002/14651858.CD012332.pub2
10.1002/14651858.CD012508.pub2
10.1002/14651858.CD012499.pub2
10.1002/14651858.CD011669.pub2
10.1002/14651858.CD007355.pub3
10.1002/14651858.CD012002.pub2
10.1002/14651858.CD003351.pub3
10.1002/14651858.CD007938.pub4
10.1002/14651858.CD012638.pub2
10.1002/14651858.CD012637.pub2
10.1002/14651858.CD009984.pub3
10.1002/14651858.CD012030.pub2

10.1002/14651858.CD012537.pub2
10.1002/14651858.CD012536.pub2
10.1002/14651858.CD012051.pub2
10.1002/14651858.CD012535.pub2
10.1002/14651858.CD011976.pub2
10.1002/14651858.CD003870.pub6
10.1002/14651858.CD009595.pub2
10.1002/14651858.CD008160.pub2
10.1002/14651858.CD008938.pub2
10.1002/14651858.CD010026.pub2
10.1002/14651858.CD005055.pub3
10.1002/14651858.CD010555.pub2
10.1002/14651858.CD010357.pub2
10.1002/14651858.CD009176.pub2
10.1002/14651858.CD002788.pub3
10.1002/14651858.CD009161.pub2
10.1002/14651858.CD008638.pub2
10.1002/14651858.CD009901.pub2
10.1002/14651858.CD005277.pub3
10.1002/14651858.CD007274.pub2
10.1002/14651858.CD008343.pub2
10.1002/14651858.CD007598.pub2
10.1002/14651858.CD003590.pub4
10.1002/14651858.CD006616.pub2
10.1002/14651858.CD007105.pub2
10.1002/14651858.CD004958.pub2
10.1002/14651858.CD008112.pub2
10.1002/14651858.CD004919.pub2
10.1002/14651858.CD004084.pub3
10.1002/14651858.CD007119.pub2
10.1002/14651858.CD008257.pub2
10.1002/14651858.CD008402.pub2
10.1002/14651858.CD005958.pub3
10.1002/14651858.CD006717.pub2
10.1002/14651858.CD005106.pub4
10.1002/14651858.CD004871.pub4
10.1002/14651858.CD008880.pub2
10.1002/14651858.CD009565.pub2
10.1002/14651858.CD008326.pub2
10.1002/14651858.CD003010.pub5
10.1002/14651858.CD004251.pub5
10.1002/14651858.CD004959.pub4
10.1002/14651858.CD010712

10.1002/14651858.CD001822.pub3
10.1002/14651858.CD009644.pub2
10.1002/14651858.CD004360.pub4
10.1002/14651858.CD004082.pub5
10.1002/14651858.CD003845.pub3
10.1002/14651858.CD003844.pub4
10.1002/14651858.CD004388.pub6
10.1002/14651858.CD003408.pub3
10.1002/14651858.CD009098.pub2
10.1002/14651858.CD008863.pub2
10.1002/14651858.CD006908.pub2
10.1002/14651858.CD006715.pub2
10.1002/14651858.CD009971.pub2
10.1002/14651858.CD006313.pub3
10.1002/14651858.CD003707.pub3
10.1002/14651858.CD004087.pub2
10.1002/14651858.CD003591.pub3
10.1002/14651858.CD007083.pub3
10.1002/14651858.CD009082.pub2
10.1002/14651858.CD005487.pub3
10.1002/14651858.CD008864.pub2
10.1002/14651858.CD010160.pub2
10.1002/14651858.CD005056.pub3
10.1002/14651858.CD001090.pub2
10.1002/14651858.CD004127.pub3
10.1002/14651858.CD010320.pub2
10.1002/14651858.CD009798.pub2
10.1002/14651858.CD010105.pub2
10.1002/14651858.CD009784.pub2
10.1002/14651858.CD003344.pub3
10.1002/14651858.CD007080.pub2
10.1002/14651858.CD009633.pub2
10.1002/14651858.CD006058.pub3
10.1002/14651858.CD009015.pub2
10.1002/14651858.CD008639.pub2
10.1002/14651858.CD002013.pub3
10.1002/14651858.CD009763.pub2
10.1002/14651858.CD007364.pub2
10.1002/14651858.CD009908.pub2
10.1002/14651858.CD006056.pub2
10.1002/14651858.CD009235.pub3
10.1002/14651858.CD009941.pub2
10.1002/14651858.CD007922.pub3

10.1002/14651858.CD003843.pub3
10.1002/14651858.CD009169.pub2
10.1002/14651858.CD003007.pub3
10.1002/14651858.CD004504.pub4
10.1002/14651858.CD000963.pub3
10.1002/14651858.CD010328.pub2
10.1002/14651858.CD010387.pub2
10.1002/14651858.CD010664.pub2
10.1002/14651858.CD004250.pub5
10.1002/14651858.CD010036.pub2
10.1002/14651858.CD001929.pub3
10.1002/14651858.CD010264.pub2
10.1002/14651858.CD008572.pub2
10.1002/14651858.CD010513.pub2
10.1002/14651858.CD012087
10.1002/14651858.CD004249.pub4
10.1002/14651858.CD012085
10.1002/14651858.CD012004
10.1002/14651858.CD008325.pub2
10.1002/14651858.CD009772.pub2
10.1002/14651858.CD012421
10.1002/14651858.CD011674.pub2
10.1002/14651858.CD002193.pub2
10.1002/14651858.CD010671.pub2
10.1002/14651858.CD010050.pub2
10.1002/14651858.CD009942.pub2
10.1002/14651858.CD007084.pub2
10.1002/14651858.CD004476.pub2
10.1002/14651858.CD009892.pub2
10.1002/14651858.CD010468.pub2
10.1002/14651858.CD008877.pub2
10.1002/14651858.CD006904.pub3
10.1002/14651858.CD006902.pub3
10.1002/14651858.CD009771.pub2
10.1002/14651858.CD010225.pub2
10.1002/14651858.CD010269.pub2
10.1002/14651858.CD011447
10.1002/14651858.CD010381.pub2
10.1002/14651858.CD006638.pub3
10.1002/14651858.CD007271.pub3
10.1002/14651858.CD006962.pub2
10.1002/14651858.CD008807.pub2
10.1002/14651858.CD010645.pub2

10.1002/14651858.CD009852.pub2
10.1002/14651858.CD010824.pub2
10.1002/14651858.CD004083.pub3
10.1002/14651858.CD009861.pub2
10.1002/14651858.CD008632.pub2
10.1002/14651858.CD009891.pub2
10.1002/14651858.CD008884.pub2
10.1002/14651858.CD004081.pub3
10.1002/14651858.CD006447.pub3
10.1002/14651858.CD007082.pub2
10.1002/14651858.CD009201.pub2
10.1002/14651858.CD011107.pub2
10.1002/14651858.CD007399.pub2
10.1002/14651858.CD009642.pub2
10.1002/14651858.CD003703.pub3
10.1002/14651858.CD006291.pub3
10.1002/14651858.CD010278.pub2
10.1002/14651858.CD006459.pub3
10.1002/14651858.CD009134.pub2
10.1002/14651858.CD010106.pub2
10.1002/14651858.CD010356.pub2
10.1002/14651858.CD008808.pub2
10.1002/14651858.CD001021.pub2
10.1002/14651858.CD003429.pub4
10.1002/14651858.CD002008.pub4
10.1002/14651858.CD008294.pub4
10.1002/14651858.CD002767.pub2
10.1002/14651858.CD002203.pub4
10.1002/14651858.CD008319.pub2
10.1002/14651858.CD001507.pub3
10.1002/14651858.CD007639.pub2
10.1002/14651858.CD009415.pub2
10.1002/14651858.CD008037.pub3
10.1002/14651858.CD007168.pub3
10.1002/14651858.CD006112.pub3
10.1002/14651858.CD003884.pub4
10.1002/14651858.CD001753.pub3
10.1002/14651858.CD009448.pub2
10.1002/14651858.CD004839.pub3
10.1002/14651858.CD002010.pub4
10.1002/14651858.CD004450.pub3
10.1002/14651858.CD005087.pub4
10.1002/14651858.CD010561.pub2

10.1002/14651858.CD007298.pub4
10.1002/14651858.CD007477.pub3
10.1002/14651858.CD008190.pub2
10.1002/14651858.CD007020.pub3
10.1002/14651858.CD007641.pub3
10.1002/14651858.CD003148.pub3
10.1002/14651858.CD001918.pub3
10.1002/14651858.CD009961.pub2
10.1002/14651858.CD004731.pub4
10.1002/14651858.CD010297.pub2
10.1002/14651858.CD010893.pub2
10.1002/14651858.CD010324.pub2
10.1002/14651858.CD009841.pub2
10.1002/14651858.CD008005.pub4
10.1002/14651858.CD004448.pub5
10.1002/14651858.CD001916.pub3
10.1002/14651858.CD008901.pub3
10.1002/14651858.CD009191.pub3
10.1002/14651858.CD008253.pub4
10.1002/14651858.CD001914.pub2
10.1002/14651858.CD003147.pub4
10.1002/14651858.CD009730.pub2
10.1002/14651858.CD008191.pub2
10.1002/14651858.CD008068.pub2
10.1002/14651858.CD007546.pub2
10.1002/14651858.CD007220.pub2
10.1002/14651858.CD002955.pub4
10.1002/14651858.CD005379.pub3
10.1002/14651858.CD006504.pub2
10.1002/14651858.CD009425.pub2
10.1002/14651858.CD005562.pub2
10.1002/14651858.CD006378.pub2
10.1002/14651858.CD006929.pub2
10.1002/14651858.CD009132.pub2
10.1002/14651858.CD008634.pub2
10.1002/14651858.CD004744.pub3
10.1002/14651858.CD008900.pub2
10.1002/14651858.CD004033.pub3
10.1002/14651858.CD007726.pub2
10.1002/14651858.CD003260.pub2
10.1002/14651858.CD004396.pub3
10.1002/14651858.CD009125.pub2
10.1002/14651858.CD009537.pub2

10.1002/14651858.CD003150.pub2
10.1002/14651858.CD003946.pub4
10.1002/14651858.CD005380.pub5
10.1002/14651858.CD007514.pub3
10.1002/14651858.CD009126.pub2
10.1002/14651858.CD009444.pub3
10.1002/14651858.CD008345.pub2
10.1002/14651858.CD009524.pub2
10.1002/14651858.CD006489.pub4
10.1002/14651858.CD005381.pub4
10.1002/14651858.CD010033.pub2
10.1002/14651858.CD010569.pub2
10.1002/14651858.CD009221.pub2
10.1002/14651858.CD001191.pub4
10.1002/14651858.CD003160.pub3
10.1002/14651858.CD009002.pub3
10.1002/14651858.CD011971.pub2
10.1002/14651858.CD011513.pub2
10.1002/14651858.CD009178.pub3
10.1002/14651858.CD005563.pub3
10.1002/14651858.CD009374.pub3
10.1002/14651858.CD011882.pub2
10.1002/14651858.CD002854.pub5
10.1002/14651858.CD003804.pub2
10.1002/14651858.CD003477.pub3
10.1002/14651858.CD004615.pub3
10.1002/14651858.CD007296.pub2
10.1002/14651858.CD006688.pub2
10.1002/14651858.CD006689.pub2
10.1002/14651858.CD008603.pub2
10.1002/14651858.CD003754.pub3
10.1002/14651858.CD006591.pub2
10.1002/14651858.CD004530.pub4
10.1002/14651858.CD002151.pub2
10.1002/14651858.CD003756.pub4
10.1002/14651858.CD005967.pub4
10.1002/14651858.CD007179.pub2
10.1002/14651858.CD009527.pub2
10.1002/14651858.CD008300.pub2
10.1002/14651858.CD001167.pub2
10.1002/14651858.CD006201.pub3
10.1002/14651858.CD007787.pub2
10.1002/14651858.CD004795.pub4

10.1002/14651858.CD000528.pub2
10.1002/14651858.CD008521.pub3
10.1002/14651858.CD007401.pub3
10.1002/14651858.CD009029.pub2
10.1002/14651858.CD009572.pub2
10.1002/14651858.CD008492.pub3
10.1002/14651858.CD007545.pub2
10.1002/14651858.CD005433.pub2
10.1002/14651858.CD008923.pub2
10.1002/14651858.CD004389.pub3
10.1002/14651858.CD008090.pub2
10.1002/14651858.CD001261.pub3
10.1002/14651858.CD008846.pub2
10.1002/14651858.CD007953.pub2
10.1002/14651858.CD010927
10.1002/14651858.CD006404.pub2
10.1002/14651858.CD008998.pub2
10.1002/14651858.CD009964.pub2
10.1002/14651858.CD003488.pub3
10.1002/14651858.CD008625.pub2
10.1002/14651858.CD010678.pub2
10.1002/14651858.CD000169.pub3
10.1002/14651858.CD011370
10.1002/14651858.CD010767.pub2
10.1002/14651858.CD006594.pub3
10.1002/14651858.CD000053.pub3
10.1002/14651858.CD011547
10.1002/14651858.CD008152.pub4
10.1002/14651858.CD010458.pub2
10.1002/14651858.CD003343.pub4
10.1002/14651858.CD004265.pub3
10.1002/14651858.CD007952.pub3
10.1002/14651858.CD007745.pub3
10.1002/14651858.CD000371.pub6
10.1002/14651858.CD004794.pub3
10.1002/14651858.CD006419.pub4
10.1002/14651858.CD002244.pub4
10.1002/14651858.CD006589.pub4
10.1002/14651858.CD009913.pub2
10.1002/14651858.CD012163.pub2
10.1002/14651858.CD006086.pub4
10.1002/14651858.CD012091.pub2
10.1002/14651858.CD006417.pub3

10.1002/14651858.CD008824.pub2
10.1002/14651858.CD004246.pub4
10.1002/14651858.CD006519.pub3
10.1002/14651858.CD001876.pub3
10.1002/14651858.CD010806.pub2
10.1002/14651858.CD009818.pub2
10.1002/14651858.CD005436.pub5
10.1002/14651858.CD006418.pub3
10.1002/14651858.CD003650.pub4
10.1002/14651858.CD011656.pub2
10.1002/14651858.CD008984.pub2
10.1002/14651858.CD003281.pub4
10.1002/14651858.CD005059.pub4
10.1002/14651858.CD009634.pub2
10.1002/14651858.CD008095.pub2
10.1002/14651858.CD011151.pub2
10.1002/14651858.CD004920.pub3
10.1002/14651858.CD002243.pub3
10.1002/14651858.CD009210.pub2
10.1002/14651858.CD005370.pub3
10.1002/14651858.CD009346.pub2
10.1002/14651858.CD004128.pub4
10.1002/14651858.CD003709.pub4
10.1002/14651858.CD009121.pub2
10.1002/14651858.CD011436.pub2
10.1002/14651858.CD000521.pub3
10.1002/14651858.CD010135.pub2
10.1002/14651858.CD007874.pub2
10.1002/14651858.CD003004.pub4
10.1002/14651858.CD010570.pub2
10.1002/14651858.CD004085.pub4
10.1002/14651858.CD009484.pub2
10.1002/14651858.CD007878.pub3
10.1002/14651858.CD005144.pub3
10.1002/14651858.CD009016.pub2
10.1002/14651858.CD009491.pub2
10.1002/14651858.CD007205.pub2
10.1002/14651858.CD005576.pub3
10.1002/14651858.CD012230
10.1002/14651858.CD008646.pub2
10.1002/14651858.CD006837.pub3
10.1002/14651858.CD002787.pub3
10.1002/14651858.CD008045.pub2

10.1002/14651858.CD011052.pub2
10.1002/14651858.CD010726.pub2
10.1002/14651858.CD011364.pub2
10.1002/14651858.CD001893.pub2
10.1002/14651858.CD003842.pub5
10.1002/14651858.CD003587.pub3
10.1002/14651858.CD007871.pub3
10.1002/14651858.CD006623.pub3
10.1002/14651858.CD006883.pub3
10.1002/14651858.CD011812.pub2
10.1002/14651858.CD006667.pub3
10.1002/14651858.CD009906.pub2
10.1002/14651858.CD008075.pub3
10.1002/14651858.CD011833.pub2
10.1002/14651858.CD010698.pub2
10.1002/14651858.CD005364.pub3
10.1002/14651858.CD011413.pub2
10.1002/14651858.CD007272.pub2
10.1002/14651858.CD010172.pub2
10.1002/14651858.CD010807.pub2
10.1002/14651858.CD007733.pub3
10.1002/14651858.CD009761.pub2
10.1002/14651858.CD012763
10.1002/14651858.CD004711.pub3
10.1002/14651858.CD004089.pub3
10.1002/14651858.CD008674.pub2
10.1002/14651858.CD003474.pub3
10.1002/14651858.CD006243.pub2
10.1002/14651858.CD007847.pub2
10.1002/14651858.CD008926.pub2
10.1002/14651858.CD008941.pub2
10.1002/14651858.CD009553.pub2
10.1002/14651858.CD007913.pub2
10.1002/14651858.CD003721.pub3
10.1002/14651858.CD005212.pub3
10.1002/14651858.CD009557.pub2
10.1002/14651858.CD000563.pub7
10.1002/14651858.CD004253.pub4
10.1002/14651858.CD001877.pub5
10.1002/14651858.CD008792.pub2
10.1002/14651858.CD004272.pub3
10.1002/14651858.CD006242.pub2
10.1002/14651858.CD003475.pub2

10.1002/14651858.CD009765.pub2
10.1002/14651858.CD009206.pub2
10.1002/14651858.CD008729.pub2
10.1002/14651858.CD010895.pub2
10.1002/14651858.CD001768.pub3
10.1002/14651858.CD003139.pub3
10.1002/14651858.CD003366.pub3
10.1002/14651858.CD007077.pub3
10.1002/14651858.CD003860.pub4
10.1002/14651858.CD011093.pub2
10.1002/14651858.CD008932.pub3
10.1002/14651858.CD011396.pub2
10.1002/14651858.CD005001.pub3
10.1002/14651858.CD011652.pub2
10.1002/14651858.CD010802.pub2
10.1002/14651858.CD004561.pub3
10.1002/14651858.CD003374.pub4
10.1002/14651858.CD011152.pub2
10.1002/14651858.CD006956.pub2
10.1002/14651858.CD005660.pub3
10.1002/14651858.CD007780.pub2
10.1002/14651858.CD007886.pub2
10.1002/14651858.CD007635.pub2
10.1002/14651858.CD007781.pub2
10.1002/14651858.CD008506.pub2
10.1002/14651858.CD004320.pub3
10.1002/14651858.CD007378.pub2
10.1002/14651858.CD008359.pub2
10.1002/14651858.CD005477.pub4
10.1002/14651858.CD002199.pub4
10.1002/14651858.CD001544.pub4
10.1002/14651858.CD008361.pub2
10.1002/14651858.CD003769.pub4
10.1002/14651858.CD003144.pub2
10.1002/14651858.CD003431.pub3
10.1002/14651858.CD001543.pub4
10.1002/14651858.CD008836.pub2
10.1002/14651858.CD004078.pub2
10.1002/14651858.CD008237.pub2
10.1002/14651858.CD005391.pub3
10.1002/14651858.CD008034.pub2
10.1002/14651858.CD009350.pub2
10.1002/14651858.CD007814.pub2

10.1002/14651858.CD004322.pub3
10.1002/14651858.CD009092.pub2
10.1002/14651858.CD009244.pub2
10.1002/14651858.CD008368.pub2
10.1002/14651858.CD008211.pub3
10.1002/14651858.CD009475.pub2
10.1002/14651858.CD006041.pub3
10.1002/14651858.CD004323.pub4
10.1002/14651858.CD009495.pub2
10.1002/14651858.CD008879.pub2
10.1002/14651858.CD009487.pub2
10.1002/14651858.CD009259.pub2
10.1002/14651858.CD010168.pub2
10.1002/14651858.CD005200.pub3
10.1002/14651858.CD008531.pub2
10.1002/14651858.CD009863.pub2
10.1002/14651858.CD006506.pub3
10.1002/14651858.CD008593.pub3
10.1002/14651858.CD006439.pub4
10.1002/14651858.CD007821.pub3
10.1002/14651858.CD001181.pub4
10.1002/14651858.CD002200.pub3
10.1002/14651858.CD003430.pub2
10.1002/14651858.CD011670.pub2
10.1002/14651858.CD010814.pub2
10.1002/14651858.CD006875.pub3
10.1002/14651858.CD006476.pub3
10.1002/14651858.CD009569.pub3
10.1002/14651858.CD009839.pub2
10.1002/14651858.CD007047.pub2
10.1002/14651858.CD006325.pub3
10.1002/14651858.CD008975.pub2
10.1002/14651858.CD008205.pub2
10.1002/14651858.CD009160.pub2
10.1002/14651858.CD006647.pub4
10.1002/14651858.CD008944.pub2
10.1002/14651858.CD010774.pub2
10.1002/14651858.CD003298.pub3
10.1002/14651858.CD006301.pub4
10.1002/14651858.CD008382.pub2
10.1002/14651858.CD008890.pub4
10.1002/14651858.CD008796.pub3
10.1002/14651858.CD007786.pub3

10.1002/14651858.CD010439.pub2
10.1002/14651858.CD006247.pub3
10.1002/14651858.CD010885.pub3
10.1002/14651858.CD009678.pub2
10.1002/14651858.CD008011.pub3
10.1002/14651858.CD009219.pub4
10.1002/14651858.CD006945.pub4
10.1002/14651858.CD010349.pub2
10.1002/14651858.CD010685.pub3
10.1002/14651858.CD008483.pub2
10.1002/14651858.CD001025.pub3
10.1002/14651858.CD008591.pub2
10.1002/14651858.CD004857.pub2
10.1002/14651858.CD006528.pub2
10.1002/14651858.CD007139.pub2
10.1002/14651858.CD005472.pub3
10.1002/14651858.CD007504.pub2
10.1002/14651858.CD008937.pub2
10.1002/14651858.CD004851.pub3
10.1002/14651858.CD006533.pub2
10.1002/14651858.CD006525.pub2
10.1002/14651858.CD001760.pub2
10.1002/14651858.CD006726.pub2
10.1002/14651858.CD006534.pub2
10.1002/14651858.CD002317.pub2
10.1002/14651858.CD009138.pub2
10.1002/14651858.CD006389.pub2
10.1002/14651858.CD003196.pub2
10.1002/14651858.CD008696.pub2
10.1002/14651858.CD004185.pub3
10.1002/14651858.CD004366.pub6
10.1002/14651858.CD008705.pub2
10.1002/14651858.CD008142.pub2
10.1002/14651858.CD008704.pub2
10.1002/14651858.CD007662.pub2
10.1002/14651858.CD005330.pub4
10.1002/14651858.CD003388.pub4
10.1002/14651858.CD008851.pub2
10.1002/14651858.CD006239.pub2
10.1002/14651858.CD004687.pub4
10.1002/14651858.CD002018.pub2
10.1002/14651858.CD009083.pub2
10.1002/14651858.CD010828.pub2

10.1002/14651858.CD006531.pub2
10.1002/14651858.CD009317.pub2
10.1002/14651858.CD005000.pub2
10.1002/14651858.CD011142.pub2
10.1002/14651858.CD004690.pub4
10.1002/14651858.CD008324.pub3
10.1002/14651858.CD009895.pub2
10.1002/14651858.CD008619.pub2
10.1002/14651858.CD010628.pub2
10.1002/14651858.CD006833.pub2
10.1002/14651858.CD007194.pub2
10.1002/14651858.CD003909.pub2
10.1002/14651858.CD007803.pub2
10.1002/14651858.CD011777
10.1002/14651858.CD004044.pub4
10.1002/14651858.CD011611.pub2
10.1002/14651858.CD011269.pub2
10.1002/14651858.CD004692.pub4
10.1002/14651858.CD011612.pub2
10.1002/14651858.CD011268.pub2
10.1002/14651858.CD012013
10.1002/14651858.CD011565.pub2
10.1002/14651858.CD010204.pub2
10.1002/14651858.CD003384.pub3
10.1002/14651858.CD006727.pub3
10.1002/14651858.CD011119.pub2
10.1002/14651858.CD012189
10.1002/14651858.CD011567.pub2
10.1002/14651858.CD010673.pub2
10.1002/14651858.CD011170.pub2
10.1002/14651858.CD011004.pub2
10.1002/14651858.CD012371
10.1002/14651858.CD011286.pub2
10.1002/14651858.CD011520.pub2
10.1002/14651858.CD003200.pub7
10.1002/14651858.CD003380.pub4
10.1002/14651858.CD003648.pub4
10.1002/14651858.CD005143.pub3
10.1002/14651858.CD006161.pub3
10.1002/14651858.CD006776.pub2
10.1002/14651858.CD007092.pub2
10.1002/14651858.CD007617.pub2
10.1002/14651858.CD005025.pub3

10.1002/14651858.CD007456.pub2
10.1002/14651858.CD008273.pub2
10.1002/14651858.CD006777.pub2
10.1002/14651858.CD007982.pub2
10.1002/14651858.CD007978.pub2
10.1002/14651858.CD004811.pub3
10.1002/14651858.CD007457.pub2
10.1002/14651858.CD007459.pub2
10.1002/14651858.CD001865.pub3
10.1002/14651858.CD008722.pub2
10.1002/14651858.CD008416.pub2
10.1002/14651858.CD003267.pub2
10.1002/14651858.CD009453.pub2
10.1002/14651858.CD010038.pub2
10.1002/14651858.CD004807.pub2
10.1002/14651858.CD007458.pub3
10.1002/14651858.CD009445.pub2
10.1002/14651858.CD004134.pub3
10.1002/14651858.CD009405.pub2
10.1002/14651858.CD007979.pub3
10.1002/14651858.CD003717.pub3
10.1002/14651858.CD010232.pub2
10.1002/14651858.CD010523.pub2
10.1002/14651858.CD009736.pub2
10.1002/14651858.CD010825.pub2
10.1002/14651858.CD009727.pub2
10.1002/14651858.CD000011.pub4
10.1002/14651858.CD009921.pub2
10.1002/14651858.CD001399.pub4
10.1002/14651858.CD010790.pub2
10.1002/14651858.CD010288.pub3
10.1002/14651858.CD008649.pub2
10.1002/14651858.CD000407.pub4
10.1002/14651858.CD001917.pub4
10.1002/14651858.CD010155.pub3
10.1002/14651858.CD009530.pub3
10.1002/14651858.CD001401.pub3
10.1002/14651858.CD008185.pub4
10.1002/14651858.CD006111.pub3
10.1002/14651858.CD004449.pub4
10.1002/14651858.CD011130.pub2
10.1002/14651858.CD002201.pub5
10.1002/14651858.CD011385.pub2

10.1002/14651858.CD009806.pub2
10.1002/14651858.CD009354.pub4
10.1002/14651858.CD010429.pub2
10.1002/14651858.CD003426.pub5
10.1002/14651858.CD001505.pub4
10.1002/14651858.CD003149.pub3
10.1002/14651858.CD001127.pub3
10.1002/14651858.CD004730.pub4
10.1002/14651858.CD010517.pub2
10.1002/14651858.CD005599.pub5
10.1002/14651858.CD007862.pub4
10.1002/14651858.CD007743.pub6
10.1002/14651858.CD011272.pub2
10.1002/14651858.CD005405.pub4
10.1002/14651858.CD007923.pub4
10.1002/14651858.CD003424.pub4
10.1002/14651858.CD007843.pub3
10.1002/14651858.CD001915.pub5
10.1002/14651858.CD008036.pub4
10.1002/14651858.CD006663.pub4
10.1002/14651858.CD004344.pub6
10.1002/14651858.CD011175.pub2
10.1002/14651858.CD011579.pub2
10.1002/14651858.CD010338.pub3
10.1002/14651858.CD005088.pub4
10.1002/14651858.CD008227.pub3
10.1002/14651858.CD011180.pub2
10.1002/14651858.CD002007.pub4
10.1002/14651858.CD008816.pub3
10.1002/14651858.CD012040.pub2
10.1002/14651858.CD010858.pub2
10.1002/14651858.CD009422.pub3
10.1002/14651858.CD003146.pub3
10.1002/14651858.CD002009.pub6
10.1002/14651858.CD001912.pub4
10.1002/14651858.CD002769.pub5
10.1002/14651858.CD011358.pub2
10.1002/14651858.CD000406.pub5
10.1002/14651858.CD002202.pub2
10.1002/14651858.CD004197.pub5
10.1002/14651858.CD006842.pub4
10.1002/14651858.CD012380.pub2
10.1002/14651858.CD012389.pub2

10.1002/14651858.CD006401.pub4
10.1002/14651858.CD008482.pub5
10.1002/14651858.CD012284.pub2
10.1002/14651858.CD004198.pub3
10.1002/14651858.CD011441.pub2
10.1002/14651858.CD012330.pub2
10.1002/14651858.CD009803.pub2
10.1002/14651858.CD004878.pub4
10.1002/14651858.CD004976.pub3
10.1002/14651858.CD004877.pub3
10.1002/14651858.CD006607.pub4
10.1002/14651858.CD005530.pub3
10.1002/14651858.CD002744.pub4
10.1002/14651858.CD003645.pub3
10.1002/14651858.CD004418.pub4
10.1002/14651858.CD008268.pub2
10.1002/14651858.CD004872.pub3
10.1002/14651858.CD004879.pub4
10.1002/14651858.CD006435.pub2
10.1002/14651858.CD007720.pub2
10.1002/14651858.CD001955.pub3
10.1002/14651858.CD007368.pub2
10.1002/14651858.CD003123.pub3
10.1002/14651858.CD006207.pub4
10.1002/14651858.CD004882.pub3
10.1002/14651858.CD008395.pub2
10.1002/14651858.CD004407.pub3
10.1002/14651858.CD006338.pub3
10.1002/14651858.CD004559.pub4
10.1002/14651858.CD000422.pub3
10.1002/14651858.CD000980.pub4
10.1002/14651858.CD003124.pub4
10.1002/14651858.CD000247.pub3
10.1002/14651858.CD006602.pub4
10.1002/14651858.CD004874.pub4
10.1002/14651858.CD000436.pub3
10.1002/14651858.CD007074.pub2
10.1002/14651858.CD004823.pub4
10.1002/14651858.CD008695.pub2
10.1002/14651858.CD009039.pub2
10.1002/14651858.CD007718.pub2
10.1002/14651858.CD008008.pub2
10.1002/14651858.CD004106.pub4

10.1002/14651858.CD007033.pub3
10.1002/14651858.CD007695.pub3
10.1002/14651858.CD008469.pub2
10.1002/14651858.CD008328.pub2
10.1002/14651858.CD003797.pub2
10.1002/14651858.CD003533.pub2
10.1002/14651858.CD000994.pub3
10.1002/14651858.CD006100.pub2
10.1002/14651858.CD003573.pub2
10.1002/14651858.CD004357.pub4
10.1002/14651858.CD006923.pub3
10.1002/14651858.CD009339.pub2
10.1002/14651858.CD002986.pub2
10.1002/14651858.CD006829.pub2
10.1002/14651858.CD009157.pub2
10.1002/14651858.CD005304.pub3
10.1002/14651858.CD009293.pub2
10.1002/14651858.CD002991.pub3
10.1002/14651858.CD008250.pub2
10.1002/14651858.CD010256
10.1002/14651858.CD002314.pub3
10.1002/14651858.CD010257
10.1002/14651858.CD000998.pub3
10.1002/14651858.CD009611.pub3
10.1002/14651858.CD010179
10.1002/14651858.CD002742.pub2
10.1002/14651858.CD002308.pub2
10.1002/14651858.CD002316.pub2
10.1002/14651858.CD004434.pub5
10.1002/14651858.CD009296.pub2
10.1002/14651858.CD000364.pub4
10.1002/14651858.CD008888.pub2
10.1002/14651858.CD010352
10.1002/14651858.CD009305.pub2
10.1002/14651858.CD007313.pub3
10.1002/14651858.CD009041.pub2
10.1002/14651858.CD006922.pub3
10.1002/14651858.CD007891.pub3
10.1002/14651858.CD009607.pub2
10.1002/14651858.CD003563.pub2
10.1002/14651858.CD002878.pub2
10.1002/14651858.CD003792.pub2
10.1002/14651858.CD000060.pub2

10.1002/14651858.CD006826.pub2
10.1002/14651858.CD003002.pub3
10.1002/14651858.CD009585.pub2
10.1002/14651858.CD000052.pub3
10.1002/14651858.CD001277.pub3
10.1002/14651858.CD001116.pub4
10.1002/14651858.CD006924.pub3
10.1002/14651858.CD010177.pub2
10.1002/14651858.CD009769.pub2
10.1002/14651858.CD010391.pub2
10.1002/14651858.CD009437.pub2
10.1002/14651858.CD010013.pub2
10.1002/14651858.CD009764.pub2
10.1002/14651858.CD009019.pub2
10.1002/14651858.CD003564.pub3
10.1002/14651858.CD008290.pub2
10.1002/14651858.CD007736.pub2
10.1002/14651858.CD003794.pub4
10.1002/14651858.CD003559.pub4
10.1002/14651858.CD009910.pub2
10.1002/14651858.CD003137.pub5
10.1002/14651858.CD008231.pub3
10.1002/14651858.CD008806.pub2
10.1002/14651858.CD006089.pub4
10.1002/14651858.CD008800.pub2
10.1002/14651858.CD006458.pub3
10.1002/14651858.CD010277.pub2
10.1002/14651858.CD001477.pub4
10.1002/14651858.CD005532.pub3
10.1002/14651858.CD006323.pub3
10.1002/14651858.CD006619.pub3
10.1002/14651858.CD004785.pub5
10.1002/14651858.CD003699.pub4
10.1002/14651858.CD000023.pub4
10.1002/14651858.CD005149.pub4
10.1002/14651858.CD006822.pub4
10.1002/14651858.CD009119.pub2
10.1002/14651858.CD004975.pub3
10.1002/14651858.CD009609.pub2
10.1002/14651858.CD006088.pub4
10.1002/14651858.CD008115.pub3
10.1002/14651858.CD000530.pub3
10.1002/14651858.CD001480.pub4

10.1002/14651858.CD010056.pub2
10.1002/14651858.CD001266.pub4
10.1002/14651858.CD001269.pub5
10.1002/14651858.CD006452.pub4
10.1002/14651858.CD001833.pub3
10.1002/14651858.CD006639.pub4
10.1002/14651858.CD001478.pub6
10.1002/14651858.CD003257.pub5
10.1002/14651858.CD008965.pub4
10.1002/14651858.CD005189.pub4
10.1002/14651858.CD009066.pub2
10.1002/14651858.CD005188.pub3
10.1002/14651858.CD002109.pub4
10.1002/14651858.CD006482.pub4
10.1002/14651858.CD006206.pub4
10.1002/14651858.CD010130.pub2
10.1002/14651858.CD001831.pub5
10.1002/14651858.CD010473.pub2
10.1002/14651858.CD005975.pub3
10.1002/14651858.CD004875.pub5
10.1002/14651858.CD002745.pub4
10.1002/14651858.CD001957.pub6
10.1002/14651858.CD009088.pub3
10.1002/14651858.CD007094.pub4
10.1002/14651858.CD001954.pub4
10.1002/14651858.CD007716.pub4
10.1002/14651858.CD006895.pub3
10.1002/14651858.CD010636.pub2
10.1002/14651858.CD006821.pub3
10.1002/14651858.CD007897.pub3
10.1002/14651858.CD004884.pub4
10.1002/14651858.CD004783.pub5
10.1002/14651858.CD009194.pub3
10.1002/14651858.CD010596.pub2
10.1002/14651858.CD000219.pub4
10.1002/14651858.CD007577.pub3
10.1002/14651858.CD010586.pub2
10.1002/14651858.CD006915.pub3
10.1002/14651858.CD001726.pub5
10.1002/14651858.CD004405.pub5
10.1002/14651858.CD006362.pub4
10.1002/14651858.CD008116.pub3
10.1002/14651858.CD004402.pub3

10.1002/14651858.CD011530.pub2
10.1002/14651858.CD010907.pub2
10.1002/14651858.CD009345.pub2
10.1002/14651858.CD007880.pub3
10.1002/14651858.CD009946.pub2
10.1002/14651858.CD008858.pub3
10.1002/14651858.CD004873.pub5
10.1002/14651858.CD005187.pub5
10.1002/14651858.CD007719.pub4
10.1002/14651858.CD011857.pub2
10.1002/14651858.CD007095.pub3
10.1002/14651858.CD004406.pub4
10.1002/14651858.CD004786.pub5
10.1002/14651858.CD009612.pub2
10.1002/14651858.CD005978.pub3
10.1002/14651858.CD011487.pub2
10.1002/14651858.CD011360.pub2
10.1002/14651858.CD004267.pub4
10.1002/14651858.CD011534.pub2
10.1002/14651858.CD010010.pub3
10.1002/14651858.CD005437.pub4
10.1002/14651858.CD010651.pub2
10.1002/14651858.CD002190.pub5
10.1002/14651858.CD011177.pub3
10.1002/14651858.CD000245.pub4
10.1002/14651858.CD004417.pub5
10.1002/14651858.CD010115.pub2
10.1002/14651858.CD001289.pub2
10.1002/14651858.CD002990.pub3
10.1002/14651858.CD010844.pub2
10.1002/14651858.CD010327.pub2
10.1002/14651858.CD002996.pub3
10.1002/14651858.CD007676.pub2
10.1002/14651858.CD000238.pub2
10.1002/14651858.CD010909.pub2
10.1002/14651858.CD007714.pub2
10.1002/14651858.CD010749.pub2
10.1002/14651858.CD010456.pub2
10.1002/14651858.CD006595.pub3
10.1002/14651858.CD009471.pub2
10.1002/14651858.CD009878.pub2
10.1002/14651858.CD010283.pub2
10.1002/14651858.CD001288.pub4

10.1002/14651858.CD009285.pub3
10.1002/14651858.CD010509.pub2
10.1002/14651858.CD006322.pub3
10.1002/14651858.CD006897.pub3
10.1002/14651858.CD010382.pub2
10.1002/14651858.CD010139.pub2
10.1002/14651858.CD011306.pub2
10.1002/14651858.CD011438.pub2
10.1002/14651858.CD003793.pub3
10.1002/14651858.CD011090.pub2
10.1002/14651858.CD011437.pub2
10.1002/14651858.CD011032.pub2
10.1002/14651858.CD001287.pub5
10.1002/14651858.CD009552.pub3
10.1002/14651858.CD010066.pub2
10.1002/14651858.CD011397.pub2
10.1002/14651858.CD002997.pub4
10.1002/14651858.CD011293.pub2
10.1002/14651858.CD001392.pub3
10.1002/14651858.CD008351.pub3
10.1002/14651858.CD008989.pub3
10.1002/14651858.CD007949.pub2
10.1002/14651858.CD007525.pub3
10.1002/14651858.CD011721.pub2
10.1002/14651858.CD008202.pub2
10.1002/14651858.CD011017.pub2
10.1002/14651858.CD011715.pub2
10.1002/14651858.CD011050.pub2
10.1002/14651858.CD010346.pub2
10.1002/14651858.CD011801.pub2
10.1002/14651858.CD011716.pub2
10.1002/14651858.CD009953.pub2
10.1002/14651858.CD007524.pub4
10.1002/14651858.CD011205.pub2
10.1002/14651858.CD008532.pub3
10.1002/14651858.CD011714.pub2
10.1002/14651858.CD011826.pub2
10.1002/14651858.CD010744.pub2
10.1002/14651858.CD007851.pub3
10.1002/14651858.CD011440.pub2
10.1002/14651858.CD011511.pub2
10.1002/14651858.CD012067.pub2
10.1002/14651858.CD011818.pub2

10.1002/14651858.CD010758.pub2
10.1002/14651858.CD011439.pub2
10.1002/14651858.CD001001.pub3
10.1002/14651858.CD011434.pub2
10.1002/14651858.CD005305.pub4
10.1002/14651858.CD006429.pub3
10.1002/14651858.CD005074.pub4
10.1002/14651858.CD011285.pub2
10.1002/14651858.CD001284.pub2
10.1002/14651858.CD001390.pub4
10.1002/14651858.CD011802.pub2
10.1002/14651858.CD012066.pub2
10.1002/14651858.CD012286.pub2
10.1002/14651858.CD012158.pub2
10.1002/14651858.CD012255.pub2
10.1002/14651858.CD012331.pub2
10.1002/14651858.CD011425.pub2
10.1002/14651858.CD011859.pub2
10.1002/14651858.CD009834.pub3
10.1002/14651858.CD011897.pub2
10.1002/14651858.CD010347.pub2
10.1002/14651858.CD005603.pub3
10.1002/14651858.CD006580.pub5
10.1002/14651858.CD011682.pub2
10.1002/14651858.CD012226.pub2
10.1002/14651858.CD011699.pub2
10.1002/14651858.CD010834.pub3
10.1002/14651858.CD005959.pub2
10.1002/14651858.CD008471.pub2
10.1002/14651858.CD008130.pub2
10.1002/14651858.CD001704.pub4
10.1002/14651858.CD001250.pub2
10.1002/14651858.CD004577.pub3
10.1002/14651858.CD004124.pub3
10.1002/14651858.CD001256.pub2
10.1002/14651858.CD005960.pub2
10.1002/14651858.CD000168.pub3
10.1002/14651858.CD008241.pub2
10.1002/14651858.CD007908.pub2
10.1002/14651858.CD009496.pub2
10.1002/14651858.CD000523.pub4
10.1002/14651858.CD008262.pub2
10.1002/14651858.CD004963.pub3

10.1002/14651858.CD008470.pub2
10.1002/14651858.CD005595.pub3
10.1002/14651858.CD004575.pub3
10.1002/14651858.CD008628.pub2
10.1002/14651858.CD009030.pub2
10.1002/14651858.CD009890.pub2
10.1002/14651858.CD008413.pub2
10.1002/14651858.CD005465.pub3
10.1002/14651858.CD009073.pub2
10.1002/14651858.CD005079.pub3
10.1002/14651858.CD009363.pub2
10.1002/14651858.CD008987.pub2
10.1002/14651858.CD000339.pub3
10.1002/14651858.CD009587.pub2
10.1002/14651858.CD001255.pub5
10.1002/14651858.CD004439.pub3
10.1002/14651858.CD009808.pub2
10.1002/14651858.CD004962.pub3
10.1002/14651858.CD010071.pub3
10.1002/14651858.CD007146.pub3
10.1002/14651858.CD000227.pub4
10.1002/14651858.CD009065.pub2
10.1002/14651858.CD007601.pub4
10.1002/14651858.CD008579.pub3
10.1002/14651858.CD008887.pub2
10.1002/14651858.CD008129.pub2
10.1002/14651858.CD009949.pub2
10.1002/14651858.CD009076.pub2
10.1002/14651858.CD004961.pub4
10.1002/14651858.CD010144.pub2
10.1002/14651858.CD008106.pub3
10.1002/14651858.CD009651.pub2
10.1002/14651858.CD010960.pub2
10.1002/14651858.CD010261.pub2
10.1002/14651858.CD009699.pub2
10.1002/14651858.CD009848.pub2
10.1002/14651858.CD007789.pub2
10.1002/14651858.CD010606.pub2
10.1002/14651858.CD010836.pub2
10.1002/14651858.CD003324.pub3
10.1002/14651858.CD000434.pub4
10.1002/14651858.CD009679.pub2
10.1002/14651858.CD010789.pub2

10.1002/14651858.CD007428.pub3
10.1002/14651858.CD010675.pub2
10.1002/14651858.CD011166.pub2
10.1002/14651858.CD010847.pub3
10.1002/14651858.CD007121.pub4
10.1002/14651858.CD001880.pub6
10.1002/14651858.CD007759.pub4
10.1002/14651858.CD009348.pub2
10.1002/14651858.CD010467.pub2
10.1002/14651858.CD008875.pub2
10.1002/14651858.CD011387.pub2
10.1002/14651858.CD010134.pub2
10.1002/14651858.CD010358.pub2
10.1002/14651858.CD010959.pub2
10.1002/14651858.CD001159.pub2
10.1002/14651858.CD011136.pub2
10.1002/14651858.CD009026.pub2
10.1002/14651858.CD007837.pub2
10.1002/14651858.CD009237.pub2
10.1002/14651858.CD010265.pub2
10.1002/14651858.CD006850.pub3
10.1002/14651858.CD010969.pub2
10.1002/14651858.CD012382
10.1002/14651858.CD008930.pub2
10.1002/14651858.CD001689.pub3
10.1002/14651858.CD001781.pub3
10.1002/14651858.CD001431.pub5

STROBE Statement—checklist of items that should be included in reports of observational studies

| | Item No | Recommendation | Page No |
|---|---|---|---|
| **Title and abstract** | 1 | (*a*) Indicate the study's design with a commonly used term in the title or the abstract | 1,2 |
| | | (*b*) Provide in the abstract an informative and balanced summary of what was done and what was found | 2 |
| **Introduction** | | | |
| Background/rationale | 2 | Explain the scientific background and rationale for the investigation being reported | 4 |
| Objectives | 3 | State specific objectives, including any prespecified hypotheses | 4 |
| **Methods** | | | |
| Study design | 4 | Present key elements of study design early in the paper | 4 |
| Setting | 5 | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection | 4,5 |
| Participants | 6 | (*a*) *Cohort study*—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up<br>*Case-control study*—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls<br>*Cross-sectional study*—Give the eligibility criteria, and the sources and methods of selection of participants | 5 |
| | | (*b*) *Cohort study*—For matched studies, give matching criteria and number of exposed and unexposed<br>*Case-control study*—For matched studies, give matching criteria and the number of controls per case | N/A |
| Variables | 7 | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable | 5,6 |
| Data sources/ measurement | 8* | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group | 6 |
| Bias | 9 | Describe any efforts to address potential sources of bias | 7,8 |
| Study size | 10 | Explain how the study size was arrived at | 5 |
| Quantitative variables | 11 | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why | N/A |
| Statistical methods | 12 | (*a*) Describe all statistical methods, including those used to control for confounding | 7 |
| | | (*b*) Describe any methods used to examine subgroups and interactions | N/A |
| | | (*c*) Explain how missing data were addressed | 8 |
| | | (*d*) *Cohort study*—If applicable, explain how loss to follow-up was addressed<br>*Case-control study*—If applicable, explain how matching of cases and controls was addressed<br>*Cross-sectional study*—If applicable, describe analytical methods taking account of sampling strategy | N/A |
| | | (*e*) Describe any sensitivity analyses | N/A |

Continued on next page

| | | | |
|---|---|---|---|
| **Results** | | | |
| Participants | 13* | (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed | 5 |
| | | (b) Give reasons for non-participation at each stage | 5 |
| | | (c) Consider use of a flow diagram | 32 |
| Descriptive data | 14* | (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders | 21 |
| | | (b) Indicate number of participants with missing data for each variable of interest | 21 |
| | | (c) *Cohort study*—Summarise follow-up time (eg, average and total amount) | N/A |
| Outcome data | 15* | *Cohort study*—Report numbers of outcome events or summary measures over time | 23 |
| | | *Case-control study*—Report numbers in each exposure category, or summary measures of exposure | N/A |
| | | *Cross-sectional study*—Report numbers of outcome events or summary measures | N/A |
| Main results | 16 | (*a*) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included | 7,8,9 |
| | | (*b*) Report category boundaries when continuous variables were categorized | N/A |
| | | (*c*) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period | N/A |
| Other analyses | 17 | Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses | N/A |
| **Discussion** | | | |
| Key results | 18 | Summarise key results with reference to study objectives | 9,10 |
| Limitations | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias | 10 |
| Interpretation | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence | 9,10 |
| Generalisability | 21 | Discuss the generalisability (external validity) of the study results | 8 |
| **Other information** | | | |
| Funding | 22 | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based | 11 |

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.